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ABSTRACT 
 
Introduction:  
Obesity is a major risk factor for ischaemic heart disease. Obesity-induced metabolic 
abnormalities have been associated with increased oxidative stress which may play an 
important role in the increased susceptibility to myocardial dysfunction and ischaemia-
reperfusion (I/R) injury seen in obesity. The pineal gland hormone, melatonin, has powerful 
antioxidant properties. Previous studies have shown that short-term or acute melatonin 
administration protects the normal healthy heart of lean animals against I/R damage. However, 
the effects of melatonin on the heart in obesity remain unknown.  Moreover, the myocardial 
signalling mechanisms associated with the cardioprotective effects of melatonin have not been 
established.   
Aim:  
Using a rat model of diet induced obesity, we set out to: 1) investigate the effects of chronic 
melatonin administration on the development of diet-induced systemic alterations including 
biometric and metabolic parameters and oxidative stress, 2) determine whether chronic 
melatonin treatment protects the myocardium against ischaemia-reperfusion injury, and 3) 
determine whether melatonin treatment confers cardioprotection by altering the reperfusion 
injury salvage kinase (RISK) pathway signalling  and the pro-apoptotic p38 MAPK, AMPK and 
GLUT-4 expression. 
Methods: 
 Male rats weighing 200±20g were randomly allocated to four groups: 1) C, control rats 
receiving a standard commercial rat chow and drinking water without melatonin; 2) CM, control 
rats receiving melatonin (4mg/kg/day) in drinking water; 3) D, diet-induced obesity rats, 
receiving a high calorie diet and drinking water without melatonin; 4) DM, diet-induced obesity 
rats, receiving melatonin in drinking water. After 16 weeks of treatment and feeding, rats were 
weighed and blood and myocardial tissue collected to document biochemical and molecular 
biological changes. Hearts were perfused on the isolated working rat heart perfusion apparatus 
for the evaluation of myocardial function and infarct size.  The Reperfusion Injury Salvage 
Kinases (RISK) pathway (PKB/Akt (Ser-473), ERK p42/ p44) and p38 MAPK (mitogen-
activated protein kinase) were investigated in pre-and post-ischaemic hearts using Western 
blotting techniques. Post-ischaemic activation of AMPK (5’AMP-activated protein kinase) (Thr-
172) and GLUT-4 (glucose transporter) expression were also investigated. Serum and 
baseline myocardial glutathione (GSH) content were measured. In addition, serum lipid 
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peroxidation products: thiobarbituric reactive substances (TBARS), conjugated dienes (CD) 
and lipid hydroperoxide (LOOH), were also determined. 
Results:  
The high-calorie diet caused increases in body weight, visceral adiposity, heart weight, serum 
insulin, leptin, blood triglycerides, and low HDL-cholesterol levels.  Blood glucose levels were 
similar for both diet fed rats and controls. Myocardial glutathione, serum glutathione, total 
cholesterol, TBARS, LOOH, CD as well as total cholesterol (TC) levels were not affected by 
the high calorie diet.  Chronic melatonin treatment reduced body weight gain, visceral 
adiposity, heart weight, blood triglycerides, serum insulin, HOMA index, serum leptin (DM vs D, 
p<0.01), and increased blood HDL-C in diet treated rats while there was no effect on these 
parameters in control rats, despite the reduction in body weight, heart weight and visceral 
adiposity.  Melatonin treatment had no effect on myocardial or serum GSH and LOOH in either 
control or diet animals.  It however reduced TBARS and CD in the diet and control groups, 
respectively. At baseline, chronic melatonin treatment caused a significant increase in 
phospho-PKB/total PKB ratio and a concomitant reduction in phospho-p38 MAPK/total p38 
MAPK ratio of control hearts while there were no such effects on diet-induced-obesity hearts. 
Infarct size was significantly reduced by melatonin in both diet and control groups (DM: 
16.6±2.0%; D: 38.4±2.6% (p < 0.001), and CM: 12.8±1.5%; C: 30.4±1.0%, p<0.001).  After 
coronary artery occlusion and 30 minutes of reperfusion, melatonin increased percentage 
recovery of aortic output (DM: 28.5±6.5%; D: 6.2±6.2%, p<0.01), cardiac output (DM: 
44.4±5.2%; D: 26.6±5.1%, p < 0.01) and total work (DM: 34.5±5.6%; D: 20.4±7.9%, p<0.05) of 
diet-induced obesity hearts, while having no effect on control hearts. During reperfusion, hearts 
from melatonin treated rats had increased activation of PKB/Akt (p<0.01), ERK42/44 (p<0.05), 
and reduced p38 MAPK activation (p<0.05).  There was no difference in post-ischaemic 
activation of AMPK (Thr-172) and GLUT-4 expression in either control or diet fed rats.   
Conclusions: 
 We successfully demonstrated that chronic melatonin treatment prevented the development of 
diet-induced metabolic abnormalities and improved ex vivo myocardial function. Melatonin 
protected the heart against ischaemia-reperfusion injury that was exacerbated in obesity. This 
was achieved by activation of the RISK pathway. The antioxidant properties of melatonin were 
involved in these cardioprotective effects. 
Key words: Antioxidant, cardioprotection, diet-induced obesity, melatonin, myocardial 
ischaemia-reperfusion injury, insulin resistance. 
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ABSTRAK 
 
Inleiding 
Vetsug of obesiteit is een van die hoof risikofaktore vir iskemiese hartsiekte. Obesiteit-
geinduseerde metaboliese abnormaliteite gaan met verhoogde oksidatiewe stres gepaard wat 
op sy beurt ‘n belangrike rol mag speel in die miokardiale wanfunksie en verhoogde 
vatbaarheid vir iskemie-herperfusie (I/H) beskadiging, kenmerkend van vetsug. Melatonien, die 
hormoon afgeskei deur die pineaalklier, is ‘n kragtige anti-oksidant. Vorige studies het getoon 
dat kort-termyn of akute toediening van melatonien die normale hart van gesonde diere teen 
I/H beskadiging deur middel van sy anti-oksidant aksies beskerm. Die effek van melatonien op 
die hart in obesiteit is egter nog onbekend. Hierbenewens is die miokardiale seintransduksie 
meganismes geassosieer met die beskermende effekte van die hormoon nog nie ontrafel nie. 
Doelstellings 
‘n Model van dieet-geinduseerde obesiteit in rotte is gebruik om die volgende te bepaal: (i) die 
effek van kroniese melatonientoediening op die ontwikkeling van dieet-geinduseerde 
sistemiese veranderinge soos biometriese en metaboliese parameters en oksidatiewe stres (ii) 
die effek van kroniese melatonienbehandeling op die respons van die hart op I/H beskadiging 
en (iii) die rol van herperfusie beskadiging op die aktivering van PKB/Akt en ERK42/44 (die sg 
RISK seintransduksiepad), die pro-apoptotiese p38MAPK, AMPK sowel as die uitdrukking van 
GLUT-4. 
Metodes 
Manlike Wistar rotte (200±20g) is ewekansig in vier groepe verdeel: (i) C, kontrole rotte wat ‘n 
standaard rotdieet en drinkwater sonder melatonien ontvang (ii) CM, kontrole rotte wat 
melatonien (4mg/kg/dag) ontvang (iii) D, dieet-geϊnduseerde vet rotte wat ‘n hoë kalorie dieet 
en drinkwater sonder melatonien ontvang (iv) DM, dieet-geϊnduseerde vet rotte wat melatonien 
(4mg/kg/dag) in die drinkwater ontvang. Na 16 weke van behandeling, is die rotte geweeg, 
bloed en hartweefsel gekollekteer vir biochemiese en molekulêre biologie bepalings. Harte is 
geperfuseer volgens die werkhartmodel, blootgestel aan iskemie/herperfusie vir evaluering van 
funksionele herstel en infarktgrootte. Uitdrukking en aktivering van PKB/Akt (Ser-473), 
ERKp42/p44 en p38MAPK van pre-en postiskemiese hartweefsel is met behulp van Western 
blot bepaal. Postiskemiese aktivering van AMPK (5’AMP-aktiveerde proteϊen kinase) (Thr-172) 
en GLUT-4 (glukose transporter) is op soortgelyke wyse bepaal. Serum en basislyn 
hartweefsel glutatioon (GSH) inhoud asook tiobarbituursuur reaktiewe substans (TBARS), 
gekonjugeerde diene (CD) en lipiedhidroperoksied (LOOH) konsentrasies is bepaal. 
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Resultate 
Die hoë kalorie diet het ‘n toename in liggaamsgewig, visserale vet, hartgewig, serum insulien, 
leptien, plasma trigliseried en lae HDL-cholesterol vlakke teweegebring. Bloed glukosevlakke 
was egter dieselfde in die vet en kontrole rotte. Miokardiale glutatioon, serum glutatioon, totale 
cholesterol, TBARS, LOOH, CD is nie deur die dieet beinvloed nie. Chroniese melatonien 
behandeling het die liggaamsgewig, visserale vet, hartgewig, plasma trigliseried, serum 
insulien en leptien, HOMA indeks verlaag (DM vs D, p<0.05) en die HDL-cholesterol verhoog 
in die dieetrotte, terwyl dit geen effek op hierdie parameters in kontrole rotte gehad het nie 
(uitgesonderd ‘n afname in liggaamsgewig, hartgewig en visserale vet). Melatonien 
behandeling het geen effek op hart of serum GSH en LOOH in kontrole en vet rotte gehad nie. 
Dit het egter die TBARS en CD in beide vet en kontrole rotte verlaag. Chroniese melatonien 
toediening het ‘n beduidende toename in basislyn fosfo PKB//totale PKB ratio en ‘n afname in 
fosfo p38MAPK/totale p38MAPK ratio teweegebring in harte van kontrole rotte, maar 
soortgelyke effekte is nie in die harte van die vet rotte waargeneem nie. Infarktgrootte is 
beduidend deur melatonienbehandeling verlaag in beide dieet en kontrole groepe (DM: 16.6± 
5.2%, D: 38.4 ±2.6% (p<0.001); CM: 12.8± 1.5%; C 30.4±1.0 (p<0.001). Na koronere arterie 
afbinding en 30 min van herperfusie, het melatonien die persentasie herstel van aorta omset 
(DM: 28.5± 6.5%; D: 6.2± 6.2%, p<0.01), kardiale omset ( DM: 44.4± 5.2%D: 26.6±5.1%, 
p<0.01) en totale werk (DM: 34.5 5.6%; D 20.4± 7.9%, p<0.05) in die harte van dieetrotte 
verbeter, terwyl dit sonder effek was in kontrole harte. Tydens herperfusie het harte van 
melatonienbehandelde rotte verhoogde aktivering van PKB/Akt (p<0.01) en ERKp42/p44 
(p<0.05) getoon, terwyl aktivering van p38MAPK verlaag is (p<0.05). Geen verskil in 
postiskemiese aktivering van AMPK en GLUT-4 uitdrukking is in beide kontrole en dieetrotte 
waargeneem nie. 
Gevolgtrekkings 
Ons het daarin geslaag om aan te toon dat chroniese melatonienbehandeling die ontwikkeling 
van dieet-geϊnduseerde metaboliese abnormaliteite beduidend kan voorkom en ex vivo 
miokardiale funksie verbeter. Melatonien het ook die hart teen iskemie/herperfusie beskadiging 
beskerm in beide kontrole en dieetrotte. Bogenoemde veranderinge het met aktivering van 
PKB/Akt en ERKp42/p44 gepaard gegaan. Die anti-oksidant effekte van melatonien was 
heelwaarskynlik hierby betrokke. 
Sleutelwoorde 
Anti-oksidant; miokardiale beskerming; dieet-geϊnduseerde vetsug; obesiteit; melatonien; 
iskemie/herperfusie beskadiging; insulienweerstandigheid. 
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CHAPTER ONE 
INTRODUCTION 
 
The prevalence of obesity continues to increase throughout the world. Obesity refers to an 
excess body fat accumulation that usually leads to health problems. People are defined as 
being obese if they have a BMI (body mass index) exceeding 30 kg/m2.  Overweight refers to a 
BMI between 25 and 30 kg/m2. Obesity has been recognized as a public health problem of 
pandemic proportions affecting both developed and developing countries (Haslam & James, 
2005).  Kelly et al. (2008) analyzed the global burden of obesity in 2005 and found that at least 
33.0% of the world’s adult population (1.3 billion people) was overweight or obese. Among 
them 300 million were obese.  It is predicted that up to 57.8% of the adult population (3.3 
billion people) could be either overweight or obese by 2030, if the actual trend continues.  
Wang et al. (2009) reported that by 2030 more than 85% of United States (US) adult 
population would become overweight or obese with as many as  51.1% of them being obese. 
In  the South African context, the prevalence of obesity has also reached epidemic proportions 
with almost 57% of the women and 29% of the men over the age of 30 years being identified 
as overweight or obese (Poane et al., 2002).  
 
Together with this alarming prevalence, obesity is associated with increased risk for numerous 
co-morbidities including type 2 diabetes, hypertension, cardiovascular diseases, obstructive 
sleep apnoea syndrome, osteoarthritis and some cancers (Guh et al., 2009). These figures 
clearly indicate that the financial burden on the government and society will increase due to 
increased health care expenditures attributable to obesity and its related complications 
(Haslam & James, 2005).  Importantly, obesity has been identified as an independent risk 
factor for cardiovascular diseases in general.  Cardiovascular disease is the world’s leading 
cause of morbidity and mortality and contributes to 29% of all deaths (16.7 million deaths) 
each year (Barry et al., 2008). Furthermore, metabolic syndrome which is the cluster of 
cardiovascular risk factors which include obesity, has also reached pandemic proportions. In 
most developed and developing countries between 20% and 30% of the adult population can 
be characterized as having the metabolic syndrome (Grundy, 2008) 
  
Acute coronary occlusion results in ischaemic heart disease, the leading cause of morbidity 
and mortality in the Western world and some developing countries including South Africa. 
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Here, it is the fifth highest cause of mortality (WHO, 2009) while it is the leading cause of 
mortality in the Western Cape Province (Bradshaw et al., 2004).  The clinical consequences of 
ischaemic heart disease include angina pectoris, acute myocardial infarction (AMI), chronic 
post myocardial infarction, heart failure and sudden cardiac death.  Obesity and related 
metabolic abnormalities including insulin resistance, dyslipidaemia, and hypertension have 
been associated with myocardial infarction or necrosis of the myocardium (Fedorowski et al., 
2009; Prasad et al., 2009; Ranjith et al., 2007).  In addition, independently of other co-
morbidities such as hypertension, atherosclerosis and myocardial infarction, an increased 
adiposity alone has been shown to impair both cardiac diastolic and systolic function 
(Mittendorfer et al., 2008). It has been demonstrated that obesity increases left ventricular 
hypertrophy and exacerbates myocardial susceptibility to ischaemia and reperfusion (I/R) 
injury (Du Toit et al., 2008). However, although obesity remains the driving force behind the 
prevalence of myocardial infarction, the link between obesity and myocardial infarction is 
complex and not yet fully understood. 
 
The unifying hypothesis linking obesity (central obesity) and its cardiovascular complications is 
an increase in oxidative stress (condition characterized by an elevated reactive 
oxygen/nitrogen species production and insufficient antioxidant capacity) associated with a 
dysregulation of adipose tissue-derived proteins (adipocytokines), each predisposing the 
obese individual to the insulin resistance state (Furukawa et al., 2004; Vincent et al., 2006; 
Evans et al., 2002 & 2005).  Excessive reactive oxygen/nitrogen species generation has been 
shown to play a crucial role in pathogenesis of cardiovascular disorders such as heart failure 
and myocardial ischaemia/reperfusion injury (Dhalla et al., 2000a&b; Molavi & Mehta, 2004; 
Ferrari et al., 2004). Therefore the use of antioxidants to treat obesity and its cardiovascular 
complications seems logical.  In addition, the beneficial effects of antioxidant treatment on I/R-
induced myocardial damage have been demonstrated (Sethi et al., 2000; Abe et al., 2008).   
Finally, oxidative stress has recently been shown to play a key role in the metabolic syndrome 
(Hopps et al., 2009; Roberts et al., 2009).  Therefore, the prevention of an increase in oxidative 
stress may be crucial to stop the development of obesity-related metabolic complications.  
 
Melatonin or N-acetyl-5-methoxytryptamine, the hormone which is primarily secreted by the 
pineal gland, has powerful antioxidant properties (Tan et al., 2007).  Unlike other antioxidants, 
it is a small, highly lipophilic and hydrophilic molecule able to cross all morphological barriers 
and to act not only in every cell but also within every subcellular compartment (Pandi-Perumal 
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et al., 2006).  Melatonin is involved in a wide range of physiological functions in humans and 
animals (Pandi-Perumal et al., 2006).  Acute melatonin treatment protects the heart against I/R 
injury  via both its direct free radical scavenging activities and its indirect actions in stimulating 
antioxidant enzymes (Reiter & Tan, 2003; Sahna et al., 2005; Petrosillo et al., 2009; Lochner et 
al., 2006; Genade et al., 2008). The long-term administration of melatonin also reduced 
myocardial infarction (Lochner et al., 2006) in lean animals, indicating its potential future 
therapeutic use. Chronic administration of melatonin was associated with amelioration of 
physiological changes associated with obesity (Hussein et al., 2007; Prunet-Marcassus et al., 
2003;  She et al., 2009), suggesting potential beneficial effects of melatonin  in obesity 
management.  However, to our knowledge, the effects of melatonin in obesity are incompletely 
elucidated. In addition, the effects of melatonin on the heart in obesity remain unknown. The 
preventive effects of chronic melatonin administration starting before the establishment of 
obesity have to be established.  
 
In order to expand our knowledge of some of these outstanding issues, the effects of chronic 
melatonin treatment were investigated in rat model of diet-induced obesity. We focused on the 
effects of melatonin on myocardial function and ischaemia/reperfusion injury. Thus, to gain 
more insight into the overall effects of melatonin treatment in obese animals compared to lean 
animals, particularly on the ischaemic heart, we review the current literature on myocardial 
ischaemia/ reperfusion injury and the impact of obesity on cardiovascular disease including the 
obesity-induced systemic and cardiac alterations. The effects of melatonin on the heart as well 
as its actions in obesity are also reviewed.  The present study adds knowledge gained in 
previous studies done on acute and short-term melatonin treatment on the heart. This is the 
first study to investigate the effects of chronic melatonin supplementation on the heart in 
obesity.  
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CHAPTER TWO 
LITERATURE REVIEW 
 
2.1. ISCHAEMIA-REPERFUSION INJURY: AN OVERVIEW 
2.1.1. Concepts 
  
The term “ischaemia” refers to an insufficient blood supply to any area of the body. When 
applied to the myocardium, it refers to the condition in which the blood flow to the heart muscle 
is diminished and thus the supply of oxygen and nutrients to the myocardium is inadequate or 
insufficient to maintain normal oxidative metabolism (Jennings & Yellon, 1992).  The pivotal 
feature of this condition is that oxygen supply to the mitochondria is inadequate to support 
oxidative phosphorylation (Solaini & Harris, 2005). Clinical myocardial ischaemia generally 
results from the formation of atherosclerotic lesions in the coronary arteries and when this 
situation is not rectified, it leads to myocardial infarction (MI) or cell death (Opie, 2004).   
Early reperfusion is necessary for maintaining cell viability and protecting the heart against 
myocardial infarction. However, reperfusion itself induces severe and irreversible damage to 
the myocardium and coronary arteries. This phenomenon is known as “myocardial reperfusion 
injury” (Yellon & Hausenloy, 2007). In most instances, the concept of ischaemia/reperfusion 
injury (I/R) refers to a mixture of injury induced by sustained ischaemia and reperfusion 
(Skyschally et al., 2008). This section briefly describes myocardial alterations/changes 
associated with ischaemia followed by reperfusion. The description of vascular alterations is 
beyond the focus of our study (for review see Carden & Granger, 2000 and Opie, 2004). 
2.1.2. Ischaemic injury 
  
Myocardial ischaemia results in damage of which the gravity (e.g., reversibility or irreversibility) 
depends on severity of the coronary flow reduction, and the length of the ischaemic insult as 
well as the location being affected (e.g., possibility of collateral flow).  As Skyschally et al. 
(2008) have noted, it is technically impossible to determine in a distinct piece of myocardium 
whether the observed damage/injury (e.g., necrosis) is exclusively caused by ischaemia or 
reperfusion or the combination of both. The two forms of injury induced by ischaemia are 
defined as being reversible and irreversible damage. 
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2.1.2.1. Levels of injury 
 
Depending on the duration of ischaemia, three levels of myocardial injury have been identified 
namely arrhythmias, contractile dysfunction and irreversible damage. With the first, short term 
ischaemia (less than 5 minutes) leads to an abrupt decrease in oxygen demand associated 
with a reduction in contractility as the blood flow decreases. This level is associated with 
arrhythmias (due to electrical alterations including ions channel or ion homeostasis disruption) 
(Roden et al., 2002), does not promote ventricular contractile dysfunction and is reversible on 
reperfusion (Powers et al., 2007).  The second, ischaemic periods of up to 5 to 20 minutes, 
leads to cardiac injury commonly known as myocardial stunning which, first described by 
Heyndrickx et al. (1975), refers to a reversible regional depression of myocardial contractility 
that persists after reperfusion despite the normalisation of blood flow. It is primarily 
characterized by a reversible contractile dysfunction due to a depressed energy production 
and an alteration in ion homeostasis without cardiac myocyte death (Roden et al., 2002).  The 
third, ischaemic periods beyond 20 to 30 minutes, leads to irreversible damage characterized 
by cell death or myocardial infarction (Verma et al., 2002; Skyschally et al., 2008).  Previously, 
necrosis, also termed “oncosis” was regarded as the only mode of cell death, but it is currently 
known that cells may also die via apoptosis and autophagy (Opie et al., 2004).  Necrosis is 
described as an accidental or spontaneous cell death characterized by organelle swelling and 
membrane rupture, independent of energy supply and caspase cleavage. Apoptosis or 
programmed cell death type I is characterized by cell shrinkage with DNA fragmentation and 
membrane blebbing. It is an energy-requiring and caspase-dependent process. Autophagy or 
programmed cell death type II, differs from apoptosis as it is caspase-independent and 
morphologically resembles necrosis (for review see Buja & Weerasinghe, 2008; Kang & Izumo, 
2003).   
 
The major determinants of the final infarct size (amount of tissue irreversibly damaged) include 
the size and the location of the perfusion territory distal of the coronary occlusion, the residual 
blood flow during ischaemia through collaterals (the severity of ischaemia), the temperature, 
and the hemodynamic situation during ischaemia (Skyschally et al., 2008). The mechanism of 
infarction will be described later after the description of reperfusion injury. 
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2.1.2.2. Metabolic and ultrastuctural changes associated with ischaemia  
  
It has been observed that ischaemia is associated with ultrastructural alterations characterized 
by swelling of the sarcoplasmic reticulum, myofibril contracture, and mitochondrial damage 
including swelling, decreased matrix density and partial loss of cristae (Puri et al., 1975; 
Jennings & Ganote, 1976; Schaper et al., 1986).  These ultrastructural changes are linked to 
metabolic changes which include depletion of energy stores (Puri et al., 1975); accumulation of 
metabolic by-products such as lipid metabolites, intracellular acidosis, intracellular calcium 
(Ca2+) accumulation, reactive oxygen species and increased Na+   which, together with the loss 
of K+ during ischaemia, is largely responsible for the increased cytosolic Ca2+ and the induction 
of mitochondrial dysfunction as well as  the impairment of contractile function (Iwai et al., 2002; 
Murphy & Steenbergen, 2008). 
  
2.1.3. Myocardial reperfusion injury 
  
It has been mentioned that the myocardium can tolerate 15 to 20 minutes of ischaemia (Verma 
et al., 2002; Skyschally et al., 2008) and the restoration of blood flow may result in 
arrhythmias, contractile dysfunction, microvascular impairment (endothelial dysfunction) as 
well as irreversible myocardial damage (infarction) (Kloner, 1993).  “Lethal reperfusion injury” 
refers to the damage caused by reperfusion, resulting in death and loss of cells that were only 
reversibly injured during the preceding ischaemic episode (Kloner, 1993).  It takes place in the 
first minutes of reperfusion and, although reperfusion limits the progression of ischaemic injury, 
it worsens ischaemic alterations.  Lethal reperfusion injury may contribute up to 50% towards 
the final size of the myocardial infarct (Yellow & Hausenloy, 2007).  I/R-induced contractile 
dysfunction is mediated by the generation of reactive oxygen/nitrogen species (Bolli et al., 
1988 & 1989), a cytosolic calcium overload (Du Toit & Opie, 1992) and an altered contractile 
protein structure (Kloner et al., 1989).  
 
Other types of myocardial dysfunction are reperfusion arrhythmias (Roden et al., 2002), 
stunning (Dorge et al., 1998; Bolli & Marbán, 1999) and the no-reflow phenomenon (Ito, 2006) 
which are beyond the focus of our study. We will only focus on irreversible injury and 
particularly myocardial infarction.    
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2.1.4. Mechanism of myocardial infarction  
  
A myocardial infarction is the result of a prolonged ischaemic event as previously mentioned. 
The major effects of ischaemia are poor oxygen delivery (hypoxia) and poor washout of 
metabolites including lactate and protons associated with a severe cellular acidosis (low pH). 
The resultant depressed mitochondrial metabolism and the consequent impairment in 
glycolysis and fatty acid metabolism lead to a decreased energy production and inhibition of 
ions pumps with a subsequent alteration in ion homeostasis (increased Ca2+ and K+ loss). In 
addition, there is membrane damage by fatty acid metabolites and free radicals or as a result 
of lysosomal activation induced by severe cellular acidosis. All these reactions (leading to 
proteolysis, contracture and mitochondrial damage) exacerbate the ischaemic insult and 
culminate in cell death or infarction (Opie, 2004).   
 
It is well established that reperfusion injury is also mediated by excessive oxygen/nitrogen 
radical generation, increased Ca2+ overload, microvascular injury (endothelial dysfunction), and 
altered myocardial metabolism as well as by the restoration of physiological pH. In addition, 
inflammation and the opening of mitochondrial permeability transition pore (MPTP) (non 
selective pore) contribute to reperfusion injury (Buja et al., 2005; Yellow & Hausenloy, 2007).  
Indeed, during reperfusion, reactive oxygen species (ROS) are generated by xanthine oxidase 
(mainly from endothelial cells) and the re-energized electron transport chain (ETC) in the 
cardiomyocyte mitochondria as well as by NADPH oxidase (mainly from neutrophils) (Dhalla et 
al., 2000a). ROS mediate myocardial injury by: 1) inducing mitochondrial permeability 
transition pore (MPTP) opening, 2) acting as neutrophil chemo-attractants, 3) mediating 
dysfunction of the sarcoplasmic reticulum, 4) contributing to intracellular Ca2+ overload and 5) 
damaging essential molecules (lipid, DNA, protein). MPTP opening induces mitochondrial 
swelling. The rapid washout of lactic acid and metabolites together with the re-energized ETC 
in the setting of increased intracellular Ca2+ results in cardiomyocyte death by hypercontracture 
(Powers et al., 2007). 
2.1.5. New cardioprotective strategies: an opened road 
  
The purpose of the cardioprotective strategies or injury prevention is directed at reducing 
myocardial I/R injury i.e., the reduction of infarct size and the full restoration of myocardial 
function. Two accepted endogenous mechanisms are ischaemic preconditioning (IPC) and 
postconditioning (IPOC), which refer to the cardioprotection obtained by applying short periods 
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of ischaemia separated by short reperfusion intervals either before the index ischaemia or at 
the beginning of reperfusion, respectively (Jennings et al., 1991; Murry et al., 1986; Zhao & 
Vinten-Johansen, 2006).  Because of the need to intervene before the index ischaemic event, 
IPC is clinically not possible.  Recently, a better understanding of the mechanisms of IPC and 
IPOC has opened the road to other possibilities in cardioprotection including remote ischaemic 
“conditioning” and pharmacological conditioning (for review see Hausenloy & Yellon, 2008).  
The first refers to short ischaemic periods applied to organs other than the heart (muscle for 
example) which confers cardioprotection.  The second involves the use of pharmacological 
agents (in place of IPOC or IPC) that are able to activate the same intracellular signalling 
pathways as do IPC or IPOC.  In view of this, research has focused on activation of the 
reperfusion injury salvage kinase (RISK) pathway which includes  protein kinase B (PKB/Akt) 
and extracellular regulated kinases 42 and 44 (ERK42/44), the inhibition of  proteins kinase C-
delta and opening of mitochondrial permeability transition pore (MPTP) (for reviews see 
Hausenloy & Yellon (2007), Yellon & Hausenloy (2007) and  Hausenloy (2009)).   
 
Nowadays, there is an increasing need for effective cardioprotective strategies that are able to 
improve the clinical outcomes of patients with ischaemic heart disease, which is the worldwide 
number one killer (Lopez et al., 2006).  In this regard, we have recognized that I/R injury is 
influenced by cardiovascular risks factors (e.g., diabetes, obesity, hyperlipidaemia, 
hypercholesterolemia, ageing) which may favour or abolish cardioprotection induced by pre or 
post-conditioning (Ferdinandy et al., 2007; Balakumar et al., 2009). Thus, from our 
understanding of pre and postconditioning, the road has been opened to cardioprotection; 
however, an ideal strategy must retain its efficacy even under pathological conditions. This 
means that it must not only be effective in lean normal subjects but also in obese or diseased 
subjects. To gain more insight into cardioprotection in obesity, the impact of obesity on 
cardiovascular disease is reviewed in the following section. The effects of obesity on I/R injury 
in particular are discussed in obesity-related cardiac alterations (section 2.2.3). 
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2.2. OBESITY AND CARDIOVASCULAR DISEASE 
 
2.2.1. Introduction 
 
Obesity is defined as a chronic metabolic disorder characterized by an increased amount of 
body fat to the extent that adverse health consequences may occur.  Several epidemiological 
and animal studies have established a strong association between obesity and the 
development of cardiovascular disorders including coronary heart disease, heart failure and 
sudden death (Zalesin et al., 2008; Poirier et al., 2006; Abel., 2008; Harmancey et al., 2008; 
Wong et al., 2007; Chess & Stanley, 2008). The link between obesity and cardiovascular 
disease and the mechanism underlying the development of diet-induced metabolic 
abnormalities still remain poorly elucidated.  Increased fat accumulation and adipose tissue-
derived hormone abnormalities, lipotoxicity with increased oxidative stress and insulin 
resistance, have been suggested to be the possible mechanisms linking obesity to its 
cardiovascular complications (Van Gaal et al., 2006; Grattagliano et al., 2008; Cornier et al., 
2008; Chess & Stanley, 2008; Savage et al., 2007). Thus, this section discusses the obesity-
induced metabolic alterations that may contribute to cardiac alterations. Vascular alterations as 
well as atherosclerosis, hypertension and other obesity-related disorders are beyond the focus 
of our study (for review see Poirier et al., 2006).  
 
2.2.2. Obesity-induced systemic metabolic alterations 
 
2.2.2.1. Metabolic syndrome (MS) 
 
 Obesity, particularly central obesity, leads to a cluster of metabolic abnormalities associated 
with increased cardiovascular disease risk (Eckel et al., 2005).  This clustering has been 
termed the metabolic syndrome (MS), a concept  proposed and published by the WHO and 
other medical groups including the National Cholesterol Education Program’s Adult Treatment 
Panel III (NCEP ATPIII) for an easy clinical diagnosis and treatment of an increased 
cardiometabolic risks (Cornier et al., 2008).  Metabolic syndrome components include visceral 
obesity, insulin resistance, glucose intolerance, atherogenic dyslipidaemia, raised blood 
pressure, and a pro-inflammatory state (Opie, 2007).   The concept of metabolic syndrome has 
been the subject of debate regarding its definition and utility (Cornier et al., 2008; Raeven, 
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2004). Indeed, beside cardiovascular disease as the primary clinical outcome of the metabolic 
syndrome, it has been demonstrated that metabolic syndrome is also associated with other 
pathological conditions such as type II diabetes mellitus, non alcoholic fatty liver disease, 
reproductive disorders and some cancers (Pothiwala et al., 2009). Therefore, the concept of 
metabolic syndrome must be considered as an evolving concept and its definition could be 
extended to its new additional clinical components (Cornier et al., 2008; Huang, 2009). 
 
The pathophysiology of metabolic syndrome has been largely reviewed (Cornier et al., 2008; 
Eckel et al., 2005; Grundy, 2004; Pothiwala et al., 2009; Steinberger et al., 2009). Its 
progressive development has been represented (see fig.2.1) as a result of the intersection 
between obesity and insulin resistance which is characterized by abdominal obesity, abnormal 
circulating lipids, and high blood pressure and glucose (Steinberger et al., 2009). From this 
intersection emerges an increase in visceral fat, oxidative stress, inflammation, adipocytokines 
dysfunction, and vascular abnormalities, and increased circulating cortisol; a hallmark of 
cardiovascular disease and type 2 diabetes mellitus (Steinberger et al., 2009).    
Oxidative 
stress
Vascular 
abnormalities
Inflammation
Adipocytokines
Visceral fat Insulin 
resistance
Obesity
Abdominal obesity
Abnormal lipids
Metabolic
syndrome
High blood pressure
High glucose
T2 DMCVD
Cortisol
Ethnicity Genetics
 
Figure 2- 1 Schematic representation of components of the metabolic syndrome (MS) 
CVD, cardiovascular disease; T2DM, type 2 diabetes mellitus (adapted from Steinberger et al., 2009). 
 
Obesity has been referred to as the only central and reversible cardiovascular risk factor that 
favourably influences all other associated cardiovascular risk markers including high-density 
lipoprotein cholesterol, high-sensitivity C-reactive protein, hypertension, low-density lipoprotein 
cholesterol, triglycerides and renin-angiotensin-aldosterone system/sympathetic nervous 
system (Zalesin et al., 2008). In addition, the expression of these metabolic conditions has 
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been found to be the result of complex interactions between genetics or ethnicity and 
environmental factors including life style (physical activity, dietary intake, television-watching 
habits) (Zalesin et al., 2008; Steinberger et al., 2009). Consequently, the increasing obesity 
pandemic is the driving force behind the actual rising prevalence of the metabolic syndrome 
where increased adiposity and subsequent metabolic alterations play an important role 
(Grundy, 2008). 
 
2.2.2.2. Role of adipose tissue in diet-induced metabolic alterations 
 
The metabolic syndrome by definition has been associated with increased adiposity (Grundy, 
2008).  It is now known that adipose tissue plays a crucial role in normal and pathological 
processes in the body (Vazquez-Vela et al., 2008). Under normal conditions, adipose tissue 
acts as a store of the surplus energy during increased food intake or reduced energy 
expenditure (Sethi & Vidal-Puig, 2007). The surplus energy is deposited in adipose tissue in 
the form of neutral triglycerides (Sethi & Vidal-Puig, 2007). As a consequence, circulating free 
fatty acids (FFA) increase and excessive fats accumulate inappropriately in non-adipose 
tissues, such as liver and muscles, including the heart, and negatively affect their normal 
metabolism and function (Christoffersen et al., 2003; Shimabukuro, 2009). This situation has 
been referred to as steatosis-induced lipotoxicity and plays an important role in cardiac 
alterations induced by obesity (Banerjee & Peterson, 2007).   
 
Beside its role as energy store, it is now recognized that adipose tissue also behaves as a 
secretory and endocrine organ releasing a range of bioactive substances into the circulation 
(Kershaw & Flier, 2004). These substances have both local (autocrine and/or paracrine) and 
systemic (endocrine) actions in the regulation of a variety of physiological/metabolic processes 
including adipocyte differentiation, local and systemic inflammation, overall energy balance, 
blood pressure, and glucose and lipid metabolism (Ahima & Osei, 2008; Matsuzawa, 2006).  
The role of adipose tissue as a secretory organ will be summarized in the following section. 
 
2.2.2.2.1. Adipose tissue-derived secretion 
 
Adipose tissue secretes a range of bioactive substances including adipocytokines (also called 
adipokines) such as leptin, adiponectin, resistin, visfatin, apelin, omentin, and chemerin 
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(Kershaw & Flier, 2004; Vazquez-Vela et al., 2008; Matsuzawa, 2006).  Others that are also 
secreted by other tissues include tumor necrosis factor α (TNF-α), interleukin 6 (IL–6), 
monocyte chemo-attractant protein 1 (MCP-1), lipoprotein lipase, plasminogen activator 
inhibitor 1 (PAI-1), and angiotensinogen (AT) (Vazquez-Vela et al., 2008).   
 
Obesity results in dramatic alterations in the release of bioactive substances by adipose tissue 
(see fig.2.2).  Compared to normal subjects, circulating leptin levels are elevated in obesity (Lin 
et al., 2000) and contrary to expectations, circulating adiponectin levels are decreased in 
obese subjects despite being produced in adipose tissue (Arita et al., 1999).  Similar to leptin, 
apelin, angiotensin II (ATII), TNF-α and IL-6 are elevated in obesity (Du Toit et al., 2008; Maury 
et al., 2009).  
  
Adipocytokines are active in a range of processes, such as the control of nutritional intake 
(leptin), insulin sensitivity and inflammatory processes (TNF-α, IL-6, resistin, visfatin, 
adiponectin) (Vazquez-Vela et al., 2008). Adipocytokines have been viewed as a bridge 
connecting obesity and insulin resistance (for review see Zhuang et al., 2009) and are 
implicated in cardiovascular function (for review see Gualillo et al., 2007). Though other 
adipose tissue-derived secretions have been shown to play an important role in systemic 
metabolic alterations associated with obesity (Qatanani & Lazar, 2007; Vazquez-Vela et al., 
2008), only the role of leptin and adiponectin will be briefly discussed in this section.  
 
2.2.2.2.1.1. Leptin 
 
Leptin is a non glycosylated peptide hormone mainly produced by adipocytes (Zhang et al., 
1994).    It is encoded by the obese (ob) gene and plays an important role in food intake and 
body weight gain regulation in diet-induced obesity (Lin et al., 2000).  Leptin has anorexic 
properties and acts as regulator factor in the hypothalamus inducing a reduction in food intake 
and an increase in energy expenditure.  In peripheral tissues, leptin appears to prevent fat 
deposition in non-adipose tissue, thus enhancing insulin sensitivity in muscle and fat and 
preventing “lipotoxicity” of pancreatic β-cells (Zhuang et al., 2009).  At a certain stage of food 
intake leptin actions become defective and leptin resistance occurs (Lin et al., 2000).   
 
Using the mouse model of diet-induced obesity, Lin et al. (2000) have shown that increased 
body weight gain was associated with an elevation in circulating leptin levels.   
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In this study, during 19 weeks of feeding, they found that in the early stage of obesity (from 
one week) leptin levels were increased and mice responded to exogenous leptin injection.  At 
the middle stage (from eight weeks onwards), the increase in leptin levels was accompanied 
by a reduction in food intake and a gradual loss of leptin sensitivity (i.e., variable with the dose 
of leptin injected in the test). At the later stage (from fifteen weeks), they found that there was 
an increase in food intake associated with a loss in leptin sensitivity.  Although the mechanism 
causing central leptin insensitivity is not fully understood, it has been suggested that the 
presence of high levels of leptin may induce desensitization of the hypothalamic leptin receptor 
by down-regulation of leptin receptor density or even saturation of the receptors with 
endogenous leptin as a result of the elevated leptin output (Widdowson et al., 1997).   
 
Elevated serum leptin levels are associated with hyperinsulinaemia and correlate positively 
with visceral fat accumulation (Kim-Motoyama et al, 1997). Leptin and insulin (secreted by 
pancreatic ß-cells) are considered as peripheral adiposity signals to the central nervous 
system in the control of food intake and metabolism where the secretion of insulin increases 
with meals and circulating nutrients (Benoit et al., 2004).  During the development of diet-
induced obesity, there is a crosstalk between leptin and insulin signalling (Morrison et al., 
2009).  Leptin can modulate insulin sensitivity and/or be induced by insulin (Morrison et al., 
2009). Hyperinsulinaemia is associated with hyperleptinaemia and a compensatory reduction 
in leptin sensitivity (leptin resistance) through dysregulation of the adipose tissue-hypothalamic 
axis (Almanza-Perez et al., 2008; Anubhuti & Arora, 2008; Benoit et al., 2004).  Leptin 
resistance is reversible. It has recently been shown that weight loss by prolonged calorie 
restriction was accompanied with a reduction in leptin levels and improvement of obesity and 
its related metabolic abnormalities (Hammer et al., 2008).   
 
With regard to its cardiovascular effects, there is a strong association between leptin 
resistance and the activation of the sympathetic nervous system, prothrombotic effects, 
endothelial dysfunction, vascular smooth muscle hypertrophy, myocardial remodelling, heart 
failure, atherosclerosis and hypertension, and other related metabolic disorders (Gualillo et al., 
2007; Lago et al., 2008).  
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2.2.2.2.1.2. Adiponectin  
  
Adiponectin has been shown to be the link between obesity and its cardiovascular 
complications (Shibata et al., 2009). It has antiatherogenic (Lara-Castro et al., 2007), 
antidiabetic and anti-inflammatory properties (Matsuzawa, 2006). Plasma adiponectin 
concentrations have been found to correlate negatively with waist circumference, visceral fat 
area, serum triglyceride concentration, fasting plasma glucose, fasting plasma insulin, and 
systolic and diastolic blood pressure (Ryo et al., 2004).  Adiponectin administration increases 
fatty acid oxidation in the muscle and potentiates insulin-mediated inhibition of hepatic 
gluconeogenesis (Matsuzawa, 2006).  It has also been shown to be cardioprotective. 
Administration of adiponectin protected the heart against ischaemia/reperfusion injury by 
reducing myocardial infarct size through activation of 5’AMP-activated protein kinase (AMPK) 
and by the suppression of cardiac production of TNF-α through activation of the 
cyclooxygenase-2-prostaglandin-E2 (COX-2–PGE2) pathway (Shibata et al., 2005).  A recent 
study by Gonon et al. (2008) demonstrated that adiponectin protects against myocardial 
ischaemia/reperfusion injury via activation of AMPK, protein kinase B (PKB)/Akt and nitric 
oxide.  Because adiponectin is downregulated in obese subjects (Arita et al, 1999), its 
circulating levels have been identified as the clinical marker of cardiometabolic diseases 
(Matsuzawa, 2006). 
 
In cardiovascular disease, downregulation of circulating adiponectin (hypoadiponectaemia) has 
been associated with increased visceral fat accumulation, hyperlipidaemia, endothelial 
dysfunction, hyperglycaemia, inflammatory atherosclerosis, increased coronary heart disease 
risk and hypertrophy (Gualillo et al., 2007). The mechanism of this downregulation is not yet 
fully understood. The downregulation of adiponectin is associated with elevated tumor necrosis 
factor-α (TNF-α) levels in obesity.  Incubation of human visceral adipose tissue from patients 
without diabetes mellitus with TNF-α (5.75 nmol/l), has shown a decrease in adiponectin 
mRNA expression of 97% (Hector et al., 2007).  This could explain the association of elevated 
TNF-α secretion with reduced levels of adiponectin seen in obese subjects (Arita et al., 1999).  
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Figure 2- 2 Obesity and adipocyte response (Vazquez-Vela et al., 2008)   
 
Adipose tissue-derived proteins secretion during energy equilibrium (A) and obesity (B) 
 During energy equilibrium without obesity, adipocytes are leptin responsive and non-hypertrophic and, 
therefore, non-adipose tissues are leptin and insulin sensitive. Under these conditions adipocytes 
secrete adipocytokines (leptin and adiponectin) to stimulate insulin sensitivity and fatty acids (FA) 
oxidation with increased AMPK activation. This is characterized by increased glucose uptake, reduced 
circulating insulin and glucose levels. At the same time, adipocytokines that promote insulin resistance 
(apelin and resistin) are reduced. During obesity, adipocytes are hypertrophic and non-adipose tissues 
become resistant to leptin and insulin action. Adipocytes secrete high amounts of FA as well as 
adipocytokines that promote insulin resistance resulting in ectopic accumulation of lipids (lipotoxicity) in 
pancreas, liver and skeletal muscle. TNF-α, IL-6, apelin and resistin secretion increases while 
adiponectin decreases. This is associated with elevated leptin production and leptin resistance 
(Vazquez-Vela et al., 2008). 
 
2.2.2.3. Obesity-induced dyslipidaemia   
  
It is well established that obesity is associated with circulating lipid abnormalities or 
dyslipidaemia (Franssen et al., 2008).   This entails dysregulation of lipid metabolism involving 
several different processes (lipoprotein hydrolysis, fatty acids uptake, synthesis, and 
esterification) leading to an increase in serum triglyceride and free fatty acids (FFA) levels 
combined with the deposition of triglyceride in non-adipose tissue (Franssen et al., 2008). The 
term “Atherogenic lipoprotein phenotype” or “lipid triad” is used to describe a common form of 
  16
dyslipidaemia, characterized by three lipid abnormalities. These include increased plasma 
triglyceride levels, decreased high density lipoprotein- cholesterol (HDL-c) concentrations and 
the presence of small dense low density lipoproteins (sdLDL) particles (Bamba & Rader, 
2007).  Atherogenic dyslipidaemia is one of the important elements used for the diagnosis of 
metabolic syndrome (Grundy et al., 2005). It has been described as an early feature of the 
metabolic syndrome and frequently precedes glucose intolerance (Reaven, 1988).   
 
The mechanism of development of dyslipidaemia has been intensively reviewed (Chan et al., 
2004; Vinik, 2005, Howard et al., 2003). Dyslipidaemia results from the action of 
hyperinsulinaemia on lipoprotein metabolism (Avramoglu et al., 2006).  The reduction in high 
density lipoprotein-cholesterol (HDL-c) may result from a reduction in flux of apolipoproteins 
and phospholipids from chylomicrons and very low density lipoproteins (VLDL) particles, which 
are normally used in HDL-c maturation (Franssen et al., 2008).  In addition, an increase in 
circulating FFA and hepatic insulin resistance, accompanied by increased apolipoprotein-B 
(Apo-B), induce  the assembly and secretion of VLDL by the liver leading to  an overall 
increase in serum  triglyceride or hypertriglyceridaemia  and a reduced    HDL-c (Avramoglu et 
al., 2006).    
 
 Although an increase in low-density lipoprotein cholesterol (LDL-c) levels is a cardiovascular 
risk factor, it is not a component of the metabolic syndrome (Grundy, 2008).  In fact, structural 
changes occur in LDL-cholesterol particles, which become smaller, dense and more 
atherogenic. The obesity-induced atherogenic dyslipidemia has been implicated in the genesis 
of atherosclerosis (Mittendorfer et al., 2008; Libby, 2002). Hence, the increased risk of 
coronary heart disease in obesity is in part due to its strong association with atherogenic 
dyslipidaemia (Bamba & Rader, 2007).  
 
2.2.2.4. Obesity- induced insulin resistance  
  
2.2.2.4.1. Concept of insulin resistance 
 
Insulin is a pleiotropic hormone produced and released into circulation by pancreatic β-cells 
with effects on metabolism and various cellular processes in different tissues of the body 
including adipose tissue, liver and muscle (Jellinger, 2007).  
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Insulin stimulates glucose uptake in skeletal muscle and the heart, suppresses the production 
of glucose and very low density lipoprotein (VLDL) in the liver, and inhibits FFA release from 
adipose tissue and synthesis of proteins from amino acids (Kahn & Flier, 2000).  The concept 
of insulin resistance refers to the condition in which the body produces insulin but does not 
respond to it properly because of a decreased cellular sensitivity to its effects on glucose 
uptake, metabolism and storage (Muniyappa et al., 2008).  
 
Based upon the relationship between insulin resistance, hyperglycaemia, dyslipidaemia, and 
hypertension as mediators for cardiovascular disease, Reaven created the concept of 
syndrome X or insulin resistance syndrome as a cluster of common metabolic abnormalities 
and clinical outcomes associated with insulin resistance (Reaven, 1988).  Insulin resistance is 
associated with elevated circulating fasting insulin levels (Du Toit et al., 2008; Kim & Reaven, 
2008).  It can be measured by various methods including amongst others fasting plasma or 
serum insulin concentration, quantitative insulin sensitivity check index (QUICK index), and 
homeostasis model assessment (HOMA) index (Muniyappa et al., 2008). The HOMA index is 
calculated as the product of fasting insulin (mU/L) and glucose concentration (mmol/L) divided 
by 22.5. To gain more insight into the phenomenon of insulin resistance in obesity and its 
possible interaction with melatonin treatment, its mechanism of action and signalling are 
summarized below. 
 
2.2.2.4.2. Mechanisms of obesity-induced insulin resistance 
 
It is well established that high fat/calorie feeding causes obesity and the subsequent 
development of insulin resistance (DeFronzo & Ferrannini, 1991; Haag & Dippenaar, 2005).  It 
has been demonstrated that rats with diet-induced obesity developed insulin resistance and 
dyslipidaemia with (Lima-Leopoldo et al., 2008) or without (Du Toit et al., 2008) glucose 
intolerance. This insulin resistance was accompanied by hyperleptinaemia (Dourmashkin et 
al., 2005). It could also be developed in mouse (Lin et al., 2000; Thakker et al., 2006), and 
rabbit (Zhao et al., 2008) models of diet-induced obesity.  
 
Obesity is the most important factor in the aetiology of insulin resistance (Cornier et al., 2008; 
Raeven, 1988). Genetic and ethnic predisposition including family history, increased circulating 
free fatty acids (FFA) and tumor necrosis factor-α (TNF-α) associated with the  dysregulation 
of  adipose tissue-derived secretion (see fig.2.2) have been mentioned as factors that 
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influence the development of insulin resistance (Mlinar et al., 2007).  In particular, elevated 
circulating free fatty acids in obesity are identified as the driving force behind insulin resistance 
(Eckel et al., 2005).  However, not all overweight/obese persons develop insulin resistance and 
a normal weight does not equate to insulin sensitivity.  For example, the study done by 
McLaughlin et al. (2004) has found that among people who developed insulin resistance 36% 
were obese (BMI ≥ 30.0 kg/m2), 30% overweight or obese (BMI ≥ 25kg/m2)  while 16% were of 
normal weight (BMI ≤25kg/m2).   
 
The mechanisms of obesity induced insulin resistance are presented in fig.2.3 and 2.4.  Briefly, 
in obesity, elevated tumour necrosis factor-alpha (TNF-α) induces the release of free fatty 
acids (FFA) from adipose tissue into the circulation. In the liver, the deposition of FFA with the 
action of apolipoprotein-B, results in increased accumulation of triglyceride (TRIG) and an 
increased secretion of very low density lipoprotein (VLDL). Together with this there is a 
decrease in serum high density lipoprotein-cholesterol (HDL-C) and an increase in low density 
lipoprotein-cholesterol (LDL-C) accompanied by gluconeogenesis.  In muscle, FFA and TNF-α 
inhibit insulin-mediated glucose uptake pathways which result in a reduced insulin sensitivity 
contributing to hyperglycaemia. Accumulation of excessive FFA as triglyceride droplets in 
muscle and other non-adipose tissues can induce excessive reactive oxygen species 
production and increase oxidative stress which is also implicated in the pathogenesis of insulin 
resistance (Grattagliano et al., 2008). The obesity-induced oxidative stress is discussed in 
section 2.2.2.5.    
 
Other factors such adipocytokines have been implicated as the link between increased 
adipose tissue accumulation and insulin resistance (Zhuang et al., 2009).  Adiponectin 
improves insulin sensitivity favouring glucose and fatty acid oxidation in muscle. In liver, it 
induces fatty acid oxidation, decreases gluconeogenesis and lipid synthesis. Adiponectin 
levels increase with weight loss and decreases with insulin resistance. The role of leptin has 
previously been reviewed in section 2.2.2.2.  In the early stage of diet-induced increased body 
weight, leptin increases insulin sensitivity by decreasing fat deposition in peripheral tissues. At 
a later stage, long-term increases in circulating leptin lead to a reduced role of leptin and the 
development of insulin resistance.  Although other adipocytokines also play a crucial role in 
obesity-induced insulin resistance (Maury et al., 2010; Antuna-Puente et al., 2008; Trujillo & 
Scherer, 2006), the description of their involvement is beyond the focus of our study.   
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The exact mechanism of insulin resistance is however, not completely understood.  
Glucocorticoid hormones associated with high circulating FFA contribute to the impairment of 
insulin actions by various mechanisms (Kennedy et al., 1993; Mlinar et al., 2007).  
 
 
Figure 2- 3 Mechanisms implicated in FFA induced-insulin resistance. 
 
Free fatty acids (FFA) are released in abundance from an expanded adipose tissue mass. In the liver, 
FFA increase production of glucose, triglycerides and secretion of very low density lipoproteins (VLDL). 
Associated lipid/lipoprotein abnormalities include reduction in high density lipoprotein (HDL) cholesterol 
and increased low density lipoproteins (LDL). FFA also reduce insulin sensitivity in muscle by inhibiting 
insulin-mediated glucose uptake.  Associated defects include a reduction in glucose partitioning to 
glycogen and increased lipid accumulation in triglyceride (TRIG).   Increases in circulating glucose and 
to some extent FFA, increase pancreatic insulin secretion resulting in hyperinsulinaemia.  
Hyperinsulinaemia may result in enhanced sodium reabsorption and increased sympathetic nervous 
system (SNS) activity and contribute to hypertension (adapted from Eckel et al., 2005). 
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Figure 2- 4 Other factors implicated in mechanism of insulin resistance. 
 
Superimposed and contributory to the insulin resistance produced by excessive FFA are the paracrine 
and endocrine effect of the proinflammatory state. Produced by a variety of cells in adipose tissue 
including adipocytes and monocyte-derived macrophages, the enhanced secretion of interleukin-6 (IL-6) 
and tumor necrosis factor alpha (TNF-α) among others results in more insulin resistance and lipolysis of 
adipose tissue triglyceride stores to circulating FFA. IL-6 and other cytokines are increased in the 
circulation and may enhance hepatic glucose production, the production of very low density lipoproteins 
(VLDL) by the liver and insulin resistance in muscle. Cytokines and FFA also increase the production of 
fibrinogen and plasminogen activator inhibitor-1 (PAI-1) by the liver that complements the 
overproduction of PAI-1 by adipose tissue. This results in a pro-thrombotic state. Reductions in the 
production of the anti-inflammatory and insulin sensitizing cytokine adiponectin are also associated with 
the metabolic syndrome and may contribute to the pathophysiology of the syndrome. FFA: free fatty 
acids (adapted from Eckel et al., 2005) 
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2.2.2.4.3. Insulin signalling in obesity 
 
2.2.2.4.3.1. Insulin signalling in sensitive tissues (fig.2.5) 
 
To confer its action, insulin binds to its receptors (IR) in the cell membrane and causes its 
autophosphorylation creating docking sites for downstream interacting proteins  such as insulin 
receptor substrate 1 to 4 (IRS1-4) from where three potential signal transduction pathways 
may occur (see fig.2. 5): 1) the phosphatidylinositol-3 kinase (PI-3K) dependent pathway, 2) 
the mitogen-activated protein kinase (MAPK) pathway and  3) the CAD/Cbl/TC10 pathway 
(Saltiel & Kahn, 2001).  The PI-3K dependent pathway is initiated by tyrosine phoshorylation of 
insulin receptor substrate (IRS-1-4) which, when phosphorylated, associates with the p85, 
subunit of PI-3K to produce phosphatidylinositol-3, 4, 5-phosphate (PIP3).  Increased PIP3 
results in activation of protein kinase B (PKB/Akt) via activation of phosphoinositide-dependent 
kinase 1 (PDK1) and other down stream effector molecules which mediate the metabolic 
effects of insulin including translocation of glucose transporter 4 (GLUT-4) to the membrane, 
and glycogen synthesis via PKB/Akt mediated inhibitory phosphorylation of glycogen synthase 
kinase 3 (GSK-3) (Shulman et al.,1999).  In parallel with PKB/Akt, PDK1 is also able to 
activate the atypical protein kinase C (PKC) ζ and λ (see fig.2.5). This insulin-induced 
activation of PKC ζ and λ has however not yet been demonstrated in heart tissue (Bertrand et 
al., 2008). The MAPK-dependent pathway is initiated by the successive activation of Shc, Grb2, 
mSOS, and Ras.  Ras activation triggers the cascade of Raf to MEK1 to extracellular regulated 
kinase (ERK) 42 and 44.  ERK 42 and 44 are MAPK subtypes that mediate the mitogenic and 
the pro-inflammatory effects of insulin (Sasaoka et al., 1994).  The third pathway (CAP/Cbl) 
has been suggested for glucose uptake in order to be fully manifested (Saltiel & Kahn, 2001). 
In this pathway, from the phosphorylation of insulin receptor substrate (IRS), the adapter 
protein CAP recruits proto-oncogen Cbl to the phosphorylated IRS and the activation of Cbl 
results in  a cascade reinforcing   translocation of  GLUT-4  also stimulated by PI-3K pathway 
but has not yet been established in cardiac tissue (Bertrand et al., 2008).   These pathways act 
in a concerted fashion to coordinate the regulation of vesicle trafficking, protein synthesis, 
enzyme activation and inactivation, and gene expression, which result in the regulation of 
glucose, lipid and protein metabolism (see fig. 2.5). 
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2.2.2.4.3.2. Compromised insulin signalling 
 
Defects in insulin signalling may occur at several levels: prereceptor (abnormal insulin), 
receptor (decreased receptor number or affinity), glucose transporters (decreased Glut-4 
expression), or post-receptor (abnormal signal transduction and phosphorylation).  Among 
these defects, post-receptor insulin signalling abnormalities contribute significantly to insulin 
resistance and are associated with various clinical consequences including among others 
hyperglycaemia-induced tissue damage, dyslipidaemia, inflammation, hypertension, and 
metabolic syndrome (Reaven et al., 2004).  As previously discussed, a major contributor to the 
development of insulin resistance is excess circulating fatty acids. The molecular mechanism 
underlying defective insulin-stimulated glucose transport activity can be attributed to increases 
in intracellular lipid metabolites such as fatty acyl-CoA and diacyl-glycerol, which in turn 
activate PKC-ε leading to defects in insulin signalling through Ser/Thr phosphorylation of 
insulin receptor substrate (IRS)-1 and a subsequent inhibition of PI-3 K and PKB/Akt (Morino 
et al., 2006; Chess & Stanley, 2008).  
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Figure 2- 5  Principal components of the insulin signalling pathways.  
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 Fig.2.5: Activation of insulin receptor in the cell membrane by insulin causes its 
autophosphorylation, creating docking sites for downstream interacting proteins such as insulin 
receptor substrate 1 to 4 (IRS1-4). These are also autophosphorylated providing further 
docking sites from where three potential signal transduction pathways occur: PI3K-dependent 
pathway for metabolism (glucose metabolism, glycogen synthesis and protein synthesis), 
CAP/Cbl pathway (additional pathways required for glucose transporter-4 (GLUT4) 
translocation), and the mitogen-activated protein kinase (MAPK) pathway (for gene 
expression, proliferation, differentiation). IRS: insulin receptor substrate; PI3K: 
phosphoinositide-3-kinase; PDK-1: phosphoinositide-dependent kinase 1; PKB/Akt: protein 
kinase B; aPKC: atypical protein kinases C; mTOR: mammalian target of rapamycin; p70S6K: 
p70 ribosomal S6 kinase; PEPCK: phosphoenol pyruvate carboxykinase; GSK-3: glycogen 
synthase kinase 3 (Mlinar et al, 2007; Saltiel & Kahn, 2001). 
 
2.2.2.5. Oxidative stress and obesity  
 
2.2.2.5.1. Oxidative stress  
 
Obesity and its related metabolic alterations are associated with increased oxidative stress 
(Grattagliano et al., 2008; Keaney et al., 2003; Mittal & Kant, 2009; Urakawa et al., 2003; 
Vincent et al., 1999; Vincent et al., 2001).  Oxidative stress occurs when there is an imbalance 
between tissue free radicals and reactive oxygen/nitrogen species (ROS/RNS) levels and 
antioxidant capacity.  Under these conditions, free radicals or reactive oxygen/nitrogen 
compounds accumulate intracellularly and cause damage because of insufficient antioxidant 
defense capacity against their production and action (Grattagliano et al., 2008; Hansel et al., 
2004; Singal et al., 1998).  Reactive oxygen species are chemical entities composed of free 
radicals and non-radical derivatives. Reactive oxygen species (ROS) include hydrogen 
peroxide (H2O2), hypochlorous acid (HOCL), superoxide (˙O2¯), hydroxyl (˙OH), peroxyl (˙RO2¯) 
and hydroperoxyl (HO2¯) radicals. Major reactive nitrogen species (RNS) are nitric oxide (NO) 
and peroxynitrite (ONOO-) (Evans et al., 2005).   
 
In well balanced conditions, free radicals play a role in the regulation of cell function and may 
also act as intracellular and extracellular/intercellular signalling molecules.  In the unbalanced 
state, they have been implicated in the aetiology and pathology of many pathological 
conditions including obesity and its complications (Minoguchi et al., 2006; Roberts & Sindhu, 
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2009).   Excessive free radicals and ROS production can directly affect organs and tissues and 
cause cell injury by damaging DNA, proteins, and carbohydrate and lipid constituents leading 
to cell death or apoptosis (Li et al., 2005).     
 
Oxidative stress in tissue is measured by the determination of the levels of lipid peroxidation 
markers including thiobarbituric reactive acid substances (TBARS), malondialdehyde (MDA), 
lipid hydroperoxides (PEROX), F2-isoprostanes (8-epiPGF2α), and conjugated dienes (CD). It 
has been shown that lipid peroxidation is increased in obesity and has been associated with a 
low systemic antioxidant defense (Van Gaal et al., 1998; Vincent et al., 2005; Furukawa et al., 
2004; Ozata et al., 2002). Therefore, the levels of major dietary antioxidants including vitamin 
C (ascorbate), vitamin A, vitamin E, α-lipoic acid and trace minerals (zinc, selenium, and 
magnesium) can also indicate the oxidative stress levels. They have been found to be lowered 
in obesity (Singh et al., 1998).  Other measurements such as the levels of cellular enzymatic 
and non enzymatic antioxidants including superoxide dismutase (SOD) and its cytosolic (Cu-
ZnSOD) and mitochondrial (Mn-SOD) forms, catalase (CAT), glutathione peroxide (GPx), 
glutathione reductase (GRd), and glutathione (GSH) content, have also been used as oxidative 
markers.  The levels of these antioxidants are often reduced in obesity (for review see Vincent 
et al., 2007). 
 
2.2.2.5.2. Obesity-induced oxidative stress 
 
Obesity is associated with elevated oxidative stress and reduced antioxidant content compared 
to the non obese individuals (Mittal & Kant, 2009).   Obesity has been shown to be associated 
with elevated lipid peroxidation in adult men (Ozata et al., 2002), women (Furukawa et al., 
2004), and premenopausal women (Van Gaal et al., 1998) and children (Olusi et al., 2002).  In 
addition, it was associated with low systemic antioxidant defense such as low content of 
antioxidant enzymes, tissue dietary antioxidants and glutathione (Vincent et al., 2007).  This 
has also been reported by Roberts et al. (2006) showing that  chronic consumption of high 
fat/high refined sugars (sucrose and glucose) results in an elevation in oxidative stress by 
upregulation of superoxide generating NADPH oxidase and a significant reduction in 
mitochondrial, and cytoplasmic SOD (Mn SOD, CuZn-SOD, respectively).  
 
Oxidative stress is enhanced as body weight increases. In a study evaluating the metabolic 
profile of 148 clinically healthy middle-aged women, Wu et al. (2009) found that anthropometric 
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measurements (body mass index, waist circumference, both central and peripheral fat mass 
accumulations), leptin, high-sensitivity C-reactive protein (hs-CRP) and PAI-1 were higher in 
the overweight group.  In addition, in all groups, these parameters were positively associated 
with oxidative stress as measured by urinary excretion of 8-epi-PGF2α.  Using an animal 
model of obesity, Vincent et al. (1999) found that obesity was associated with increased 
myocardial oxidative stress. In this study, left ventricular tissue from obese Zucker rats had a 
high concentration of TBARS and hydroperoxide. 
 
The potential mechanism underlying oxidative stress in obesity include hyperglycaemia, 
increased muscle activity to carry excessive weight, elevated tissue lipid levels, inadequate 
antioxidant defenses, chronic inflammation, endothelial ROS production and hyperleptinemia 
(Vincent et al., 2006).  These mechanisms have been linked to elevated FFA, blood glucose, 
cortisol, and angiotensin II, adipocytokines (dysregulation) and increased inflammatory 
cytokines (TNF-α, IL-6) in obesity (Eriksson et al., 2007).  Using adult male Sprague-Dawley 
rats, Li et al. (2005) have demonstrated that high fat diet-induced obesity is accompanied by 
increased  serum and visceral advanced glycation end products (AGEs), activation of p38 
MAPK  and apoptosis in the heart and in the liver (Li et al., 2005) which could explain the basic 
mechanism of obesity-induced tissue damage.  In addition, the hexosamine pathway has also 
been indicated as a possible mediator in hyperglycaemia-induced glucotoxicity (Evans et al., 
2005).   
 
A study done by Vincent et al. (2001), has shown that ROS accumulation in the heart was 
closely associated with myocardial lipid content but not insufficient antioxidant defenses or a 
greater rate of superoxide production. Therefore, in the high fat diet-induced obesity model, 
oxidative stress may also include the toxic effects of fatty acid moietes, the generation of toxic 
by-products of mitochondrial or peroxisomal oxidation, increased oxygen consumption, or fatty 
acids-induced apoptosis (Finck et al., 2003; Chess & Stanley, 2008).   
 
2.2.2.5.3. Role of oxidative stress in adipose tissue dysfunction and insulin resistance 
 
Increased oxidative stress is associated with adipose tissue dysfunction.  This was 
demonstrated by a study done by Katsuki et al. (2006) where decreased circulating 
adiponectin levels have been associated with elevated oxidative stress in men. Recently, using 
3T3-L1 cells differentiated into adipocytes and then exposed to extraneous H2O2, Chen et al. 
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(2009) have reported that oxidative stress downregulated adiponectin and upregulated PAI-1 
and IL-6 expression.  Reactive oxygen species (ROS) has been implicated in the aetiology of 
insulin resistance (Eriksson et al., 2007). Furukawa et al. (2004) suggested that the increased 
NADPH oxidase and a concomitant reduction in antioxidant enzymes in obesity lead to 
oxidative stress in remote tissues triggering insulin resistance.  At the same time, increased 
ROS production by adipose tissue leads to oxidative stress in adipose tissue and triggers a 
consecutive dysregulation of adipocytokines. This dysregulation includes elevated PAI-1, TNF-
α, MCP-1 and decreased adiponectin and is associated with insulin resistance (Furukawa et 
al., 2004).   
 
The increased ROS in the pre-diabetic stage may be due to obesity-induced FFA uptake 
leading to increased mitochondrial uncoupling and β-oxidation of FFA (Qatanani et al., 2007). 
In diabetic patients, reactive oxygen species generation is considered as a consequence of 
insulin resistance-induced hyperglycaemia (Grattagliano et al., 2008).  At a molecular level, 
oxidative stress may lead to insulin resistance by activation of serine /threonine kinases that 
negatively affect both the secretion of insulin by β-cells and insulin signalling cascades (Evans 
et al., 2003). The stress-activated kinases include JNK/SAPK, p38 MAPK, PKC α and β, IKKθ, 
and NFκB pathways. Activation of these pathways may enhance cytokine production which 
impairs insulin action (Eriksson et al., 2007).   
 
In view of the above, the question is whether antioxidant supplementation would reverse the 
detrimental actions of obesity by reducing oxidative stress and leading to subsequent 
restoration of insulin sensitivity.  Accordingly, a study done by Vincent et al. (2009) has 
demonstrated that antioxidants (combination of vitamin E, vitamin C, and β-carotene) 
supplementation (8 weeks) moderately lowered the homeostasis model assessment (HOMA) 
index at 15% in overweight young adults. This  was associated with an increase in adiponectin 
levels and a reduction in plasma lipid hydroperoxide and endothelial adhesion molecules. 
 
2.2.3. Obesity-induced cardiac alterations 
 
Cardiac alterations associated with obesity remain complex (Abel et al., 2008; Harmancey et 
al., 2008; Mittendorfer & Peterson, 2008; Chess & Stanley, 2008). It has been noticed that 
metabolic remodelling or metabolic flux alterations may precede functional and structural 
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alterations (Harmancey et al., 2008). This section will focus on the impact of obesity on cardiac 
structure, metabolism and function in normoxia and ischaemia/reperfusion injury.  
2.2.3.1. Heart environment in obesity 
 
Systemic alterations associated with obesity may affect the heart through various mechanisms. 
This may include direct effects from adipose tissue secretions and effects from haemodynamic 
and metabolic factors (Abel et al., 2008; Poirier et al., 2006).  
 
2.2.3.1.1. Humoral or direct factors 
 
Adipose tissue dysfunction in obesity leads to increased oxidative stress and inflammation 
associated with dysregulation of production of adipose tissue-derived substances (see section 
2.2.2.2).  Increased oxidative stress results in a compromised heart with respect to its 
metabolism and function (Abel et al., 2008; Banerjee & Peterson, 2007).  Obesity has been 
described as inflammatory disease with elevated circulating cytokines (Dixon et al., 1990)  
associated with upregulation of the expression of myocardial pro-inflammatory cytokines after 
infarction (Thakker et al., 2006).  
 
2.2.3.1.2. Metabolic factors 
 
Obesity-induced metabolic factors include fuel availability and delivery abnormalities. Fuel 
availability is influenced by insulin resistance, abnormal glucose metabolism (leading to 
formation of AGEs and glucotoxicity) along with dyslipidaemia (characterized by elevated 
circulating FFA and a consecutive lipotoxicity) (Chess & Stanley, 2008).  Fuel delivery to the 
obese myocardium is compromised by endothelial dysfunction and coronary artery disease or 
/and macro vascular disease (Abel et al., 2008; Poirier et al., 2006).  
 
2.2.3.1.3. Haemodynamic factors 
  
It is well established that haemodymanic alterations affect the heart in obesity (Alpert, 2001). 
These factors affect cardiac structure and function, and include: volume expansion, a 
subsequent increase in preload and cardiac output and hypertension (Alpert, 2001). Other 
factors associated with obstructive sleep apnoea syndrome (OSAS) negatively affects left 
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ventricle filling and can cause ventricular arrhythmias, and eventually heart failure (Kato et al., 
2009).  OSAS mechanisms include a breathing disorder which induces increased sympathetic 
activity, renin-angiotensin system activation, and a direct action of metabolic factors on 
haemodynamic (e.g. apnoea-induced hypoxemia triggers nitric oxide production and a 
resultant endothelial dysfunction) (Kato et al., 2009). Although haemodynamic mechanisms 
are important in cardiac alterations associated with obesity (for review see Poirier et al., 2006; 
Vasan, 2003), we will only focus on cardiac fuel availability and metabolism. 
 
2.2.3.2. Impact of obesity on myocardial metabolism 
 
Obesity  and its associated metabolic changes affect myocardial metabolism through complex 
mechanisms involving adipocytokines signalling, altered insulin signalling, and fuel (glucose 
and lipid) availability (Lopaschuk et al., 2007).  Adipocytokines and insulin signalling have been 
previously discussed in obesity-induced systemic alterations (section 2.2.1). For reviews on 
cardiac energy metabolism in the normal heart and in obesity, see Coort et al. (2007), Stanley 
et al. (2005) and Lopaschuk et al. (2007).   Here we give a brief summary focusing on obesity.   
 
The heart is omnivorous and can utilize fatty acids, carbohydrates, and lactate as substrates 
depending on their concentration in the circulating blood. Cardiomyocytes oxidise 
predominantly long chain fatty acids (LCFA) (60-70%) while glucose (20%) and lactate (10%) 
are metabolized to lesser extent. This is due to the substrate selection via the Randle cycle 
(inhibition of glucose uptake and catabolism by free fatty acid (FFA) oxidation) (Bertrand et al., 
2008; Randle et al., 1963).  Figure 2.6 represents myocardial metabolism under conditions of 
elevated fatty acids.  Long chain fatty acids enter the sarcolemma by passive diffusion and a 
protein-mediated transport system by fatty acid transport protein (FATP) or a plasma 
membrane fatty acid binding protein (FABPpm) (Coort et al., 2007; Chess & Stanley, 2008).  
Once in the cytosol, the non-esterified FFA bind to FABP and are then activated by 
esterification to fatty acyl-CoA.  Long chain fatty acyl-CoA can be esterified into triglycerides or 
transported across the inner mitochondrial membrane for further β-oxidation.   
 
In obesity, the heart is subjected to increased FFA delivery leading to increased FFA oxidation 
and reduced glucose utilization (see fig.2.6). Continued excessive FFA uptake overwhelms the 
FFA accumulation capacity of the heart causing contractile dysfunction (Young et al., 2002).  
Excess lipid storage contributes to intramyocellular FFA accumulation (steatosis) and 
  29
lipotoxicity (via diacyl glycerol/protein kinase C and ceramide pathways), and can cause 
mitochondrial dysfunction, leading to cell death and consequent left ventricular (LV) 
dysfunction (Mittendorfer & Peterson, 2008) (see fig.2.6).  On the other hand, increased FFA 
β-oxidation can result in increased reactive oxygen species and contribute to increased 
oxidative stress, cell death and/or Ca2+ handling abnormalities (Dixon et al., 1990), leading to 
heart failure (Chess & Stanley, 2008).  Recently, Lima-Leoporldo et al. (2008) demonstrated 
that obesity induces upregulation of genes involved in myocardial Ca2+ handling.  In this study, 
rats fed with a high fat diet developed metabolic abnormalities including glucose intolerance, 
hyperinsulinemia and hyperleptinemia, associated with increased gene expression of proteins 
related to Ca2+ transport, SERCA2a, ryanodine receptor 2 (RYR2) and phospholamban (PLB) 
without causing  changes in sarcolemmal Ca2+ handling genes, NCX and Cacna1c (Lima-
Leopoldo et al., 2008).  Although the mechanism responsible for the alteration in genes 
responsible for myocardial Ca2+ handling is still unknown, it could reflect a compensatory 
mechanism to the impaired myocardial Ca2+ handling evident in obesity (Mittendorfer & 
Peterson, 2008).   
 
 
Figure 2- 6 Myocardial metabolism under conditions of elevated fatty acids  
(Chess & Stanley, 2008) FATP, fatty acid transport proteins; FFAs, free fatty acids; DAG, diacylglycerol; 
PKC, protein kinase C; PPAR: Peroxisome proliferator-activated receptor; PDH, pyruvate 
dehydrogenase; RXR, retinoid X receptor; PGC, peroxisome proliferator-activated receptor- coactivator. 
IR, insulin receptor; IRS, insulin receptor substrate. 
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The excess FFA accumulation in the myocardium is also associated with impaired insulin 
signalling (Chess & Stanley, 2008; Martins et al., 2008) (see fig.2.6).   It has been  observed 
that rats fed a high fat diet, compared to their controls, exhibited an impaired  myocardial 
insulin signalling by reducing phosphorylation of protein kinase B (PKB/Akt), decreasing 
phosphorylation of IRS-1/IRS-2 and associated PI-3K activity with a concomitant 
hypophoshorylation of phospholamban (PLB) (Ouwens et al., 2005) accompanied by a 
reduced myocardial acetyl-Co A carboxylase (ACC) phoshorylation (Ouwens et al., 2007). 
 
2.2.3.3. Cardiac hypertrophy/remodelling in obesity 
 
Cardiac hypertrophy refers to an increase in the size of the entire heart, but more commonly, 
hypertrophy occurs in specific cardiac chambers relative to body size (Abel et al., 2008). Two 
types of hypertrophy namely concentric and eccentric hypertrophy may occur in response to 
external stimuli.  Concentric hypertrophy indicates an increase in wall thickness relative to 
chamber size while the eccentric hypertrophy is characterized by chamber enlargement that is 
more prominent than the increase in wall thickness (Abel et al., 2008).   
 
Cardiac hypertrophy associated with obesity results from a compensatory increase in cardiac 
output to meet the increased metabolic (oxygen) demand which is associated with excess 
adipose tissue in obese patients (Poirier et al., 2006).  This increased cardiac output is 
accomplished by increasing stroke volume and as consequence, the left ventricular chamber 
dilates to accommodate the increased venous return with eventual development of an 
eccentric or concentric hypertrophy (Vasan, 2003; Mathieu et al., 2008).  
 
 While eccentric left ventricular (LV) hypertrophy is commonly present in  patients with severe 
obesity (Poirier et al, 2006),  Woodiwiss et al. (2008) recently demonstrated that central 
obesity was correlated with LV mean wall thickness, concentric LV hypertrophy and 
remodelling, but not with LV end-diastolic diameter or eccentric LV hypertrophy.   From these 
observations it was concluded that obesity may promote left ventricular concentric rather than 
eccentric geometric remodelling and hypertrophy independently of blood pressure (Woodiwiss 
et al., 2008).    
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Studies in an animal model of diet-induced obesity have shown that compared to their normal 
controls, hearts isolated from obese rats were hypertrophied as indicated by increased heart 
weight / body weight ratios (Du Toit et al., 2005) and LV/tibia length (Du Toit et al., 2008). 
 
2.2.3.4. Cardiac function 
 
Obesity is a risk factor for left ventricular diastolic dysfunction, systolic dysfunction, and clinical 
heart failure and contributes to cardiac dysfunction even in the absence of other frequently 
encountered cardiovascular risk factors (Poirier et al, 2006). Increased adiposity per se 
independent of atherosclerosis and myocardial infarction impairs both diastolic and systolic 
function (Wong et al., 2004; Mittendorfer et al., 2008). LV diastolic dysfunction has consistently 
been shown to be associated with obesity but data on the relationship between LV systolic 
dysfunction and obesity lack consistency (Abel et al., 2008).   
 
Recently, it has been demonstrated that central obesity measured by body mass index, waist 
circumference, and waist hip ratio   was associated with a lower LV ejection fraction and LV 
diastolic dysfunction (Ammar et al., 2008). In the study of LV performance in obese patients, 
Nakajima et al. (1985)  demonstrated  that alterations in cardiac performance in obese patients 
with left ventricular enlargement and wall thickening are attributed not only to the excess of 
body weight but also to the duration of obesity.  In this regard, it has been reported that 
depressed LV function was an early abnormality associated with obesity, and paralleled the 
degree of obesity (de Divitiis et al., 1981).  It is therefore evident that mechanisms leading to 
cardiac dysfunction include alterations in volume and pressure and myocardial metabolism, 
which may initially be adaptations that evolve into maladaptive responses over time 
(Harmancey et al., 2008; Alpert, 2001; Nakajima et al., 1985).  
  
Beside these human studies, convincing evidences using animal models of diet-induced 
obesity have demonstrated a reduced cardiac performance/efficiency associated with obesity 
(Akki & Seymour, 2009; Du Toit et al., 2005).  Isolated hearts from rats fed with a western diet 
for 9 weeks showed a decline in myocardial function and a concomitant increase in myocardial 
oxygen consumption (Akki & Seymour, 2009).  Du Toit et al. (2005) have also found that after 
16 weeks of feeding rats a high calorie diet, basal function of the hearts from obese rats was 
significantly depressed compared to age-matched controls.   
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2.2.3.5. Myocardial ischaemia-reperfusion injury in obesity  
  
Myocardial ischaemia and reperfusion damage has been described in section 2.1.  It is 
characterized by a left ventricular dysfunction, myocardial infarction and arrhythmias.  Obesity 
and related metabolic abnormalities including insulin resistance, dyslipidaemia, and 
hypertension have been associated with an increased incidence of myocardial infarction 
(Fedorowski et al., 2009; Prasad et al., 2009; Ranjith et al., 2007).  In a study done by Zeller et 
al. (2008), 70% of people with acute myocardial infarction (AMI) were overweight or obese.  In 
a cross sectional study of 40 men with AMI, using the concentration of total creatine 
phosphokinase (CPK) and CPK-MB isoenzyme as an estimate of myocardial infarction, Iglesia 
Bolanos et al. (2009) have reported a strong association between abdominal obesity and 
myocardial infarction. The same association has been reported by Prasad et al. (2009) 
showing that among patients with acute myocardial infarction the prevalence of metabolic 
syndrome was 45%, obesity being the essential feature. 
 
While an in vivo animal study by Thim et al. (2006) has reported that the size of myocardial 
infarction induced by ischaemia/reperfusion is unaltered in rats with metabolic syndrome, an in 
vitro study by Du Toit et al. (2008) found that isolated hearts from obese rats fed a high calorie 
diet are more vulnerable to myocardial ischaemia/reperfusion injury than control rats fed a 
standard rat chow for 16 weeks.  In the latter study hearts were perfused with glucose only.  
This increased susceptibility to myocardial ischaemia/reperfusion injury has also been 
observed in a mouse model of ischaemic cardiomyopathy induced by brief repetitive ischaemic 
episodes (Thakker et al., 2008): diet-induced obese (DIO) mice showed increased 
susceptibility to ischaemia and reperfusion injury compared to lean mice.  This was due to the 
development of microinfarctions associated with an exaggerated inflammatory response in 
hearts from DIO animals.  In other studies, the exacerbation of ischaemia and reperfusion 
injury seen in  DIO models compared to the their control has  also been linked to increased 
inflammatory markers including chemokines and cytokines (Thakker et al., 2006), elevated 
serum angiotensin II (Du Toit et al., 2005) and high circulating free fatty acids (FFA) (Thakker 
et al., 2008).  This exacerbation of I/R injury in obesity is also the overall result of a cascade of 
maladaptative metabolic changes of FFA metabolism (Lopaschuk et al., 2007). 
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2.2.3.6. Diet-induced obesity models and cardioprotection 
 
Although the diabetic heart in humans is sensitive to ischaemic injury (Fedorowski et al., 2009; 
Prasad et al., 2009; Ranjith et al., 2007; Zeller et al., 2008), there is a controversy regarding 
the impact of obesity on ischaemia/reperfusion injury in animal studies.  For example, one has 
to note that contrary to pre-diabetic DIO animals (Du Toit et al., 2008; Li et al., 2008), and  type 
2 diabetic BBZ rats hearts (Li et al., 2008), hearts from obese diabetic animals displayed a 
reduced infarct size compared to their non-diabetic control (Bouhidel et al., 2008; Kristiansen 
et al., 2004; Wang et al., 2004).  In addition, comparing lean and obese diabetic rats, although 
there was no significant difference between infarct sizes of hearts from diabetic rats, 
Kristansen et al. (2004) have noted that the post ischaemic haemodynamic recovery was 
significantly smaller in obese diabetic rats (Zucker diabetic fatty) than in the lean diabetic 
animals. Furthermore, it was observed that both diabetic rat hearts have a smaller infarct size 
than the non diabetic control rats (Kristiansen et al., 2004), suggesting a possible protective 
effect.   
 
To explain these findings, it has been mentioned that the older type II diabetic rats had an 
impaired cardiac function compared to their age-matched non diabetic rats (Wang et al., 2004). 
This should explain the different features between these studies: Du Toit et al., 2008 (>16 
weeks of feeding) and (Bouhidel et al., 2008; Kristiansen et al., 2004) (< 16 weeks of feeding).  
Other possible explanations would be the difference in the severity of the ischaemic insult and 
the substrate presentation.  However, this cannot be considered since these studies have 
been conducted under the same experimental conditions for both groups. The last 
consideration refers to hyperglycaemia as indicated by Wang et al. (2004), supporting the fact 
that in ex vivo models, the onset of type II diabetes does not increase the sensitivity to 
ischaemia/reperfusion injury.  Therefore, it appears that the observed increased susceptibility 
to ischaemia/reperfusion injury could be explained by the fact that the glucose levels of obese 
rat model used by Du Toit et al. (2008) were not significant different  from those of  control lean 
rats. In addition, rats were older (Du Toit et al., 2008) than those of other studies (Bouhidel et 
al., 2008; Kristiansen et al., 2004). The impact of age may explain the increased myocardial 
susceptibility to I/R injury seen in DIO rats (Du Toit et al., 2008; Li et al., 2008). 
 
Beside this increased myocardial susceptibility to ischaemia/reperfusion injury seen in animal 
models of diet-induced obesity, studies have demonstrated that cardioprotective strategies 
effective in normal conditions are impaired in experimental obesity (Balakumar et al., 2009; 
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Katakam et al., 2007).   Using obese Zucker diabetic fatty rats subjected to a preconditioning 
protocol, Kristiansen et al. (2004) found that post-ischaemic haemodynamic recovery was 
impaired.  Also postconditioning proved to be less effective in obesity.  Bouhidel et al. (2008) 
using obese ob/ob mice have demonstrated that hearts from obese animals subjected to post-
conditioning protocol exhibited impaired protective responses compared to corresponding 
controls. In this study, hearts from obese mice have showed an increased infarct size with a 
concomitant reduction in activation of PKB/Akt and ERK42/44 and AMPK during reperfusion.  
This has been linked to the loss of cardioprotective effects of leptin in obese ob/ob mice (Dixon 
et al., 2009; Smith et al., 2006) and a strong stimulus has been suggested for an effective post 
or preconditioning in these animal  models (Bertrand et al., 2008; Tsang et al., 2005).  
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2.3. EFFECTS OF MELATONIN ON THE HEART 
 
2.3.1. Overview 
 
Melatonin or N-acetyl-5-methoxytryptamine is the hormone secreted mainly by the pineal 
gland, located in the center of the brain, under the control of the central nervous system via the 
suprachiasmatic nucleus (SCN) of the hypothalamus.  The pineal gland is only active in 
darkness while light suppresses its activity (Nowak & Zawilska, 1998).  After secretion, 
melatonin is released into the circulation and gains access to various fluids, tissues and 
cellular compartments (Claustrat et al., 2005). As a consequence, the levels of melatonin in the 
pineal gland and in blood are high at night and low during the day (Altun et al., 2002). 
 
Melatonin was firstly purified and characterized from the bovine pineal gland extract by Lerner 
et al. (1958). It is a highly conserved molecule found in almost all groups of organisms, from 
bacteria, plants, protozoa to humans (Hardeland & Fuhrberg, 1996). The molecular structure of 
melatonin is presented in fig.2.7.  In pinealocytes, melatonin is synthesised from serotonin by 
two enzymes arylalkylamine-N-acetyltransferase and hydroxyindole-O-methyl transferase (AA-
NAT).  From the blood stream, its precursor amino acid tryptophan is first converted by 
tryptophan hydroxylase to 5-hydroxytryptophan, which is then decarboxylated to serotonin. The 
biosynthesis and metabolism of melatonin has recently been reviewed by Pandi-Perumal et al. 
(2006), Tan et al. (2007), Hardeland (2008) and Zawilska et al. (2009).  
 
 
                                          Figure 2- 7  Molecular structure of melatonin 
 
Melatonin is involved in a wide range of physiological functions in humans and animals (for 
review Pandi-Perumal et al., 2006). It plays the classical role of a chronobiotic or endogenous 
synchroniser which exhibits a circadian variation controlled by the suprachiasmatic nucleus 
(SCN), the circadian pacemaker. Melatonin has also been shown to have anti-excitatory, 
antioxidant, anti-inflammatory, immunomodulatory and vasomotors effects (Hardeland et al., 
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2006).  Some of these actions are partially subject to circadian variations and an additional 
interdependence and independence exist between some of the other fields of actions (see 
fig.2.8). Many of these biological actions of melatonin are produced through activation of 
membrane receptors (Pandi-Perumal et al., 2006).  Because melatonin is a highly lipophilic 
and hydrophilic compound, it is able to cross all morphological barriers and to act not only in 
every cell but also within every subcellular compartment.  Therefore, some of its intracellular 
actions are independent of any receptor (for example, free radical scavenging) while others are 
mediated by nuclear receptors (Carlberg, 2000; Wiesenberg et al., 1998).  
 
It has been demonstrated that the heart is connected to the SCN via multisynaptic autonomic 
neurons, and hence endogenous melatonin may affect heart physiology (Scheer et al., 2001).  
Melatonin through its anti-adrenergic effects influences blood pressure (Kitajima et al., 2001), 
myocardial contractility (Abete et al., 1997) and antioxidant reserve (Girouard et al., 2004).  In 
addition, melatonin receptors have been identified in the heart and arteries (Ekmekcioglu et al., 
2003; Pang et al., 2002) and decreased melatonin levels were observed in cardiovascular 
pathological conditions including ischaemic heart disease or myocardial infarction (Domingeuz- 
Rodriguez et al., 2002 & 2005; Yaprat et al., 2003).  This section will only focus on the effects 
of melatonin on the heart, especially its antioxidant properties in experimental ischaemia and 
reperfusion injury models. The possible underlying mechanisms of its actions will be 
discussed. 
 
2.3.2. Antioxidant actions of melatonin 
  
Oxidative stress has been shown to play a crucial role in cardiovascular diseases (Dhalla et 
al., 2000a; Lefer & Granger, 2000; Molavi & Mehta, 2004; Singal et al., 1998). As previously 
mentioned (section 2.2.2.5.), oxidative stress is characterized by amongst others, DNA 
damage, lipid peroxidation and oxidized protein (Valko et al., 2007). Alterations to the cellular 
and subcellular organelles may result in cardiac defects and a subsequent dysfunction, 
arrhythmias, and infarction, a hallmark of myocardial ischaemia/reperfusion injury (see fig.2.9 
p.38) (Dhalla et al., 2000b; Opie, 2004).   
 
Melatonin is able to neutralize a number of toxic reactants including reactive oxygen species 
and free radicals (Reiter et al., 2000; Reiter et al., 2008). It has also been shown to stimulate 
antioxidative enzymes (Rodriguez et al., 2004; Vural et al., 2001) and to increase the efficacy 
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of the classic antioxidants vitamin E, vitamin C and glutathione (GSH) when used in 
combination with melatonin (Gitto et al., 2001). Furthermore, it has been observed that several 
metabolites which are formed when melatonin neutralizes damaging reactants, are themselves 
scavengers (Tan et al., 2001; Tan et al., 2007; Reiter et al., 2007), suggesting that a cascade 
of reactions increases the efficacy of melatonin when used in pathological conditions 
associated with increased oxidative stress (Korkmaz et al., 2008; Reiter et al., 2003).   
 
H3CO CH3
H
N
O
N
H
Melatonin
Anti-
excitatory
actions
Antioxidant and 
antinitrosant
activities
Chronobiotic
Antiinflammatory
actions
Vasomotor 
actions
Immuno-
modulatory
actions
 
Figure 2- 8 Major fields of actions of melatonin  
 
The chronobiotic actions overlap with all other effects of melatonin and an additional interdependence 
and independence exist between some of the other areas of actions (Hardeland & Poeggeler, 2008). 
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Figure 2- 9 Oxidative stress and cardiomyocyte 
 
A schematic representation depicting the involvement of defects in subcellular organelles due to 
oxidative stress as a consequence of either increased formation of reactive oxygen species and/or 
decreased antioxidant reserve (Dhalla et al., 2000a). 
 
2.3.2.1. Free radical scavenging actions (see table 2.1 and fig. 2.11) 
 
Melatonin lowers oxidative cellular and molecular damage through neutralization of free 
radicals (for review Reiter et al., 2004 & 2009) without being pro-oxidant (Chan & Tang, 1996). 
The free radical scavenging actions of melatonin were first theorized by Chen et al. (1993) and 
demonstrated by Tan et al. (1993) in a study showing that melatonin scavenges the hydroxyl 
radical (˙OH).  This discovery was subsequently confirmed in cell free systems and in vivo (for 
review Reiter et al., 2000).  Indeed, melatonin possesses an electron rich aromatic indole ring 
and functions as an electron donor thereby reducing and repairing electrophilic radicals 
(Martinez et al., 2005).  Beside the hydroxyl radical, melatonin has been shown to scavenge 
other free radicals and reactive oxygen species. These include: hydrogen peroxide (Tan et al., 
2002), superoxide (Ximenes et al., 2005), singlet oxygen (Matuszak et al., 2003), hypochlorous 
acid (Zavodnik et al., 2004), peroxyl, alkoyl radicals, nitric oxide and peroxynitrite anion 
(Allegra et al., 2003; Hardeland, 2005).  
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The mechanism by which melatonin interacts with free radicals is only partially understood.  
The product of the reaction of melatonin scavenging the hydroxyl radical is the indolyl radical 
which also neutralizes ˙OH to produce cyclic 3- hydroxymelatonin (C3-OHM).  Once C3-OHM 
is formed in vivo, it is excreted in the urine where it is used as a biomarker of ˙OH generation. 
It has also been shown that C3-OHM can further be oxidized to N1-acetyl-N2-formyl-S-
methoxykynuramine (AFMK). This compound is also able to donate its electrons and neutralize 
radical species (Tan et al., 2001). AFMK can interact with ROS and RNS to form AMK. AMK 
can further react with peroxynitrite (ONOO-) to form 3-acetamidomethyl-6-methoxycinnolinone 
(AMMC) and N1-acetyl-5-methoxy-3-nitro kynuramine (AMNK). Recently, AMK was shown to 
scavenge singlet O2 (Schaefer & Hardeland, 2009). Other melatonin metabolites (2- and 6-
hydroxymelatonin, 1-nitromelatonin, and nitrosomelatonin) have also been mentioned for their 
antioxidant effects (Tan et al., 2007). Thus, in view of the cascade of reactions that include 
AFMK, as pointed out by Tan et al. (2007), a single melatonin molecule can scavenge 10 
ROS/RNS molecules.  In addition, melatonin and its metabolites have been shown to also 
reduce electron leakage and free radical formation by the mitochondria (Acuna-Castroviejo et 
al., 2007; Rodriguez et al., 2007). Importantly, melatonin has been shown to protect the heart 
by inhibition of the mitochondrial permeability transition pore (MPTP) (Petrosillo et al., 2009). 
 
2.3.2.2. Antioxidant stimulation (see table 2.1 and fig.2.11) 
 
 Beside its free radical scavenging properties, melatonin regulates antioxidant activities and 
gene expression (Rodriguez et al., 2004; Tomas-Zapico & Coto-Montes, 2005). It stimulates 
the antioxidant enzymes, such as superoxide dismutases (SOD), both MnSOD and CuZnSOD, 
catalase (CAT), glutathione peroxidase (GPx) (Barlow-Walden et al.,1995), glutathione 
reductase (GRd) as well as  the enzyme glucose-6-phosphate dehydrogenase (G6PD) (Reiter 
et al., 2000).  In addition, melatonin administration down-regulates the pro-oxidant enzymes, 
such as nitric oxide synthases, lipoxygenases (Hardeland, 2005), myeloperoxidase (MPO) and 
its downstream inflammatory pathways (Galijasevic et al., 2008). Furthermore, it enhances the 
levels of intracellular glutathione (GSH) (important antioxidant) by stimulating the rate-limiting 
enzyme in its synthesis, γ-glutamylcysteine synthase (Urata et al., 1999). GSH is used by Gpx 
as a substrate to metabolize H2O2; in this process GSH is converted to oxidized glutathione 
(GSSG). To maintain the high levels of GSH, melatonin promotes the activity of glutathione 
reductase (GRd), which converts GSSG back to GSH (Reiter et al., 2000). NADPH is a 
cofactor of G6PD in the conversion of GSSH to GSH (Reiter et al., 2007) (see fig.2.11). 
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It has been observed that serum melatonin levels correlate positively with the enzymatic 
antioxidant defense system levels (Gumral et al., 2009). Melatonin has been shown to 
normalize the antioxidant content when lowered by a pathological condition or drug 
metabolism associated with increased free radical generation in the heart (Cruz et al., 2009; 
Baydas et al., 2002; Oz et al., 2006).   Garcia et al. (2009) have recently reported that 
melatonin increased the mRNA levels of MnSOD, CAT, and GRd in the presence of the pro-
oxidant agent aluminium, independently of the animal model used. These stimulatory effects 
have been linked to receptor- mediated pathways. 
 
2.3.2.3. Role of melatonin receptors  
 
Beside the non specific direct antioxidant actions of melatonin, melatonin also acts through 
specific receptors mediated pathways to confer other effects including the regulation and 
stimulation of antioxidative enzymes (Rodriguez et al., 2004; Tomas-Zapino & Coto-Montes, 
2005). In mammals, two types of melatonin receptors, the MT1 and MT2, have been identified 
in the central nervous system (CNS) and peripheral organs including the heart and the blood 
vessels (Ekmekcioglu et al., 2003; Pang et al., 2002). These receptors belong to the G-protein-
coupled receptor (GPCR) superfamily and are involved in the cardioprotective effects of 
melatonin (Rezzani et al., 2006; Lochner et al., 2006; Sallinen et al., 2007; Sallinen et al., 
2008).  A third melatonin-binding site has been purified and characterized as the enzyme 
quinone reductase 2 (QR2) (Boutin, 2007; Nosjean et al., 2000) but its role in the heart has not 
yet been identified.   In addition, to confer its intracellular actions melatonin may also bind to 
calmodulin (Soto-Vega et al., 2004), to calreticulin (Hardeland, 2009), and the mitochondrial 
binding sites (Acuna-Castroviejo et al., 2007) as well as to nuclear receptors of the retinoic 
acid receptor family including RORα1, RORα2 and RZRβ (Carlberg, 2000; Wiesenberg et al., 
1998).  
 
 Despite identification of melatonin receptors MT1 and MT2, the signalling pathways in the 
heart are still poorly understood.  It is generally accepted that melatonin activation of MT1/2 
receptors, via G inhibitory protein, stimulates the phospholipase C pathway leading to 
increases in cytosolic Ca2+. This could in turn  lead to the phosphorylation of PKC which 
activates the transcription factor cAMP responsive element binding protein and activating 
transcription factor (CREB-ATF), which then modulates immediate early gene (IEG) 
transcription and gene transcription regulation, and consequently antioxidant enzyme levels 
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(Rodriguez et al., 2004; Tengattini et al., 2008). This pathway has been implicated in regulation 
and stimulation of antioxidant enzyme by melatonin (Rezzani et al., 2006). 
  
Melatonin has potent anti-adrenergic effects which could also contribute to its cardioprotective 
actions. Genade et al. (2008) showed that melatonin significantly reduced both isoproterenol 
and forskolin- induced cAMP production. Nitric oxide, guanylyl cyclase as well as PKC are 
involved in the anti-adrenergic effects. Using the appropriate inhibitors (L-NAME, 
bisindolylmaleimide (BIM) and ODQ, for NO, PKC and cGMP, respectively), these researchers 
showed that NO and guanylyl cyclase but not PKC are involved in melatonin-induced 
cardioprotection (see fig.2.10).   The study done by Arvola et al. (2006) has also demonstrated 
the anti-adrenergic effects of melatonin in guinea pig heart papillary muscle. 
 
 
Activation
Inhibition
 
Figure 2-10 Schematic representation of anti-adrenergic effects of melatonin in the isolated rat 
heart.    
Mel, melatonin; Iso, isopreterenol; AC,adenyl cyclase; GC,guanylyl cyclase,PKC, protein kinase C; 
BIM,bisindolylmaleimide; cAMP,cyclic AMP; cGMP,cyclic GMP; PDE2, phosphodiesterase 2  (Genade 
et al., 2008).   
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Table 2- 1 Antioxidant effects of melatonin 
ROS: reactive oxygen species, RNS: reactive nitrogen species. ↑: increase ↓: decrease 
 (Tengattini et al., 2008; Reiter et al., 2003). 
 
Drug metabolism 
enzyme activityCellular respiration Environmental factors
O2˙
(superoxide anion radical)
ONOO-
(peroxynitrite anion)
SOD 
(superoxide
dismutase)
H2O2 
(hydrogen peroxide)
Glutamine cysteine
γ-glutamylcysteine
synthetase
H2O
OH˙
(hydroxyl radical)
Molecules damage
(DNA damage, lipid peroxidation, oxidized protein)
H2O+O2
ROOH
GPx
(glutathione 
peroxidase)
ROH
GSH
GSSG
GRd
(glutathione 
reductase)
NADP
NADPH
Glucose-6-
dehydrogenase
Mel
Mel
Mel
Mel
Mel
Mel
Mel
Catalase
ONOOH
NO˙
(nitric oxide)
Mel
Fenton reaction                                     
(presence of Fe2+)
T
 
 
Figure 2- 11 Oxidative stress and sites of action of melatonin (Mel) 
Type  of actions Target/site of action Effects 
ROS 
 
 
Hydyrogen peroxide 
Hydroxyl radical 
Singlet oxygen 
Superoxide anion 
↓ 
↓ 
↓ 
↓ 
Scavenging 
 
 
RNS 
Nitric oxide 
Peroxynitrite anion 
↓ 
↓ 
Stimulation 
Antioxidant 
enzymes 
Superoxide dismutase 
Catalase 
Glutathione peroxidise 
Glutathione reductase 
Glucose-6-phosphatase dehydrogenase 
Gamma-glutamylcysteine synthase 
↑ 
↑ 
↑ 
↑ 
↑ 
↑ 
Inhibition 
Pro-oxidant 
enzyme 
Nitric oxide synthase 
Lipo-oxygenase 
Myeloperoxidase 
↓ 
↓ 
↓ 
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Fig.2.11.Melatonin reduces oxidative damage by multiple means. NADP: nicotinamide adenine 
dinucleotide phosphate; NADPH: the reduced form of NADP; GSH: reduced glutathione; GSSG: 
glutathione disulfide; ROH: lipid alkoxide; ROOH: organic hydroperoxide; (Kucukakin et al., 2009; Reiter 
et al., 2003; Korkmaz et al., 2009).  
 
2.3.3. Melatonin and myocardial ischaemia-reperfusion injury 
 
Myocardial ischaemia /reperfusion injury is described in section 2.1. Several in vitro and in vivo 
studies have demonstrated the cardioprotective effects of melatonin (for review see Reiter & 
Tan, 2003; Tengattini et al., 2008).  The current literature on the effects of melatonin on 
myocardial I/R injury is summarized in table 2-2.  
 
2.3.3.1. In vitro studies 
 
A study done by Salie et al. (2001) analyzing the effects of melatonin in the setting of hypoxia 
and re-oxygenation in rat cardiomyocytes, has demonstrated that melatonin protects against 
myocardial ischaemia/ reperfusion damage via inhibition of ROS generation.  In this study 
adult rat ventricular myocytes were preloaded with tetramethylrhodamine (TMRM) in 
combination with either dichlorodihydro-fluorescein diacetate (DCDHF), dihydrorhodamine 123 
(DHR) or fluo 3 to assess the specific actions of melatonin on H2O2, ROS and Ca2+ using 
confocal microscopy. Chemical hypoxia, induced by addition of 1.5 mM KCN and 20 mM 
deoxyglucose to the superfusion buffer resulted in increased H2O2, ROS and Ca2+ 
fluorescence. The addition of melatonin (50 to 100 μM) significantly reduced hypoxia-induced 
morphological damage and H2O2, ROS and intracellular Ca2+ levels. The reduction of Ca2+ by 
melatonin has also been reported by Chen et al. (1993) comparing cardiac tissue incubated 
with or without melatonin at different doses. The melatonin  induced reduction in Ca2+  may 
play an important role in  the protective effects against I/R ventricular arrhythmias as observed 
later by Tan et al. (1998), Lagneux et al. (2000), Kaneko et al.(2000), Szarszoi et al. (2001) 
and Vazan et al. (2005) using the isolated Langendorff perfused rat heart.  Melatonin at 
concentration of 1, 10 or 50 μM infused during coronary artery occlusion or reperfusion, 
significantly reduced premature ventricular contractions and/or ventricular fibrillation (Tan et 
al., 1998).  Indeed, when compared to another antioxidant vitamin C (500 μM) (concentration 
10 times that of melatonin), melatonin was more effective in preventing cardiac arrhythmias 
(Tan et al., 1998).  In addition, melatonin pre-treatment (10 mg/kg intraperitoneally (i.p)) 
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caused a significant reduction in infarct size, expressed as the percentage of the risk zone 
(Lagneux et al., 2000). Furthermore, compared to the untreated rat hearts, pre-ischaemic 
melatonin administration (100 μM) improved recovery of left ventricular developed pressure 
(LVDevP) after 30 minutes normothermic global ischaemia (Kaneko et al., 2000). This was 
accompanied by a significant reduction in ROS generation and lipid peroxide concentration in 
the heart (Kaneko et al., 2000).  
  
Using the isolated working rat heart preparation, Lochner et al. (2006) showed that melatonin 
when administered either before or during reperfusion only, significantly improved cardiac 
output and work performance and reduced infarct size compared to untreated controls. In 
addition, long-term administration of melatonin (intraperitoneal injection (2.5 or 5.0 mg/kg) or 
oral administration in drinking water (40 μg/ml for 7 days) also caused a significant reduction in 
infarct size of hearts subjected to regional ischaemia. Interestingly, this protection lasted 2 to 4 
days after discontinuation of treatment suggesting the long-term therapeutic potential of 
melatonin. In this study, the protective actions could be abolished by the melatonin receptor 
blocker, luzindole, suggesting a role for the melatonin receptor in the cardioprotective actions 
of melatonin. 
 
2.3.3.2. In vivo studies 
 
The cardioprotective effects of melatonin have also been demonstrated in vivo (Lee et al., 
2002; Sahna et al., 2005).  Melatonin at both physiological and pharmacological doses was 
able to reduce the infarct size in the rat (Lee et al., 2002; Sahna et al, 2002a; Sahna et al., 
2003; Sahna et al., 2005) and in mouse (Chen et al, 2003) hearts without significantly affecting 
the haemodynamic parameters such as mean arterial pressure (MAP), heart rate (HR) and 
blood pressure (BP) (Sahna et al., 2002a; Sahna et al., 2005).  Lee et al. (2002) showed that 
pre-treatment of rats with intermediate or high doses of melatonin (intravenous bolus of 1.0 
and 5.0 mg/kg) 10 minutes before left coronary artery occlusion, significantly suppressed 
ventricular tachycardia (VT) and fibrillation (VF), and improved the survival rate of rats when 
compared with untreated controls. These melatonin effects were accompanied by a significant 
reduction in superoxide anion production and myeloperoxidase (MPO) activity (an index of 
neutrophil infiltration in the ischaemic myocardium).  Chen et al. (2003) using the mouse heart 
reported a reduction in infarct size by the dose range of 75-150 μg/kg. The high dose of 150 
μg/kg did not confer an additional protective effects and melatonin was more effective between 
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0.5 to 2 hours after administration but not at 4 to 24 hours as it was recently shown in isolated 
rat heart (Lochner et al., 2006).  In contrast to the above, using 8-methoxy-2-
propionamidotetralin, a melatonin receptor agonist, they failed to demonstrate the involvement 
of melatonin receptors in cardioprotection.  
 
The role of endogenous melatonin in cardioprotection was first demonstrated in the study done 
by Sahna et al. (2002b) which showed that the incidence of mortality resulting from irreversible 
ventricular fibrillation (VF) was significantly higher in the pinealectomized rats (63%) than in the 
control group (25%).  Melatonin administration (0.4 mg/kg, either before ischaemia or 
reperfusion) to pinealectomized rats significantly reduced the incidence of total (irreversible 
plus reversible) and irreversible VF (Sahna et al., 2002b). In another study, Sahna et al. (2005) 
have also demonstrated that melatonin (10 mg/kg) given 10 minutes before ischaemia via the 
jugular vein significantly reduced the infarct size.  This protection was accompanied by a 
reduction in MDA and an increase GSH levels. Ceyran et al. (2008) showed that administration 
of the high dose of melatonin (50 mg/kg) to rats before ischaemia or reperfusion was 
characterized by a reduction in cardiac troponin, MDA, MPO levels and an increase in SOD 
levels. In addition, there was a decrease in Fas expression, myofibrillar oedema, vascularity, 
inflammatory infiltration and an increased Bcl-2 expression.  Recently, Chen et al. (2009) using 
both in vitro and in vivo models, showed that independently of glutathione peroxidise (GPx) 
activation melatonin protected against myocardial I/R injury and apoptosis in both deficient 
(GPx -/-) and wild type (Gpx +/+) mice  as indicated in vitro by a significant improvement in left 
ventricular end-diastolic pressure and a decrease in lactate dehydrogenase (LDH) levels. 
 
2.3.3.3. Myocardial I/R injury in pathological conditions 
 
In cardiomyopathic hamsters, melatonin reduced ventricular arrhythmias and preserved 
capillary perfusion during I/R injury (Bertuglia & Reiter, 2007). In this study the animals 
received melatonin (6 mg/kg) daily for 3 weeks before induction of I/R. During I/R oxidative and 
nitrosative stress, vasoconstriction, leukocyte adhesion, and vascular permeability were 
reduced while capillary perfusion was increased in melatonin treated group. It was concluded 
that melatonin prevents both microvascular injury and ventricular arrhythmias during post-
ischaemic reperfusion by modulating the lipid peroxide overproduction and nitrosative stress 
which are involved in the development of cardiomyopathy (Bertuglia & Reiter, 2007).   
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In chronically hypoxic rats, melatonin conferred cardioprotection by amelioration of Ca2+ 
homeostasis (Yeung et al., 2008). Melatonin treatment significantly reduced infarct size, MDA 
generation, and LDH release. The cytosolic calcium levels in isolated cardiomyocyte were also 
reduced by melatonin treatment. In addition, sarcoplasmic reticulum Ca2+-ATPase2 
(SERCA2a) expression was significantly reduced in the melatonin treated hypoxic rats group 
compared to untreated hypoxic rats while the levels of the protein expression of the Na+/Ca2+ 
exchanger and ryanodine receptor (RyR2) in chronically hypoxic rats were not different from 
those of the normoxic controls (Yeung et al, 2008).   
 
The study by Sallinen et al. (2007) has shown in rats that a myocardial infarction (MI) 
increased the amount of LV MT2 receptor proteins, MT1 and MT2 mRNA levels.  In addition, 
using the same model of MI, long-term post-infarction subcutaneous melatonin (4.5 mg/kg per 
day) administration significantly reduced the expression of dihydropyridine receptor (DHPR), 
the ryanodine receptor (RyR(2)), and sarcoplasmic reticulum Ca2+-ATPase2 (SERCA2a) 
mRNA.  This was associated with an increase in amount of MT2 receptor and atrial natriuretic 
peptide (ANP) in the LV (Sallinen et al., 2008).  This study demonstrated that in response to 
the MI, melatonin synthesis in the pineal gland may increase rapidly and melatonin receptors 
may be involved in mediating, at least, in part, the protective effects of melatonin in the heart 
after infarction. Melatonin receptors, particularly MT2, might contribute to the post-infarction 
cardioprotective actions of melatonin associated with improved myocardial contractility 
(Sallinen et al., 2007).  
 
In contrast to the substantial evidence for the cardioprotective effects of melatonin, one study 
in rabbits failed to demonstrate these effects (Dave et al, 1998). In addition, because of its free 
radical scavenging properties melatonin prevents preconditioning-induced cardioprotection in 
isolated rat hearts (Genade et al., 2006).  
 
2.3.3.4. Melatonin and mitochondria in myocardial I/R injury 
  
Mitochondria are known to be involved in the process of cell death (necrosis and apoptosis) 
following reperfusion (Makazan et al., 2007). Mitochondrial respiration, mainly at the level of 
complex I and III, is an important source of ROS generation and hence a potential contributor 
to cardiac reperfusion injury (Das, 1994).  It has recently been proposed that melatonin also 
protects against ischaemia/reperfusion-induced oxidative damage to mitochondria in the heart 
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(Giacomo & Antonio, 2007; Petrosillo et al., 2006; Petrosillo et al., 2009).  Petrosillo and 
coworkers (2006) showed that melatonin reduced the rate of mitochondrial oxygen 
consumption, complex I and complex III activity, H2O2 production. The degree of lipid 
peroxidation, cardiolipin content, and cardiolipin oxidation was also reduced. In addition, 
melatonin has recently been shown to protect the isolated heart against I/R injury by inhibition 
of mitochondrial permeability transition pore opening (Petrosillo et al., 2009). Interestingly, 
melatonin was able to prevent the impairment of mitochondrial homeostasis and restored ATP 
production in septic mice hearts (Escames et al., 2007; Rodriguez et al., 2007).  
 
2.3.3.5. Mechanism of cardioprotection 
 
The mechanisms of the cardioprotective effects of melatonin are still under investigation.  It 
has recently been shown that melatonin administered before or during early reperfusion 
activates the reperfusion injury salvage kinases (RISK) (PKB/Akt and ERK 42/44) pathway 
during early reperfusion (Genade et al., 2008). This cardioprotection by melatonin was also 
recently linked to the inhibition of mitochondrial permeability transition pore (MPTP) opening 
(Petrosillo et al., 2009) and the activation of the signal transducer and activator of transcription-
3 (STAT-3) (Lecour S, Unpublished observation).  
 
2.3.4. Melatonin and left ventricular remodelling   
 
Left ventricular (LV) remodelling refers to left ventricular hypertrophy. It is associated with 
haemodynamic overload and/or increased oxidative stress.   Melatonin was shown to reduce 
blood pressure, oxidative load and to increase nitric oxide bioavailability, hence conferring the 
anti-remodelling potential (Simko et al., 2009).  In this study, the activity of NOS and 
endothelial NOS expression increased in the left ventricles of hypertensive animals compared 
with controls. Melatonin was shown to increase NOS expression, reduce NF-κB expression 
and decrease conjugated diene concentration. This was associated with a reduction in 
collagenous protein concentration and hydroxyproline content in the left ventricle without 
affecting the LV hypertrophy, demonstrating its antifibrotic rather than its antihypertrophic 
effects (Simko et al, 2009).  These protective actions that reverse LV fibrosis, but not LV 
hypertrophy in spontaneously hypertensive rats may be caused by melatonin’s prominent 
antioxidative effect (Simko et al., 2009; Paulis et al., 2009). Nevertheless, melatonin was able 
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to prevent cardiac hypertrophy in hyperthyroid rats along with a reduced oxidative load and 
altered expression of metabolically important genes including glucose transporter (GLUT-4) 
(Ghosh et al., 2007).  
 
2.3.5. Conclusion 
 
There are over 15073 Pubmed citations related to melatonin; therefore, it is not possible to 
mention all data which document the effects of melatonin and its possible clinical importance. 
Melatonin protects the heart in pathological conditions associated with elevated increased 
oxidative stress. It most likely acts through its direct free radical scavenging activities and its 
indirect actions in stimulating antioxidant enzymes via membrane or intracellular receptors. 
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2.4. MELATONIN EFFECTS IN OBESITY 
 
2.4.1. Introduction 
 
Advancing age is characterized with elevated oxidative stress and increases in visceral fat 
accumulation, plasma insulin and leptin levels (Wolden-Hanson et al., 2000; Rasmussen et al., 
1999).  Endogenous melatonin levels are reduced with ageing (Pang et al., 1990; Reiter, 
1992).  These age-associated changes are often associated with obesity-related metabolic or 
physiological alterations including atherogenic dyslipidaemia, raised blood pressure, and a pro-
inflammatory state (Eckel et al., 2005). However, the role of melatonin in obesity is not well 
established. This section will summarize the effects of melatonin on obesity focusing on body 
weight gain, adiposity, lipid profile, hormones and glucose levels. 
2.4.2. Melatonin effects in non pathological conditions 
 
Melatonin is involved in many physiological processes including amongst others energy 
metabolism (Pandi-Perumal et al., 2006; Bartness et al., 2002). In middle-aged rats daily 
melatonin supplementation has been shown to increase plasma melatonin and to reduce body 
weight, visceral adiposity, and plasma insulin and leptin levels to youthful levels (Wolden-
Hanson et al., 2000; Rasmussen et al., 1999).  In young rats, long-term oral melatonin 
administration (4 μg/ml in drinking water) also reduced body weight gain, visceral fat weight, 
without any alteration of food intake (Kassayova et al., 2006; Bojkova et al., 2006). Melatonin 
effects on the heart weight are sex dependent. Melatonin increased (in females) or decreased 
(in males) the heart weight (Markova et al., 2003). It also increases (in males: Bojkova et al., 
2006) or reduces (in both males and females) (Kassayova et al., 2006) or has no effect on (in 
males and females: Markova et al., 2003) serum glucose levels.   
 
The action of melatonin on glucose metabolism is not clear. It varies from one animal model to 
another. It has been demonstrated that pinealectomy increased glycaemia and melatonin 
administration, after pinealectomy, normalized blood glucose (Rodriguez et al., 1989; Pruet-
Marcassus et al., 2003). In contrast to this, the study done by Bizot-Espiard et al. (1998) 
reported that neither pinealectomy nor melatonin administration in pinealectomized animals 
had any effects on serum glucose.  Further more, surprisingly, an acute administration of 
melatonin increased serum glucose (Fabis et al., 2002), suggesting a role in carbohydrate 
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metabolism. However, the exact mode of action of melatonin in regulation of carbohydrate/lipid 
metabolism is not clear. It appears that the melatonin effects depend on the dose, mode and 
time of administration as well as the age, sex, and strain of the animal model (Bojkova et al., 
2006; Kassayova et al., 2006; Markova et al., 2003; She et al., 2009).  A direct as well as an 
indirect action via the sympathetic nervous system has been suggested to explain the 
observed effects of the hormone in obesity (Pruet-Marcassus et al., 2003).  
2.4.3. Melatonin role in obesity 
 
Melatonin has been considered as an effective treatment for obesity (Barrenetxe et al., 2004). 
It has been shown that the amplitude of the nocturnal pineal melatonin peak is significantly 
decreased in overweight and obese rats (Cano et al., 2008).  In a rat model of diet-induced 
obesity with a high-fat diet, daily melatonin administration significantly decreased body weight 
(Pruet-Marcassus et al., 2003; She et al., 2009). This decrease in body weight was associated 
with a reduction in plasma glucose, leptin and triglycerides levels, and was observed as soon 
as five days after the initiation of daily melatonin treatment and continued throughout the entire 
time-course of melatonin treatment (Pruet-Marcassus et al., 2003).   
 
A study done by Hussein et al. (2007) in a rabbit model of obesity has demonstrated that 
intake of melatonin was associated with amelioration of both metabolic and morphological 
pathologies related to obesity.  In this study, when compared with the obesity group, intake of 
melatonin (treated group) was associated with: a significant decrease in blood pressure, heart 
rate, sympathetic nerve activity, body weight, food consumption, serum lipids, blood glucose 
levels and atherogenic index. These changes were accompanied with increased levels of 
glutathione peroxidase (GSH-Px) and high density lipoproteins (HDL).  In addition, there was a 
disappearance of fatty alterations in the liver and kidney as well as atheromatous changes in 
the blood vessels of the obese treated group. 
 
In addition to melatonin’s efficacy in treating diet-induced obesity, melatonin is also effective in 
treating middle-aged induced-obesity (Wolden-Hanson et al., 2000). For example, daily 
treatment with melatonin significantly decreased body weight in middle-aged rats (Rasmussen 
et al., 1999). Importantly, this melatonin-induced body weight decrease in middle-age was due 
to a significant decrease in fat content as opposed to lean body mass, and was accompanied 
by an increase in energy expenditure as expressed by elevated physical activity and body core 
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temperature, similar to that of young rats (Wolden-Hanson et al., 2000), further suggesting the 
effectiveness of melatonin for the treatment of obesity.   
2.4.4. Melatonin and insulin resistance  
 
Melatonin regulates insulin secretion, lipid and glucose metabolism (Nishida et al., 2005). 
Melatonin and its agonist NEU-P11 increase insulin sensitivity and improve the metabolic 
profile in high fat/high sucrose-fed rats (She et al., 2009).  This was accompanied by a 
reduction in oxidative stress and a stimulation of the antioxidant status with a decrease in 
glucose levels (She et al., 2009). Similar effects were also reported in type I (Akskoy et al., 
2003; Vural et al., 2001) and II (Nishida et al., 2002) diabetic rats with no effect of glucose 
levels (Klepac et al., 2005).  Pinealectomy increases (after 21 weeks) plasma insulin and 
accumulation of triglycerides followed later by a net decrease (after 35 weeks) in insulin levels 
(Nishida et al, 2003). This reflected impairment in insulin release from pancreatic β-cells, as 
seen in patients at the advanced stage of type 2 diabetic mellitus (Kuzuya et al., 2002).  
Recently, it has been shown that pineal melatonin synthesis is decreased in type 2 diabetic 
Goto–Kakizaki rats (Frese et al., 2009).  Nishida and co-workers (2002) observed that 
administration of melatonin to rats with type 2 diabetes mellitus reduces their plasma 
hyperlipidaemia, hyperinsulinaemia and hyperleptinaemia, and improves the conditions 
associated with type 2 diabetes. Melatonin has been shown to inhibit insulin secretion by 
pancreatic ß-cells (Peschke et al., 2008).  Recently, a case study done by Nieuwenhuis et al. 
(2009) has confirmed the beneficial effects of melatonin in diabetes by successfully treating a 
40-year-old woman with insulin-dependent diabetes mellitus with phototherapy.  
2.4.5. Melatonin and leptin  
 
Leptin, an adipocyte hormone, has a central role in regulating food intake, body weight and 
energy expenditure. Pinealectomy increases serum leptin (Wolden-Hanson et al., 2000).  It 
has been observed that exogenous melatonin  decreases serum leptin levels in both 
pinealectomised and intact rat models of diet-induced obesity (Canoplat et al., 2001; Wolden-
Hanson et al., 2000) before decreasing plasma insulin (Pulchalski et al., 2003).  In young and 
middle aged rats melatonin did not shown any effect on serum leptin levels (Bojkova et al., 
2008).  Melatonin acts directly on adipocytes and enhances the leptin expression in the 
presence of insulin (Alonso-Vale et al, 2004).  
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Table 2-2 CURRENT LITERATURE ON THE EFFECTS OF MELATONIN ON MYOCARDIAL ISCHAEMIA/REPERFUSION INJURY  
Types of 
studies 
 
Model 
Duration 
of I/R 
Melatonin actions Reference 
In vitro 
isolated  rat heart   
(Langendorf model) 
10/10 
( min/min) 
↓ premature ventricular contraction and fibrillation Tan et al.,1998 
In vitro 
isolated  rat heart  
(Langendorf model) 
30/30 
( min/min) 
↓ ventricular tachycardia and fibrillation; restored 
ventricular function;↓ lipid peroxidation; lowered OH˙ 
generation 
Kaneko et al., 2000 
In vitro 
isolated  rat heart  
(Langendorf model) 
5/30 
( min/min) 
↓ reperfusion arrythmias;↓ infarct size Lagneux et al., 2000 
In vitro 
isolated  rat heart  
(Langendorf model) 
20/40 
( min/min) 
↓ fibrillation; low concentration had no effect on I/R of the 
isolated perfused heart rat 
Szarszoi et al., 2001 
In vitro 
Cardiomyocyte in culture 
( rats) 
12.5 or 27.5/1.5 
Reduced morphoplogical damage, lowered oxygen free 
radical generation, reduced intracellular [Ca²+] 
Salie et al., 2001 
In vitro 
isolated and perfused  
working rat heart 
30/45 
(min/min) 
Significant improvement of hemodynamic parameters and 
↓ post-ischemic arrhythmias during reperfusion;          
↓ significantly incidence of apoptotic cells 
Dobsak et al., 2003 
In vitro 
isolated rat  heart /  
working  heart 
20/30 
(min/min) 
Global ischemia (GI): protective  effects during reperfusion, 
abolishes cardioprotection before and during  ischemia 
preconditioning protocol 
Genade et al., 2006 
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Types of 
studies 
 
Model 
Duration 
of I/R 
Melatonin actions Reference 
In vitro Isolated working rat  heart 
20/30 
(GI) or 
35/30(RI) 
(min/min) 
Before and during reperfusion: improved cardiac output 
and work performance; ↓ infarct size; long term 
significantly↓ infarct size (RI). Luzindole abolishes these 
effects.  Melatonin receptor is suggested to be involved in 
melatonin cardioprotection. 
Lochner et al., 2006 
In vitro Langendorff apparatus 
30(GI)/120 or 15 
(min/min) 
Increased content of cardiolipin with reduced peroxidized 
cardiolipin,  Reduced rates of mitochondrial oxygen 
consumption, complex I and complex III activity,  and H2O2
production;  ↑ post-ischaemic  LVDp and ↓ LVED p 
Petrosillo et al., 2006 
In vitro 
 
Langendorff and working 
heart 
35 RI/30 or 120 
(min/min) 
Anti β-adrenergic effects: reduced IFS, 
↓NOS & cAMP; increased PKB/Akt, reduced p38 MAPK 
activity. 
Genade et al., 2008 
In vitro 
Isolated heart rat 
(Langendorff method) 
( chronic hypoxic rats) 
30/120 
Min/min 
infarct size reduction, improve Ca2+ handling by preserving 
SERCA expression,  lowered MDA levels, lactate 
dehydrogenase (LDH) 
Yeung et al.,2008 
In vitro Langendorff apparatus 
30 GI /120 or 15 
(min/min) 
Cardioprotection by inhibition of MPTP opening. 
Before and during reperfusion: ↓ IFS, improves function 
recovery ( ↑ LVDp and ↓ LVED p), ↓necrosis (↓LDH);  
reduction  to MPTP sensitivity by increasing resistance to 
Ca2+, prevention of NAD+ release and mitochondrial 
cytochrome-c release 
Petrosillo et al., 2009 
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Types of 
studies 
 
Model 
Duration 
of I/R 
Melatonin actions Reference 
In vivo & 
in vitro 
In situ mice & 
isolated mice heart 
(Langendorff method) 
50min/4 hours 
40/45 
(min/min) 
Cardioprotection independently of GPx activation.  
↑LVEDp and ↓ LDH level , ↓IFS 
Chen et al., 2009 
In  vivo in situ   rat heart 
45/60 
(min/min) 
↓ ventricular  tachycardia and fibrillation; lowered total 
ventricular contractions, suppression of  superoxidase 
production (˙O2) and lowered myloperoxide  (MPO) activity, 
lowered infarct size, increased survival 
Lee et al., 2002 
In  vivo in situ   rat heart 
7/7 
(min/min) 
↓ ventricular fibrillation, lowered mortality Sahna et al., 2002b 
In  vivo in situ   rat heart 
3/120 
(min/min) 
↓ infarct size Sahna et al., 2002a 
In  vivo in situ rabbit heart 
30/180 
(min/min) 
No improvement in cardiac function, no reduction in infarct 
size 
Dave et al., 1998 
In vivo In situ mice heart 
60 /4 
(min/hours) 
Melatonin treatment 30 min before ischemia, ↓ significantly 
the infarct size/risk area. Mel treatment after ischemia was 
not protective. 
Chen et al.,2003 
In vivo in situ heart   rat 
30/120 (RI) 
(min/min) 
Regional ischaemia(RI):↓ infarct size,↓ MDA values, ↑GSH 
levels 
Sahna et al., 2005 
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Types of 
studies 
 
Model 
Duration 
of I/R 
Melatonin actions Reference 
In vivo 
in situ heart   rat 
(chronic nitric oxide 
synthase inhibited rats) 
30/120 (RI) 
(min/min) 
Regional ischaemia (RI): ↓ infarct size & BP Deniz  et al., 2006 
In vivo 
In situ heart 
cardiomyopathic 
hamsters 
30/30 
(min/min) 
↓ post ischaemic VT and VF, lowed % lethality ;          
↓ oxidative stress (lipid peroxidation: TBARS) and 
nitrosative stress (nitrite/nitrate), leukocyte adhesion, 
vascular permeability, increased capillary perfusion, 
reduced MAP. 
Bertuglia et al., 2007 
In vivo 
in situ heart   rat 
(chronic nitric oxide 
synthase inhibited rats) 
30/120 (RI) 
(min/min) 
Regional ischaemia (RI): 
↓ infarct size & BP; ↓ MDA values, ↑MPO levels 
Sahna et al., 2008 
In vivo In situ  heart rat 
20/20 
(min/min) 
↓cardiac troponin (cTn-T), MDA, MPO levels 
↑ SOD levels, Bcl-2 expression 
↓Fas expression, oedema myofibrils, vascularity, 
inflammatory infiltration 
Ceyran et al., 2008 
 
↓ decrease; ↑ increase; GI, global ischaemia, RI, regional ischaemia; I/R, ischaemia reperfusion, MPTP mitochondrial permeability 
transition pore ; SERCA2a, sarco-(endo)-plasmic reticulum Ca2+-ATPase2; LDH, lactate dehydrogenase; VT, ventricular tachycardia; 
VF, ventricular  fibrillation ; MPO, myeloperoxidase;  SOD, superoxide dismutase ; MAP, mean arterial pressure; HR, heart rate; BP, 
blood pressure; GSH, reduced glutathione; LVDp, left ventricular developed pressure; LVEDp, left ventricular end-diastolic pressure; 
TBARS, thiobarbituric acid reaction substance; MDA, malondialdehyde. 
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2.5. MOTIVATION FOR THE STUDY 
 
2.5.1. Problem statement 
  
As previously discussed, obesity is a major risk factor for myocardial infarction, one of the 
common consequences of ischaemic heart disease.  The mechanistic link between obesity 
and ischaemic heart disease is complex and not yet fully understood. High circulating free fatty 
acids can induce cellular dysfunction by increasing mitochondrial reactive oxygen species 
(ROS) generation leading to elevated systemic (Furukawa et al., 2004; Vincent et al., 2006) 
and myocardial oxidative stress (Vincent et al., 1999; Finck & Kelly, 2002; Chess & Stanley, 
2008) in obesity. Oxidative stress (elevated free radicals generation) plays an important role in 
the pathogenesis of cardiovascular disease in general (Dhalla et al., 2000a), and myocardial 
ischaemia/reperfusion injury in particular (Opie, 2004; Yellon & Hausenloy, 2007). In addition, 
it has a crucial role in development of metabolic syndrome which in turn increases the 
incidence of myocardial infarction in obesity (Anand et al., 2008; Iglesias Bolanos et al., 2009). 
Diet-induced obesity has been shown to increase myocardial susceptibility to 
ischaemia/reperfusion (I/R) injury in the rat model (Du Toit et al., 2008), demonstrating the 
strong association between more severe myocardial infarction (MI) and obesity in humans 
(Yusuf et al., 2005).  
 
Nowadays, there is a strong recommendation to use the antioxidant melatonin in the 
management of myocardial infarction (Korkmaz et al., 2009; Reiter et al., 2008).  Indeed, 
melatonin is involved in a wide range of physiological functions in humans and animals 
including amongst other antioxidant, anti-inflammatory, anti-excitatory, and vasomotor effects 
(Pandi-Perumal et al., 2006). It has been shown that subjects with myocardial infarction have 
low circulating melatonin levels (Dominguez-Rodriguez et al., 2002) and pinealectomized rats  
have been shown to have a bigger post-ischaemic myocardial infarction than non-
pinealectomized rats (Sahna et al., 2002a). Acute melatonin treatment protects the heart 
against I/R injury (Reiter & Tan, 2003; Petrosillo et al., 2009; Lochner et al., 2006; Genade et 
al., 2008; Tengattini et al., 2008).  The long-term administration of melatonin also reduces 
myocardial infarction (Lochner et al., 2006) in lean animals, indicating its potential long-term 
therapeutic utility. However, the effects of melatonin still remain far from being completely 
elucidated.  Melatonin not only has direct cardiac benefits but chronic administration of 
melatonin was associated with amelioration of physiological changes related to obesity such 
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as decreases in body weight gain, blood pressure, circulating glucose, insulin, leptin and lipid 
levels as well as increase in antioxidant enzymes (Hussein et al., 2007; Prunet-Marcassus et 
al., 2003; She et al., 2009), suggesting a possible role for melatonin in obesity management.  
However, to our knowledge, the effects of melatonin treatment on the heart in obesity remain 
unknown.  In addition, the preventive effects of chronic melatonin before the establishment of 
obesity in animal model of diet-induced obesity have not been studied. Furthermore, the 
signalling mechanisms of the cardioprotective effects of melatonin have not yet been 
completely established.   
 
The aim of this study was therefore to investigate the effects of chronic melatonin treatment on 
myocardial function and susceptibility to ischaemia-reperfusion injury in obesity. We also 
wished to elucidate some of the potential mechanisms responsible for these cardiac effects. 
2.5.2. Hypothesis 
 
We hypothesized that a high calorie diet will induce obesity which, would increase myocardial 
susceptibility to ischaemia/reperfusion injury (I/R) and exacerbate post ischaemic myocardial 
infarction and, by virtue of its antioxidant effects, chronic melatonin treatment before the 
establishment of obesity will prevent the development of insulin resistance and attenuate the 
susceptibility to I/R injury as well as the post-ischaemic myocardial infarction. 
2.5.3. Specific aims 
 
The specific aims of this study were to:  
1. Investigate the effects of chronic melatonin administration on the development of diet-
induced systemic metabolic alterations.  Physiological parameters measured were body 
and heart weight, circulating glucose, lipids, insulin, and leptin levels. Oxidative stress was 
assessed by measuring serum lipid peroxidation and glutathione (GSH) levels. 
2. Determine whether chronic melatonin treatment protects the myocardium against 
ischaemia/ reperfusion injury. End-points investigated were infarct size and function 
recovery. 
3.  Determine whether melatonin treatment confers cardioprotection by altering the 
reperfusion injury salvage kinase (RISK) (i.e. PKB/Akt and ERK p42/p44), p38 MAPK and 
AMPK as well as GLUT-4. 
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         CHAPTER THREE 
3. MATERIALS AND METHODS 
3.1. ANIMALS 
 
Age and weight matched male Wistar rats were used in this study. All animals were obtained 
from the University of Stellenbosch Central Research Facility. They received free access to 
water and food under the 12-h dark/light cycle (light from 6:00 a.m. to 6:00 p.m.) with 
temperature and humidity kept constant at 22ºC and 40%, respectively. This study was 
assessed and approved by the Committee for Ethical Animal Research of the Faculty of Health 
Sciences, University of Stellenbosch, and animals were treated according to the “Guide for the 
Care and Use of Laboratory Animals”, published by US National Institutes of Health (NIH 
publication no 85-23, revised 1985). 
3.2. STUDY DESIGN 
 
This study was divided in 3 major phases (see fig.3.1). The first, before any intervention, 
consisted of grouping, feeding and treatment.  During the second phase experimental 
procedures including anthropometric measurements, perfusion of the hearts as well as blood 
and heart tissue collection were performed. The third phase included biochemical analyses of 
collected samples (see fig.3.1). 
 
3.2.1. Grouping, feeding and treatment   
  
Male rats weighing 200±20 g were randomly allocated to the following groups: group C, control 
rats receiving a standard commercial rat chow and drinking water without melatonin; group 
CM, control rats receiving a standard commercial rat chow and melatonin in drinking water; 
group D, diet-induced obesity (DIO) rats, receiving a high calorie diet and drinking water 
without melatonin; group DM, diet-induced obesity rats, receiving a high calorie diet and 
melatonin in drinking water.  Animals were fed and treated for a period of 16 weeks (see 
fig.3.1). Food and drinking water with or without ethanol or melatonin was replaced daily to 
avoid fermentation of wet food.  
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Obesity was induced as previously described (Du Toit et al., 2008). Diet-induced obesity 
groups (D and DM) were fed a high-calorie diet consisting of 65% carbohydrates, 19% protein 
and 16% fat. Control groups (C and CM) were fed a standard rat chow (SRC) consisting of 
60% carbohydrate, 30% protein and 10% fat. The high calorie diet was prepared containing 
33% SRC and 33 % sweetened full cream condensed milk (Clover®), 7% sucrose and 27% 
water.  It has been previously shown in our laboratory that rats receiving a SRC and a high 
calorie diet consumed 371±18 and 570±23 kj of energy per day, respectively (Du Toit et al., 
2008).  
 
3.2.2. Melatonin administration 
 
Melatonin (Sigma Aldrich, St Louis, MO, USA) was orally administered (Lochner et al., 2006). 
It was first dissolved in small amount of absolute ethanol and then added to drinking water at 
final concentration of 0.05% (v/v) ethanol with melatonin (60 μg/ml or 40 μg/ml).  The drinking 
water intake of control rats was higher than that of obese rats probably due to the fact that the 
diet was essentially a liquid. In order to achieve a final dosage of 4 mg/kg/day, DM and CM 
rats respectively received 60 μg/ml and 40 μg/ml of melatonin in drinking water. Bottles 
containing melatonin solution were covered with aluminium foil as melatonin is light sensitive. 
The melatonin solution was stored at -4ºC until used.  Drinking water with or without melatonin 
was replaced every day. 
 
To test the possible long term additional effects of the melatonin vehicle (0.05% ethanol), we 
conducted a separate study where animals were divided in four groups: C, control rats 
receiving drinking water only; CE, control rats receiving 0.05% (v/v) ethanol in drinking water; 
D diet induced obesity rats receiving drinking water only, and DE, diet induced obesity rats 
receiving 0.05% (v/v) ethanol in drinking water. Absolute ethanol (1 ml) was dissolved in 2 L 
drinking water to yield a final concentration of 0.05%. Drinking water with or without ethanol 
was replaced every day. 
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Male
Wistar rats
(200±20g)
Control 
SRC
Diet-
induced 
obesity
Untreated Mel
Biochem Infarct size Biochem Infarct size
Untreated Mel
Biochem Biochem Infarct sizeInfarct size
16 weeks
Feeding & treatment
Hearts 
perfusion
Biochem. 
Analysis
Feeding          
&   
Treatment
BW
PROCEDURE
4 groups
Tissues 
Collection
1
3
2
Blood glucose & lipid profiles, serum insulin, leptin, glutathione (GSH) & lipid peroxidatation
(TBARS) assay.
Heart tissue: GSH assay, Western blots for PKB/Akt, ERK 42/44, p38 MAPK, AMPK,GLUT-4.
 
Figure 3- 1 Major phases of the study  
 
(1): grouping, feeding and treatment; (2): determination of body and visceral fat weight, heart perfusion 
and collection of blood and heart tissue samples; (3): biochemical analyses. BW, body weight; Mel, 
melatonin; TBARS, thiobarbituric acid reactive substances; Biochem, biochemical analysis; SRC, 
standard rat chow. The arrow shows the time-direction of procedure. 
 
3.3. EXPERIMENTAL PROCEDURE 
 
The experimental procedures and major phases of the studies are presented in fig.3.1.   After 
16 weeks of feeding and treatment non-fasted or overnight fasted animals were sacrificed. 
Before the sacrifice, the animals were anaesthetized, and body weights determined.  After 
collection of blood from the thoracic cavity of the rat, following the excision of the heart, 
visceral fat was collected and weighed. At the end of the reperfusion period of the isolated 
hearts, Evans blue suspension was infused (see section 3.3.1.5) and all excess non-cardiac 
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tissue removed, the hearts were rapidly blotted, weighed and subsequently frozen for infarct 
size determination. This technique has previously been used in other studies (Asai et al., 2005; 
Du Toit et al., 2005). The weight of the infused suspension was subtracted from the measured 
heart weight to obtain the final heart weight. In separate experiments, we found no differences 
between the weights of unperfused and reperfused hearts (after 2h reperfusion). The heart to 
body weight ratios were calculated and expressed in mg/g. 
 
3.3.1. Heart perfusion  
  
To perfuse the hearts a modified Krebs-Henseleit bicarbonate buffer (KHB) was used, 
containing (in mM): NaCl 119, NaHCO3 24.9, KCl 4.7, KH2PO4 1.2, Mg SO4.7H2O 0.59, and 
Na2SO4 0.59, CaCl2H2O 1.25 and Glucose 10. The KHB was oxygenated and kept at pH 7.4 
by gassing with 95% O2 and 5% CO2 at 37° C.  
 
3.3.1.1. Isolated heart perfusion technique 
 After 16 weeks of feeding and treatment rats were anaesthetized by intraperitoneal injection of 
sodium pentobarbital (Merck, Cape Town, South Africa) given at the dose of 30 mg/kg 
(Lochner et al., 2003). The rat heart was rapidly excised and arrested in ice-cold (4ºC) normal 
saline solution and thereafter mounted via the aorta onto the aortic cannula as follows. A string 
was tied around the aorta to secure it firmly to the cannula and care was taken to avoid leaks 
between the aortic cannula and the aorta as well as air bubbles in the aortic cannula.  
The hearts were first perfused in the Langendorff mode (retrogradely), in non re-circulating 
manner at a constant hydrostatic pressure (100 cm H2O) for 15 minutes. This allows the hearts 
to stabilize as well as washout of blood. The left atrium was cannulated via the pulmonary vein. 
After 15 minutes of the retrograde perfusion, the perfusion mode was switched to the working 
heart mode (see perfusion protocol fig.3. 2) (preload 15 cm H2O and afterload of 100 cm H2O) 
(Neely et al., 1967; Depre, 1998).  The subsequent contraction of the left ventricle expelled the 
perfusion solution to the aortic cannula against the constant pressure of 100 cm H2O. The 
hearts were not electrically paced. Myocardial temperature was thermostatically controlled by 
inserting a temperature probe into the pulmonary artery.  It was monitored at regular intervals 
(constant at 37ºC during reperfusion and 36º5 C during ischaemia) and the water bath was 
adjusted accordingly.  Two modes of ischaemia were used: regional and global ischaemia. 
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3.3.1.2. Induction of ischaemia 
 
3.3.1.2.1. Regional ischaemia (fig.3.2 A) 
 
After the stabilisation period, a silk suture with a ½ circle, 25 type needle size, was inserted 
underneath the proximal left anterior descending coronary artery (LAD) and after measuring 
coronary flow (CF), the suture was tightened and the LAD occluded for 40 minutes at 36.5ºC.  
Adequate regional ischaemia was indicated by a 33% reduction in CF compared to the pre-
ischaemic CF. Regional ischaemia was also confirmed by cyanosis of the myocardial surface. 
After 40 minutes of ischaemia, the silk suture was released, and the heart reperfused for 120 
minutes to determine infarct size (see perfusion protocol fig. 3.2 A).  Mechanical function was 
documented before induction of ischaemia and during reperfusion.  
 
3.3.1.2.2. Global ischaemia (fig.3.2B) 
 
The hearts were stabilized as mentioned above. After stabilisation, the aortic cannula was 
occluded causing a total cessation of coronary perfusion to the heart (no-flow ischaemia). 
During the ischaemic period, myocardial temperature was maintained at 36.5ºC, and after 20 
minutes of ischaemia, the aortic cannula was opened for reperfusion of the heart for 10 
minutes (see perfusion protocol fig 3.2 B).  At the end of reperfusion, hearts were freeze 
clamped and stored in liquid nitrogen for further biochemical analysis. 
 
3.3.1.3. Perfusion protocol (fig.3.2)  
 
Isolated hearts were perfused using two different protocols for the evaluation of myocardial 
function and infarct size as well as for biochemical analysis (western blot analysis) (see fig.3. 
2). In the case of measurement of myocardial function and infarct size, as previously 
mentioned, regional ischaemia was induced for 40 minutes of coronary artery ligation followed 
by 120 minutes reperfusion (see fig.3.2 A), whereas for the evaluation of activation of pro-
survival kinases (western blots), all hearts were subjected to a no-flow global ischaemia for 20 
minutes (36°5C) followed by 10 minutes reperfusion (see fig.3.2 B).  The pre-ischaemic 
function was documented after 15, and 30 minutes of stabilization (before ischaemia) and the 
post-ischaemic mechanical function was recorded at 30, and 60 minutes of reperfusion.  
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Figure 3- 2 Perfusion protocol.  
A, determination of infarct size and myocardial function; B, western blot analysis (RISK pathway, p38 
MAPK, AMPK and GLUT-4); LD, Langendorff; WH, working heart 
 
3.3.1.4. Myocardial function determination 
 
The coronary and aortic flow rates were measured manually. Cardiac output (CO) was 
calculated as the sum of aortic output (AO) and coronary flow (CF). The aortic systolic and 
diastolic pressure (mmHg) and heart rate (HR)(beats per minute (bpm)) were monitored and 
recorded on a computerized system through a side-arm of the aortic cannula connected to a 
Viggo-Spectramed pressure transducer coupled to the computer system. Total work 
performance (pressure power + kinetic power) developed by the heart was determined 
according to the formula described by Kannengieser et al. (1979).  To determine functional 
recovery, the post-ischaemic value was expressed as the percentage of the pre-ischaemic 
value.  All data were collected and analysed using a PhysiTutor® data acquisition system. 
 
3.3.1.5. Determination of area at risk and infarct size 
 
Myocardial infarct size was determined as previously described (Lochner et al., 2003). At the 
end of 2 hours reperfusion, the silk suture around the coronary artery was securely tied and 
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1ml of a 0.5% Evans blue suspension was slowly injected via the aorta cannula. The heart was 
then frozen overnight before being cut into 2 mm thick slices. After defrosting, the slices were 
stained with 1% w/v triphenyl tetrazolium chloride (TTC) in phosphate buffer pH 7.4 at 37ºC for 
15 minutes. Slices were then fixed in 10% v/v formaldehyde solution (at room temperature) to 
enhance the contrast between stained viable tissue and unstained necrotic tissue. At this 
stage, the damage for each slice was visible; the blue area indicating a viable tissue, the white 
or unstained area indicates a damaged or infarcted area surrounded by a red area. The red 
area together with the white area constitutes the area at risk. All slices were drawn and 
scanned.   For each slice, the left ventricle area at risk (AR) and the area of infarcted tissue in 
the risk zone were determined using computerized planimetry (UTHCSA Image Tool 
programme, University of Texas Health Science Center at San Antonio, TX, USA). For each 
heart, the areas of the tissue slices were summated. The infarct size (IFS) was expressed as 
the percentage of the area at risk (I/AR %). 
 
3.3.2. Biochemical analyses 
 
3.3.2.1. Western blot analysis 
 
3.3.2.1.1. Tissue collection 
 
Hearts were either collected without perfusion (baseline) or after reperfusion (see protocol fig. 
3.2 B).  At baseline, hearts were excised and mounted on the perfusion apparatus as 
previously described. After flushing out of the blood and removing all surrounding tissues, the 
hearts were freeze-clamped with pre-cooled Wollen-berger tongs and plunged into liquid 
nitrogen for later biochemical analyses. To evaluate the post-ischaemic protein changes, 
hearts were freeze-clamped after reperfusion following global ischaemia. In a pilot study we 
found that the optimum activation of pro-survival proteins PKB /Akt, ERK 42 and 44 occurred 
during early reperfusion at 10 minutes (results not shown). Therefore, all hearts were routinely 
freeze-clamped at this time interval. 
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3.3.2.1.2. Preparation of lysates 
 
Cytosolic PKB/Akt, ERK 42 and 44, p38 MAPK, AMPK, and GLUT-4 were extracted from 
frozen myocardial tissue. The tissue was pulverized and homogenized in 600 to 900μl of lysis 
buffer by a Polytron homogenizer. The lysis buffer was made up of (in mM) Tris-HCl 20, p-
nitrophenylphosphate 20, EGTA 1.0, EDTA 1, NaCl 150, tetra-sodium-pyrophosphate 2.5,  ß-
glycerophosphate 1.0, sodium orthovanadate 1.0, phenylmethyl sulphonyl fluoride (PMSF) 1.0, 
aprotinin 10 μg/ml and leupeptin 10 μg/ml, Triton-X100 1%, pH 7.4. Samples were then 
centrifuged at 1000xg for 10 minutes to obtain the supernatant, which was subsequently used 
for western blotting.  
 
3.3.2.1.3. Western blot technique  
  
The protein content for the expression of total and phosphorylated PKB/Akt, ERK; p38 MAPK, 
AMPK and GLUT-4 expression was determined using the Bradford technique (Bradford, 1976). 
The tissue lysates were then diluted in Laemmli sample buffer. They were boiled for 5 minutes 
and stored at -20ºC.  
 
3.3.2.1.3.1. Protein separation and transfer (tables 3.1 and 3. 2) 
 
Depending on type of protein (see table 3.1), 10 to 50 μg of protein was separated by sodium 
dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) using the standard BIO-
RAD Mini-Protean III system. The gel was made up of a 10 or 12% polyacrylamide gel 
(resolving gel) and 4% stacking gel on the top of resolving  gel (see gel composition table 3.2).   
The running buffer contained (in mM) Tris 250, glycine 192 and 1% sodium dodecyl sulphate 
(SDS). The electrophoresis separation technique is based on the mobility of ions in an electric 
field.  Samples, including the commercial molecular weights marker, were loaded into wells in 
the gel. The marker helped to localize exactly the level of each protein separated, according to 
its molecular weight (see table 3.1). After separation, proteins were then transferred to a PVDF 
membrane (ImmobilonTM P, Millipore) using a tank electrotransfer set up. The transfer buffer 
contained (in mM) Tris-HCl 25, glycine 192, and methanol (20% v/v). These membranes were 
routinely stained with Ponceau red for visualization of proteins and to confirm an adequate 
transfer.  
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3.3.2.1.3.2. Blocking of membrane and incubation with antibodies (table 3.1) 
 
Non-specific binding sites on the membranes were blocked with 5% fat-free milk in TBST (Tris-
buffered saline + 0.1% Tween 20) for  1 to 2 hours at room temperature and then incubated 
overnight at 4ºC with the primary antibodies that recognize total or phospho-specific proteins. 
In this study we used total ERK p42/p44 and phospho-ERK p42/p44 (Thr-202/Tyr- 204); total 
PKB/Atk and phospho-PKB/Akt (Ser-473); total p38 MAPK and dual phospho-p38 MAPK (Thr-
180/Tyr-182); total AMPKα and phospho-AMPK (Thr-172); and Glut-4 (purchased from Cell 
Signalling Technology).  Primary antibodies were diluted in TBST solution or in 5% milk 
solution (see table 3.1).  Membranes were washed with TBST (5x5 minutes) and then 
incubated for 1 hour at room temperature, with a diluted horseradish peroxidase-labelled 
secondary antibody (Amersham, LIFE SCIENCE). The secondary antibody was either diluted 
in TBST or in 5% fat free milk solution (see table 3.1). 
 
3.3.2.1.3.3. Visualisation or immunodetection 
 
After thorough washing with TBST, membranes were covered with ECL (enhanced 
chemiluminescence) detection reagents (Amersham, LIFE SCIENCE) and quickly exposed to 
an autoradiography film (Hyperfilm ECL, RPN 2103-Amersham, LIFE SCIENCE) to detect light 
emission through a non-radioactive method (ECL western blotting).   Films were 
densitometrically analysed (UN-SCAN-IT, Silk Scientific Inc., Orem, Utah, USA) and activated 
protein values were determined. The protein activation was expressed as a ratio of phospho- 
to total protein.  
 
Table 3- 1 Western blot analysis 
Protein Molecular 
weight 
Protein 
loaded 
Resolving gel  
(SDS-PAGE) 
Primary antibody 
dilution 
Secondary antibody 
dilution 
PKB/Akt 
 60kDa 30μg 12% 1:1000 TBST  
1:4000   
5% milk TBST  
ERK 42/44 
 42/44kDa 25μg 12%  1:1000 TBST 1:4000 TBST 
P38 MAPK 43kDa 25μg 12% 1:1000 TBST 1:4000 TBST 
AMPK 62kDa 50 μg 10% 1:1000   5% milk TBST 
1:4000  
 5% milk TBST 
Glut-4 
 45kDa 30 μg 10% 1:1000 in TBST 1:4000 in TBST 
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 Table 3- 2 SDS-polyacrylamide gel 
Reagent Stock 10% Gel 12% Gel 4% Stack gel 
dH2O distilled 4.9 ml 3.35 ml 3.05 ml 
Tris-HCl(pH 8.8) 1.5 M 2.50 ml 2.50 ml (1.5M) _____ 
Tris-HCl(pH 8.8) 0.5 M _____ _____ 1.25 ml 
SDS 10% 100 μl 100 μl 50 µl 
Acrylamide 40% 2.50 ml 3.0 ml 0.5 ml 
APS 10% 50 μl 50 μl 50 µl 
TEMED                     99% 20 μl 20 μl 10 µl 
 
3.3.2.2. Glutathione assay 
 
 To determine the myocardial antioxidant status, the levels of total glutathione were determined 
using the Glutathione Assay Kit purchased from Sigma Aldrich (St Louis, MO, USA). The total 
glutathione is the sum of the reduced glutathione (γ-glutamylcysteinylglycine) (GSH)(90-95%) 
and glutathione disulfide (GSSG) (oxidized glutathione) (5-10%).  GSH is the key antioxidant in 
animal tissue.  All reagents were prepared according to the technical bulletin accompanying 
the assay kit.  Here we described briefly the assay principle and procedure (for assay details 
see Akerboom & Sies, 1981).   The principle of this assay is the reaction in which catalytic 
amounts of GSH cause a continuous reduction of 5, 5-dithiobis (2-nitrobenzoic acid) (DTNB) to 
5-thio-2-nitrobenzoic acid (TNB) (see below reaction 1).  The GSSG formed is then recycled by 
glutathione reductase and NADPH to generate GSH (see reaction 2).  The principle is 
summarized in the following reactions (1 & 2). 
 
 
 
Frozen tissue was pulverized and an aliquot (0.1-0.3 g) was mixed and homogenised with 10 
volumes of 5% 5-sulfosalicylic acid (SSA) to remove proteins.  After 10 minutes at 4ºC, the 
suspension was centrifuged at 10,000xg for 10 minutes.   The supernatant was measured and 
kept at -80º C as the original sample. Additional dilutions were made to obtain a sample 
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solution in the detection range.  To 10 μl of sample, 150 μl of working mixture (95mM 
potassium phosphate buffer pH7.0, 0.95mM EDTA, 0.031 mg/ml 5, 5-dithiobis (2-nitrobenzoic 
acid) (DTNB), and 0.115 units /ml glutathione reductase) was added.  The mixture was then 
incubated at room temperature for 5 minutes and 50 μl of the diluted NADPH solution (48 μM 
NADPH) was added. The mixture became yellowish as the final product 5-thio-2-nitrobenzoic 
acid (TNB) is yellow.   This was measured spectrometrically at 412 nm using a plate reader.  A 
standard curve was used to determine the amount of glutathione. GSH content in unknown 
sample was calculated using the following formula: 
 
∆A412/min (sample) = slope generated by the samples after subtracting the values generated 
by the blank reaction; ∆A412/min (1nmole) = slope calculated from standard curve for 1 nmole 
of GSH; dil. = dilution factor of original sample; vol. = volume of sample in the reaction in ml.    
 
The final level of GSH was expressed in nmoles /gram of wet tissue. The same procedure was 
used for determination of serum GSH with some differences in sample extraction and 
calculation of the final GSH concentration.  200μl of serum was used as original sample in 
place of supernatant and the final levels of GSH was expressed in nmoles / ml of serum. 
 
3.3.2.3. Blood analysis 
 
3.3.2.3.1. Blood collection 
 
Blood samples were collected as previously described (Du Toit et al., 2005). Blood was 
obtained from the thoracic cavity immediately after removal of the heart and collected in serum 
separation tubes (BD Vacutainer). Tubes were centrifuged at 3,000 rpm at 4°C within 30 
minutes of collection. Serum was transferred in eppendorff tubes and stored at -80ºC for 
further analyses. 
3.3.2.3.2. Blood glucose determination 
  
Fasting blood glucose was measured using the glucose meter (Gluco PlusTM, distributed by 
CIPLA DIBCARE, Bellville, South Africa). A small drop of flesh blood, obtained by pricking the 
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distal tail with a lancet was placed on a disposable test strip and after 5 seconds, the meter 
displayed the blood glucose level expressed in mmol/l. 
3.3.2.3.3. Blood lipid levels 
  
Fasting lipid levels were determined using CardioCheck® PA analyser according to the 
instructions sheet accompanying the test strips. After the removal of the heart, 40 μl of flesh 
blood was collected and placed on a lipid test strip (PTS Panels TM; Polymer technology, IN, 
USA). After 2 minutes the levels (in mmol/L) of total cholesterol, HDL-cholesterol, triglycerides 
were displayed. Serum LDL cholesterol was not measured as this was not possible using this 
test. 
3.3.2.3.4. Insulin assay 
 
 Fasting serum was collected as described above.  The insulin level was determined using a 
competitive radioimmunoassay (RIA) (Coat-A-Count® Insulin Diagnostic Products Corporation; 
LA, USA).  
3.3.2.3.4.1. Radioimmunoassay principle 
  
A fixed concentration of labeled tracer antigen is incubated with a constant dilution of 
antiserum so that the concentration of antigen binding to sites on the antibody is limited.  For 
example only 50% of the total tracer concentration may be bound by antibody. If unlabeled 
antigen is added to this system, there is competition between the labeled tracer and the 
unlabeled antigen for the limited and constant number of binding sites on the antibody. Thus, 
the amount of tracer bound to antibody will decrease as the concentration of unlabeled antigen 
increases.  This can then be measured after separating the free and bound antibodies.   
 
In the case of insulin test, a fixed amount of labelled insulin would compete with insulin present 
in blood samples for binding sites on an insulin specific antibody. The antibody is immobilized 
in the wall of the tube. The free and bound antibodies are separated by decanting the tubes. 
The radioactivity was measured using a gamma scintillation counter (Cobra II Auto Gamma, 
ADP, South Africa).  
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3.3.2.3.4.2. Assay procedure 
 
Before the assay was performed, the components were brought to room temperature. All 
samples were done in duplicate. Uncoated polypropylene tubes were labeled for total counts 
(T) and non specific binding (NSB). Insulin antibody coated tubes were labeled for standards, 
controls and serum samples. 200 μl of the zero calibrator A was pipetted into the NSB tubes. 
200 μl of the remaining calibrator, control and sample were pipetted in their respective tubes.  
1.0 ml of 125I insulin was added to each tube and subsequently vortexed and incubated for 22-
24 hours at room temperature.  The tubes were then decanted (except for the total counts) and 
the samples allowed to drain for 2-3 minutes. Excess liquid was blotted from the lip of tubes 
and the radioactivity for each tube was determined in gamma counter for 1 minute. A standard 
curve was included to determine the concentration of the unknown samples. 
The homeostasis model assessment (HOMA) index was calculated as the product of fasting 
glucose concentration (mmol/l) multiplied by insulin concentration (μU/ml) divided by 22.5 
(Muniyappa et al., 2008).   
 
3.3.2.3.5. Leptin assay 
  
Serum was collected as previous mentioned. Serum leptin levels were measured using a rat 
leptin radioimmunoassay (RIA) kit (Linco Research, St. Charles, MO, USA) according to 
information product accompanying the kit. The RIA principle is described above. Briefly, assay 
buffer was pipetted (300 μl) in non specific binding (NSB) tubes, (200 μl) in the reference (Bo) 
tubes, and (100 μl) in standards or quality controls or samples tubes. 100 µL of Standards (0.5, 
1, 2, 5, 10, 20, and 50 ng/L) or quality controls or samples were respectively added to their 
assay buffer tubes. The anti-leptin antibody (100 µL) was added and in all tubes except the 
total and NSB tubes, mixed and incubated overnight (24 hours) at room temperature.  100 µL 
of 125I-Rat leptin tracer was added and mixed to all tubes, and incubated for an additional 
24hours.  A cold precipitating reagent (1.0 mL; anti-guinea pig IgG, raised in goats) was added 
to all tubes except the total count tubes and incubated for 20 min at 4°C to precipitate the 
antibody/leptin complex.   All tubes were then centrifuged for 20 minutes at 3000xg at 4°C. The 
supernatants were decanted and the pellet radioactivity was counted using a gamma counter 
(Cobra II Auto Gamma; ADP, South Africa).  The leptin concentrations for the samples were 
calculated from the standard curve and expressed in ng/ml.  
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3.3.2.3.6. Lipid assay 
 
Lipid peroxidation refers to the oxidative degradation of lipids. Non fasting serum samples 
were assayed for lipid peroxidation, total cholesterol (TC), triglycerides (TRIG) and 
phospholipids (PL). Serum TC and TRIG concentrations were determined using enzymatic 
colorimetric kits (KAT Medicals, Calicom Trading (PTY), South Africa) and PL (WAKO 
Chemicals, Germany) by a Labsystems Multiskan MS analyzer (AEC Amersham Co., South 
Africa). TRIG and PL were determined by the same methods, for standardization as reference 
mass for lipid peroxidation.  
Concentrations of conjugate dienes (CD), lipid hydroperoxide (LOOH) and thiobarbituric acid 
reactive substances (TBARS) were measured in non fasting serum by spectrophotometric 
methods using a GBC UV/VIS analyser (Wirsam Scientific and Precision Equipment, South 
Africa) (CD) or Labsystems Multiskan MS Analyser (AEC Amersham Co., South Africa) (LOOH 
and TBARS).  Concentrations were calculated using the appropriate molar extinction 
coefficients and standards.  
 
CD were measured at 234 nm after appropriate dilution in cyclohexane (Spectrosol) 
(Esterbauer et al., 1989; Pryor & Castle, 1984). After mixing the serum samples with 
cyclohexane, separation was enhanced by centrifugation (14,000 × g for 10 min at 10°C).  
To determine LOOH, serum was assayed in the presence of xylenol orange (3,3′-bis[N,N-
di(carboxymethyl)-aminomethyl]-o-cresolsulfonephthalein) (sodium salt) (Sigma Chemical Co., 
St Louis, MI, USA) and Fe2+ in the ferrous oxidation/xylenol orange (FOX) assay that was 
adapted to enhance the solubility of non-polar compounds by including chloroform. 
Absorbance of the resulting Fe3+-xylenol orange complex was measured at 560 nm (Jiang et 
al., 1991 & 2002).  
 
TBARS were measured according to the method of Jentzsch et al. (1996). The samples (200 
μl) were mixed with 25 μl butylated hydroxytoluene (BHT) (Fluka Chemie, Switzerland) in 
ethanol (Merck Chemicals, South Africa) and orthophosphoric acid (Sigma) buffer at pH 3.6 
and vortexed for 10 seconds. 25 μl thiobarbituric acid (TBA) (Sigma) reagent was added and 
vortexed again. After incubation at 90ºC for 45 minutes in water bath, the reaction was stopped 
by putting tubes on ice. TBARS were extracted with n-butanol. Saturated NaCl was added and 
the mixture was then centrifuged at 12,000 rpm for 1 minute.  Absorbance was read at 532 nm. 
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3.4. DATA ANALYSIS 
 
 All data were expressed as mean ± standard error of the mean (SEM). Infarct size was 
expressed as a percentage of the area at risk, and for functional recovery data, reperfusion 
aortic output and work total were expressed as a percentage of the pre-ischaemic value. When 
comparisons between two groups (diet and control groups) were made, an unpaired Student t-
test was performed. For multiple comparisons, the ANOVA (two-way when appropriate) 
followed by the Bonferroni correction was applied. A p-value of <0.05 was considered 
significant. 
  73
4.               CHAPTER FOUR 
              RESULTS  
4.1. BIOMETRIC AND METABOLIC DATA  
4.1.1. Characteristics of the diet-induced obesity model (fig.4.1) 
 
The body weight of control (C) rats was averaged 387.8 ± 11.3 g.  The high calorie diet (D) 
increased the body weight by 29.6% (p< 0.001) over a period of 16 weeks (fig.4.1A).  It also 
increased the visceral fat content by 78.1% (p<0.001).  Fasted blood glucose (fig.4.8) was not 
different between the control (C) and high calorie diet (D) groups.  Serum insulin and leptin 
levels were elevated by 80.6% (p<0.05) and 80.7% (p<0.05) respectively in the diet fed (D) 
rats (fig.4.1).   Lipid profiles were also affected. Compared to control rats, the high calorie diet 
caused a significance increase in triglyceride (1.44 ± 0.1 vs 0.87 ± 0.1; p<0.01) and a reduction 
in high density lipoprotein (HDL)-cholesterol (0.67 ±0.1vs 0.92 ± 0.1; p <0.01) (fig.4.1).   The 
heart weight of control rats was 1013±44 mg. The high calorie diet increased the heart weight 
by 29.7% (p<0.05) (fig.4.6). The heart weight to body weight ratio was 2.58±0.1 mg/g for 
control rats and the diet had no significant effects on the heart weight/body weight ratio 
(fig.4.7).  
 
4.1.2. Impact of the melatonin vehicle (0.05% v/v ethanol)   
 
Melatonin was dissolved in small amount of ethanol and added in drinking water to make the 
final solution of 0.05% (v/v) ethanol in drinking water. To test the possible long-term additional 
effects of the vehicle (0.05% (v/v) ethanol), ethanol was added to the drinking water and its 
effects documented.  The impact of vehicle on body weight (BW) and metabolic profile is 
presented in figures 4.2 and 4.3. Compared to drinking water alone, the administration of 
0.05%v/v ethanol to drinking water for 16 weeks did not have any effect on body weight gain 
(fig.4.2). BW was 356.6± 20.6g in control rats receiving 0.05% ethanol (CE) and 349.3±11.48 g 
in controls receiving drinking water only (C).  BW was 416.4 ±21.6 g for diet with ethanol (DE) 
and 446±29.1g for diet with drinking water only (D) (fig.4.2).   
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Figure 4- 1  Characteristics of our model Effects of diet on (A) body weight (n=14 -15), (B) visceral fat (n=11), (C) serum insulin (n=6), blood (D) 
HDL-cholesterol (n=6), (E) triglyceride (n=6), and (F) leptin (n=6).  C, control; D, high calorie diet. &: p value (C vs. D). 
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Figure 4- 2 Impact of vehicle on body weight (A) and fasted blood glucose (B).  
 CE, control + ethanol; C, control; DE, diet + ethanol; D, high calorie diet. n=3 to 6, p >0.05 (ethanol vs. drinking water). 
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Figure 4- 3  Impact of vehicle on fasted blood lipid profile: (A) HDL-C, (B) TRIG (triglycerides).  
CE, control + ethanol; C, control; DE, diet + ethanol; D, high calorie diet; n=3 to 6, p >0.05 (ethanol vs. drinking water). 
  77
4.1.3. Effects of chronic melatonin treatment 
4.1.3.1. Biometric parameters 
 
Chronic melatonin administration significantly reduced body weight gain by 10.7% in control 
(347.8 ± 9 vs 387.8 ±11g, p<0.05) and 8.1% in diet (461.1± 11.5 vs 501.7±8.1 g, p<0.05) 
groups (fig. 4. 4). Melatonin also reduced visceral adiposity in control (12.6 ±0.9 vs 15.7±0.7g, 
p<0.05) and in diet (25.8±1.1 vs 29.8 ±1.1g, p<0.01) groups.  Heart weight was reduced in 
both control (21%, p<0.05) and diet (29.2%, p<0.01) rats.  Heart weight / body weight ratio was 
also lowered in both control (2.16±0.1 vs 2.58; p<0.05) and in diet (1.97 vs 2.62±0.1, p< 0.01) 
groups. The effects of chronic melatonin administration on biometric parameters are presented 
in figures 4. 4-7 and table 4.1 
 
Table 4- 1 Biometric parameters 
 
Parameters  C CM D DM N 
Body weight (g) 387.8±11.2 347.0±9.7 501.7±8.1 461.1±11.1 14-15 
Absolute heart weight (mg) 1013±44.0 800.0±68.8 1314±19.9 930.0±41.6 8-10 
H W/BW ratio (mg/g) 2.58 ±0.1 2.16±0.1 2.62±0.1 1.97±0.1 8-10 
Visceral adiposity (g) 15.7 ±0.7 12.6 ±0.9 29.87 ±0.4 25.8 ±1.1 11 
 
HW/BW, heart weight to body weight ratio. C, control; CM, control with melatonin; D, high calorie diet; 
DM, high calorie diet with melatonin.  
 
     Figure 4- 4 Body weight (n= 14-15/group). 
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   Figure 4- 5  Visceral fat (n=11/group). 
 
 
   Figure 4- 6 Absolute heart weight (n=8-10/group).  
 
 
 Figure 4- 7 Heart weight / body weight (HW/BW) ratio (n=8-10/group) 
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4.1.3.2. Metabolic data 
 
The effects of chronic melatonin administration on metabolic parameters are presented in 
figures 4.8-13 and table 4.2. Fasted blood glucose levels of control (C) and diet (D) rats were 
5.6±0.2 and 5.71±0.4 mmol/L, respectively. Melatonin treatment had no significant effects on 
fasted glucose levels of either control or diet groups (fig.4.8).  Overnight fasted insulin levels 
were significantly reduced in the melatonin treated diet rats (61.3± 13.3 vs. 198.3± 32.2 μIU/ 
mL, p<0.05) while there was no significant effect of melatonin on insulin levels in control rats 
(fig.4.9). Accordingly, the homeostasis model assessment (HOMA) index was reduced by 70.7 
% (p<0.01) in diet treated (DM) group, while there was no significant difference between 
HOMA index of  treated and untreated control rats (fig.4.10).   
 
Serum leptin levels were also reduced in diet treated (DM) rats by 52.6 % (p< 0.01) while there 
was no significant difference between leptin levels of treated and untreated control (CM and C) 
rats (fig.4.11).  Blood lipid profiles were also affected by melatonin treatment. Triglyceride 
levels were 1.44 ± 01 mmol/L in diet and 0.87± 0.1 mmol/L in control untreated (C) rats.  HDL-
cholesterol levels were 0.67±0.06 and 0.92±0.06 mmol/L in diet (D) and control (C) groups, 
respectively. Melatonin administration reduced triglycerides and increased HDL-cholesterol 
levels by 25% (p<0.05) and 29.8% (p<0.05), respectively in diet fed rats (DM vs D) while 
having no effect in control (CM vs C) groups (fig.4.12 & 4.13). 
 
 
    Table 4- 2  Metabolic parameters 
Parameters C CM D DM 
Serum insulin( µIU/mL) 109.8±33.9 68.1±12.6 198.3±32.2 61.3±13.4  
Glucose (mmol/L) 5.6±0.2 5.2±0.3 5.7±0.4 5.3±0.5 
HOMA index 27.48±8.4 14.16±1.7 47.03±5.8 13.75±2.8 
Serum leptin( ng/mL) 10.56±1.8 10.62±2.8 19.09±1.8 9.06±1.5 
HDL-C (mmol/L) 0.92±0.06 1.04±0.03 0.67±0.06 0.87±0.06 
TRIG (mmol/L) 0.87±0.08 0.72±0.05 1.44±0.09 1.08±0.06 
 
C, control; CM, control with melatonin; D, high calorie diet, DM, high calorie diet with melatonin; HOMA, 
homeostasis model assessment; TRIG, triglyceride, n=6/group. 
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Figure 4- 8 Effect on fasted serum blood glucose (n=6/group) 
 
Figure 4- 9 Effect on fasted serum insulin (n=6/group) 
 
Figure 4- 10 Homeostasis model assessment (HOMA) index (n=6/group) 
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Figure 4- 11  Serum leptin (non-fasted) (n=6/group). 
 
 
Figure 4 12 Fasted blood HDL-Cholesterol (n = 6/group) 
 
 
 
Figure 4- 13 Fasted blood triglycerides (TRIG) (n = 6/group). 
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4.2. MYOCARDIAL FUNCTION DATA 
 
Chronic melatonin treatment had no significant effect on pre-ischaemic functional parameters 
(coronary flow, aortic output, work total, systolic and diastolic pressure, heart rate) of the 
isolated rat hearts from  the control (table 4. 3).  It increased however the aortic output and 
work total in diet fed rats (table 4. 3). 
 
 After coronary artery occlusion and 30 minutes of reperfusion hearts from high calorie diet fed 
rats were more prone to myocardial dysfunction compared to the control group.  Percentage 
aortic output (AO) recoveries were (6.2 ± 6.2 % vs 46.8±4.6 %, p<0.001) and work total (WT) 
(20.4±7.9% vs 48.6± 3.9%, p <0.001) (fig.4.14 & 4.16).   
 
In diet fed rats, chronic melatonin treatment increased percent recovery of aortic output 
(28.5±6.5% for DM vs. 6.2±6.2% for D, p<0.05) and work total (34.5±5.6 % for DM vs 20.4±7.9 
% for D, p<0.05) (fig.4.14 & 4.16).  Coronary flow recovery was also increased in treated 
compared to untreated high calorie diet hearts (81.2 ± 4.5% vs 66.5± 5.1%, p<0.05).  
Accordingly, cardiac output was increased by 60% in treated compared to untreated high 
calorie diet groups (44.4 ± 5.2 % for DM vs 26.6±5.1 for D, p<0.05) (fig.4.15 and table 4.3).    
 
At 60 minutes of reperfusion, retrograde perfusion mode was converted to working heart mode 
for 5 minutes to record the functional parameters at this point.  As at 30 minutes of reperfusion, 
CO values continued to be elevated (by 68.7%) in treated compared to untreated high calorie 
diet fed hearts (DM vs D) while there was no significant difference in control rats (CM vs C). 
(tables 4.3 & 4. 4; fig.4.17).   Accordingly, the percentage CO recovery was also increased in 
treated compared to untreated hearts (25.9 ± 4.9% (D) vs 37.4± 6.2% (DM), p<0.05) The 
effects of diet and chronic melatonin administration on isolated rat heart function are presented 
in tables 4.3 – 4.4 and figures 4.14-4.17.   
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Figure 4- 14 Percentage work total recovery after 30 minutes of reperfusion (n=8-10/group) 
 
 
Figure 4- 15 Percentage cardiac output recovery after 30 minutes of reperfusion (n=8-10/group). 
 
Figure 4- 16 Percentage aortic output recovery after 30 minutes reperfusion (n=8-10/group) 
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Figure 4- 17 Percentage cardiac output recovery after 60 minutes of reperfusion (n=8-10/group) 
 
Table 4- 3 Summary of pre- and post-ischaemic myocardial function  
Time Parameters C CM D DM 
CF 16.1±0.7 13.9±1.3 16±1.2 17.6±0.7 
AO 41.3±2.1 39±3.6 31±1.8    & 37±1.3    # 
CO 57.4±2.3 52.9±4.7 47±3.0 55.3±1.5 
DP 62.6±1.9 62.9±1.8 59±1.4 62.8±2.9 
SP 103±2.6 102±2.6 94±2.8 102±4.8 
HR 235±7.6 205±18 238±6.6 245±10.2 
Wtot 13.6±0.8 11.3±1.3 10±0.9    & 13.4±0.3   # 
dP/dTmax 9.7±0.7 9.8±0.8 8.3±0.9 10.7±0.9 
Stabilization 
After 30 minutes 
 
Before ischaemia  
 
(Working heart) 
 
 
-dP/dT min 9.24±0.7 10±0.8 7.1±0.6 8±2.2 
CF 11.8±0.7 12.7±1.1 11±1.4 15±1.2      # 
AO 18.9±1.5 18.1±3.4 2.5±2.5   & 9.6±2.5     # 
CO 30.7±2.1 30.8±4 13±3.4& 24.6±2.9   # 
DP 60.8±1.2 64.51.8 57±5.0 61.4±1.5 
SP 90.7±1.5 90±1.3 69±5.4 82.8±2.9 
HR 236±8.8 231±15 178±47.5 237±9.8 
Wtot 6.4±0.4 5.7±0.9 1.9±0.72  & 4.5±0.7    # 
dP/dTmax 8.4±0.6 8±0.9 6.5±0.8 7.7±1.0 
Reperfusion 
After 30 minutes 
 
Post-ischaemia 
 
(Working heart) 
 
 
 -dP/dT min 6.9±0.6 4.5±1.4 5.2±0.2 6.3±0.6 
CF 12.11±0.8 11.5±0.9 10.4±1.1 13.6±0.8   # 
AO 15.2±1.9 10.9±2.5 2.5±2.5    & 7±2.9        # 
CO 27.3±2.0 22.4±2.9 12.8±3.3  & 20.6±3.4   # 
DP 61.8±1.7 62.6±1.6 60.4±4.9 59.7±2.0 
SP 88.8±1.3 88.4±1.6 73.0±4.9 80.6±3.9 
Wtot 5.6±0.4 4.5±0.6 2.59±1.2 4.0±0.8 
dP/dTmax 7.4±0.7 7.7±0.6 4.4±0.5 6.9±1.1 
Reperfusion 
After 60 minutes 
 
Post-ischaemia 
 
(Working heart) 
 
 -dP/dT min 6.8±1.0 7.4±0.5 4.6±0.4 4.8±1.2 
      
 # p<0.05 (DM vs. D); & p <0.001 (D vs. C) 
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Table  4- 4. Functional recovery (percentage) 
Time Parameters C CM D DM 
(%) CF 73.8±4.4 92.8±4.2 66.5±5.1 81.2±4.5 # 
(%) AO 46.8±4.6 47.2±7.8 6.2±6.2    & 28.5±6.5 # 
(%) CO 54.03±3.9 60.1±6.2 26.6±5.1  & 44.4±5.2 # 
(%) W tot 48.6±3.9 51.4±5.8 20.4±7.9  & 34.5±5.6 # 
(%) dP/dTmax 91.4±9.4 79.8±3.8 95.3±16.6 75.0±8.3 
Reperfusion 
 30 minutes 
Post-ischaemia 
  (%) –dP/dT min 76.4±5.6 47.4±13.7 88.2±13.6 48.6±12.0 
(%) CF 75.75±5.8 84.5±3.9 64.4±4.4 74.5±3.9 
(%) AO 38.2±5.3 29.3±6.4 6.2±6. 2   & 18.7±7.8 
(%) CO 48.3±4.0 47.3±4.2 25.8±4.9  & 37.37±6.2 #
(%) Wtot 43.4±4.6 39.9±3.5 23.9±8.0  & 30.7±6.2 
(%) dP/dTmax 79.6±9.5 81.7±9.7 39.9±13.6 68.0±10.0 
Reperfusion 
After 60 minutes 
Post-ischaemia 
  
  
  (%) –dP/dT min 72.7±6.9 77.0±7.0 47.2±14.0 25.0±15.0 
 
Tables 4.3 and 4.4 present the averaged values of pre-and post-ischaemic myocardial function. CF, 
coronary flow(ml/min); AO, aortic output (ml/min); CO, cardiac output(ml/min); DP, diastolic pressure 
(mmHg); SP, systolic pressure (mmHg); HR, heart rate (beats /min); Wtot., work total (mWatts), 
dP/dTmax, contractility index; −dP/dTmin, relaxation index. C, control (n=8); CM control with melatonin 
(n=9); D, diet (n=8); DM, diet with melatonin (n=10); # p<0.05 (DM vs. D); & p <0.001 (D vs. C) 
 
 
4.3. MYOCARDIAL INFARCT SIZE 
 
The figure 4.18 represents the effect of diet and chronic melatonin administration on 
myocardial infarct size. Hearts from the untreated high calorie diet group had an elevated 
myocardial infarct size compared to the control (38.4± 2.6% (D) vs. 30.4± 1.0% (C), p<0.05). 
Myocardial infarct size was significantly reduced in treated rats compared to untreated 
(16.6±2.0% for DM vs 38.4±2.6% for D, p < 0.001), and 12.8±1.5% for CM vs 30.4±1.0% for C, 
p<0.001).  Melatonin reduced infarct size by 57.7% and 58.1% in control and diet groups, 
respectively.  
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Figure 4- 18  Effect of diet and chronic melatonin administration on myocardial infarct size  
C, control (n=8); CM, control with melatonin (n=9); D, diet (n=7); DM, diet with melatonin (n=10).  
 
4.4. CHRONIC MELATONIN AND INTRACELLULAR SIGNALLING 
 
To determine by which signalling mechanism melatonin confers its cardioprotection, we 
investigated the effect of melatonin on reperfusion injury salvage kinases (RISK) (PKB/Akt and 
ERKp42/p44), p38 MAPK, AMPK, and GLUT-4 using Western blot analysis. Global ischaemia 
was chosen to avoid contamination of ischaemic and non-ischaemic tissues which may occur 
with the regional ischaemia.   
4.4.1. Reperfusion injury salvage kinases (RISK) pathway 
 
 To determine whether chronic melatonin treatment affects the RISK pathway, baseline and 
post- ischaemic phosphorylation of PKB/ Akt and ERK 42/44 at 10 minutes reperfusion was 
assessed.   
4.4.1.1. Baseline PKB/Akt and ERK p42/p44 
 
Under baseline conditions, hearts were not perfused. After flushing out of the blood and 
removing all surrounding tissues, the hearts were freeze-clamped and stored in liquid nitrogen 
until assayed. Melatonin increased baseline PKB/Akt and ERK 44 activation in control hearts 
while having no effect in diet groups (fig. 4.19 & 4.20). 
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Figure 4- 19  Phosphorylation of PKB/Akt under baseline conditions  
*p<0.05 (C vs D) n=3/group. 
 
 
Figure 4- 20 Baseline phosphorylation of ERK p42/p44   
Hearts were not subjected to  perfusion. (A): ERKp42; (B): ERKp44; * p<0.05 (C vs. CM), 
 n=3 /group. 
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4.4.1.2. Post-ischaemic PKB/Akt and ERK p42/p44 
 
To evaluate the post-ischaemic protein changes, hearts were freeze-clamped after 10 minutes 
of reperfusion following global ischaemia. Chronic melatonin treatment increased PKB/Akt 
activation during reperfusion in the hearts of both control (by 74 2%, p<0.05 C vs. CM) and diet 
fed animals (by 133.6%, p<0.01, D vs DM) (fig.4. 21).  ERK 42 and 44 were only activated by 
melatonin in the diet fed group while they were not different in control groups (fig.4.22). 
 
 
Figure 4- 21 Phosphorylation of PKB /Akt after 10 minutes reperfusion 
 *p<0.05 (C vs. CM); #p<0.01 (D vs. DM), n=6/group. 
 
Figure 4- 22 Phosphorylation of ERK 42/44 after 10 minutes reperfusion 
# p<0.05 (D vs. DM), n=6/group. 
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4.4.2. Phosphorylation of p38 MAPK  
  
Chronic melatonin treatment reduced baseline phosphorylation of p38 MAPK in the control 
group by 77.6 % (p<0.05, C vs. CM) without a significant effect in diet groups (fig. 4. 23).   After 
10 minutes of reperfusion, melatonin significantly reduced the activation of p38 MAPK in both 
control (by 31.6 %, p<0.05) and diet fed (by 33. 8 %, p< 0.05) groups (fig.4.24).  
 
Figure 4- 23 Baseline phosphorylation of p38 MAPK 
 *p<0.05 (C vs. CM), n=3/group 
 
Figure 4- 24  Phosphorylation of p38 MAPK after 10 minutes reperfusion 
 *p< 0.05 (C vs. CM); #p<0.05(D vs. DM), n=6/group. 
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4.4.3. AMPK activation and GLUT-4 expression 
 
High calorie diet and chronic melatonin had no effect on AMPK activation and GLUT-4 
expression in either control or diet groups (fig. 4.25 & 4. 26). 
 
 
Figure 4- 25 Phosphorylation of AMPK after 10 minutes reperfusion (n=6 /group). 
 
 
Figure 4- 26  Expression of GLUT-4 after 10 minutes reperfusion (n=6/group). 
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4.5. CHRONIC MELATONIN CONSUMPTION AND OXIDATIVE STRESS  
 
4.5.1. Chronic melatonin consumption and glutathione levels  
 
To evaluate the myocardial antioxidant status, unperfused hearts were used.  Chronic 
melatonin consumption had no effect on baseline serum and myocardial glutathione content of 
both control and diet fed groups (fig.4.27 & 28). 
 
Table 4- 5 Glutathione (GSH) levels 
PARAMETERS C CM D DM n/group 
Serum GSH  
(nmol/mL) 
32.5±4.4 39.1±4.6 36.9±0.7 40.6±11.4 6 
Myocardial  GSH 
(nmol/g/wet weight) 
1.19±0.08 1.18±0.05 1.14±0.05 1.34±0.08 6 
 
 
 
 
Figure 4- 27 Glutathione (GSH) content in left ventricle (n=6/group)   
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Figure 4- 28 Fasted serum glutathione levels (n=6/group) 
 
4.5.2. Chronic melatonin consumption and lipid peroxidation 
 
To investigate the effects of chronic melatonin consumption on systemic lipid peroxidation, 
total cholesterol (TC), triacylglycerol (TRIG) phospholipids (PL), conjugated diene (CD), lipid 
hydroperoxide (LOOH), and thiobarbituric acid reactive substances (TBARS) were measured 
in sera from non fasted control and diet fed rats with melatonin or drinking water.  
 
High calorie diet did not affect the serum lipid peroxidation compared to control diet (table 4. 
6). There were no differences between absolute concentrations of conjugated diene (CD) and 
thiobarbituric acid reaction substances (TBARS) though there were increases in triglycerides 
or triacylglycerol (TRIG) and phopholipids (PL) concentrations (table 4.6). This was associated 
with an increase in body weight gain, confirming the results found on fasting blood lipid profile 
(fig. 4.1E&D). 
 
In control rats, melatonin treatment has no discernible effect on TRIG, TC or PL in these 
control rats (table 4. 6).  Although the absolute concentration of CD was less with melatonin as 
a trend, the other two peroxidation products (LOOH and TBARS) were not significantly 
different. When the lipid peroxidation products were normalised, the difference in CD became 
significant (fig.4.29), but still no effect was seen on lipid hydroperoxide (LOOH) (fig.4.31) and 
TBARS (table 4.6). 
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Table 4- 6 Serum lipid peroxidation 
Parameters C CM D DM 
TBARS (μ mol/L) 5.46±1.39 8.71±2.0 4.77±0.6 2.42±0.58(a) 
CD (μ mol/L) 94.6±1.74 82.7±4.14(b)  107.8±10.88 143.0±13.82 
LOOH (μmol/L) 144±0.76 144±1.47 142±6.5  164±8.55 
TBARS (normalized) 2.38±0.55 3.31±0.57 1.39±0.22 0.64±0.24(a) 
CD (normalized) 41.9±1.9 33.1±2.76(c) 30.4±2.07 33.7±5.8 
LOOH (normalized) 63.8±3.06 58.6±6.46 41.3±4.11 38.5±5.19 
PL (mmol/L) 1.35±0.06 1.39±0.09 1.87±0.25 (d) 2.34±0.32 
TC (mmol/L) 1.76±0.14 1.61±0.11 1.56±0.76 1.75±0.19 
TRIG (mmol/L) 0.93±0.08 1.21±0.15 1.84±0.35(e) 2.41±0.43 
 BW (g) 385±9.7 341±10.9 (f) 477±21.6 (e) 436±12.08 
 
BW, body weight; CD, conjugated diene; LOOH, lipid hydroperoxide; TBARS, thiobarbituric acid reactive 
substance; TC, total cholesterol; TRIG, triacylglycerol or triglyceride; PL, phospholipid; C, control; CM, 
control with melatonin; D, high calorie diet; DM, high calorie diet with melatonin.  (a), p<0.05 vs. D; (b), 
p=0.65 vs. C; (c), p<0.05 vs C; (d), p<0.05 vs. C; (e), p<0.01 vs. C; (f), p<0.01 vs. C; n=6/group.   
  
 
Figure 4- 29 Non fasted serum conjugated dienes (CD)  
(n=6/group, *p<0.05 C vs CM) 
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Figure 4- 30 Effect of chronic melatonin on non-fasted serum TBARS (n=6/group) 
 
 
In diet fed rats, melatonin reduced the absolute TBARS levels by 49.2% (p<0.05, D vs DM) 
(fig.4. 30.). LOOH and CD levels were not affected (table 4.6 & fig.4. 31).  When normalised, 
only the TBARS were decreased by melatonin in the diet fed rats (table 4.6)  
 
 
 
Figure 4- 31 Non-fasted serum lipid hydroperoxide (LOOH) (n=6/group)  
 
 
      
          CHAPTER FIVE 
5. DISCUSSION 
5.1. OVERVIEW OF OUR FINDINGS 
 
The main findings of the present study were as follows. A high calorie diet induced an increase 
in body weight gain which was characterized by an elevated visceral fat content (fig.4.1A & 
4.1B). This weight gain was associated with increased triglyceride, insulin and leptin levels and 
an increase in the homeostasis model assessment (HOMA) index (table 4. 2; fig.4.1). We also 
observed a decrease in high density lipoprotein-cholesterol (HDL-C) but no change in glucose 
levels (table 4.2; fig. 4.8).  The diet-induced obesity predisposed the heart to reperfusion 
myocardial dysfunction and exacerbated infarct size after exposure to ischaemia (fig.4.18). 
Chronic oral melatonin administration initiated before the establishment of obesity prevented 
these physiological or metabolic changes associated with increased body weight gain (fig.4.8-
13). The chronic administration of melatonin also protected the heart by reducing the 
myocardial infarct size and improving the post-ischaemic myocardial function (fig.4.18).  
Melatonin conferred these cardioprotective effects by the activation of the pro-survival kinases 
(PKB/Akt and ERK42 and 44) with a concomitant inactivation of the pro-apoptotic p38 MAPK 
during reperfusion (fig.4.21-24).  AMPK (5’ adenosine monophosphate-activated protein 
kinase) and GLUT-4 (glucose transporter) expression were not affected by melatonin 
administration (fig.4.25-26). Melatonin reduced lipid peroxidation as reflected by a reduction in 
TBARS levels in the high calorie diet fed group (table 4. 6; fig.4.30). Myocardial and serum 
glutathione levels were not affected by the high calorie diet or melatonin treatment in this study 
(table 4.5; fig.4.27-28).  
 
5.2. DIET-INDUCED OBESITY 
 
5.2.1. Diet-induced pre-diabetic state 
 
It is well established that a long term positive imbalance between energy intake and 
expenditure results in obesity (for review see Sethi & Vidal-Puig, 2007).  In the present study 
rats fed a high calorie diet gained more weight than the control rats fed a normal rat chow 
(fig.4.1A).  The high calorie diet fed rats consumed more energy per day than what was 
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required by their age matched controls. As a consequence of this calories overconsumption, 
they developed a pre-diabetic state characterized by an increased visceral fat content, 
elevated circulating insulin and triglycerides levels and reduced HDL-cholesterol levels (table 
4.1;  fig.4.2). Circulating glucose levels remained unchanged (table 4.2; fig.4.8).  Rats fed a 
high calorie diet developed insulin resistance associated with dyslipidaemia (fig.4.1C, 4.1D & 
4.1E).  This is in agreement with previous studies in rats (Du Toit et al., 2008; Lima-Leopoldo 
et al., 2008; Dourmashkin et al., 2005) in mice (Lin et al., 2000; Thakker et al., 2006), and 
rabbit (Zhao et al., 2008) models of diet-induced obesity. The dyslipidaemia including 
decreased HDL-cholesterol and elevated triglyceride levels has been described as an early 
feature of the insulin resistance or metabolic syndrome and frequently precedes glucose 
intolerance (Reaven, 1988). 
 
Adipose tissue is no longer only considered as energy store, it is now recognized as an 
endocrine organ that secretes and releases a range of factors that are implicated in 
carbohydrate and lipid metabolism into the circulation (for review see Kershaw & Flier, 2004 
and Vazquez-Vela et al., 2008).  In this study, the large visceral fat mass in diet fed rats, 
implied hypertrophy of adipose tissue which is associated with elevated circulating FFA (Du 
Toit et al., 2008) and elevated levels of insulin resistance inducing factors such as tumour 
necrosis factor-alpha (TNF-α) (du Toit et al., 2008) and reduced levels of insulin sensitizing 
factors such as adiponectin. This would be expected to lead to inhibition of glucose uptake and 
promotion of free fatty acid oxidation in muscle, which results in a reduced insulin sensitivity 
contributing to hyperglycaemia. In addition, elevated TNF-α induces the release of free fatty 
acids (FFA) from adipose tissue into the circulation, promoting hypertriglyceridaemia which is 
also consistent with the findings of the present study.  
 
The normal glucose levels seen in our model indicate that the animals were in the pre-diabetic 
state. This refers to the early stage of type 2 diabetes where ß-cells secrete sufficient insulin to 
compensate for insulin resistance and maintain euglycemia (Boden, 2001). Consistent with our 
study and a previous study done by Du Toit et al. (2008), the pre-diabetic state is very 
important in the development of cardiovascular disease since pre-diabetic subjects with a high 
insulin secretory capacity have a higher risk of cardiovascular disease compared with subjects 
who do not develop insulin resistance (Morel et al., 2005). 
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5.2.2. Diet-induced resistance to insulin and leptin action 
 
The hormones insulin and leptin are two adiposity signals to the brain (Benoit et al., 2004; Air 
et al., 2002). Both hormones circulate in direct proportion to the total amount of body fat mass 
(Rider et al., 2009), both cross the blood-brain barrier by receptor-mediated uptake systems, 
and both have specific receptors located in regions of the brain associated with the control of 
body weight (Benoit et al., 2004).   
 
In the present study, the increased visceral fat mass was associated with elevated circulating 
insulin and leptin levels (fig.4.1B, 1C &1F). This suggests a leptin resistance in our model of 
diet induced obesity. The association of hyperinsulinaemia with hyperleptinaemia in the 
present study is in agreement with previous studies in rats (Dourmashkin et al., 2005) and in 
humans (Ahren et al., 1997; Havel et al., 1996, Rider et al., 2009a).  
 
Leptin resistance refers to a systemic decrease in sensitivity to leptin actions to the extent that 
normal or increased levels produce an inadequate response (Lin et al., 2000). Amongst other 
mechanisms (for review see Martin et al., 2008), hyperleptinaemia-induced desensitization of 
the hypothalamic leptin receptor has been identified as an important cause of leptin resistance 
(Kim-Motoyama et al., 1997). The primary role of leptin appears to be as a negative feedback 
adiposity signal that acts in the brain to suppress food intake and increase energy expenditure 
(Ahima & Osei, 2008). In the common form of obesity, resistance to leptin has been ascribed 
to diminished transport of leptin across the blood-brain barrier and to elevated hypothalamic 
levels of suppressor of cytokine signalling 3 (SOCS3) and endoplasmic reticulum (ER) stress, 
which inhibit leptin signalling (Flier, 1998; Morton et al., 2005; Ozcan et al., 2009). Consistent 
with this, animals lacking leptin or functional leptin receptors (e.g., leptin resistance) are 
grossly obese.  
  
The high levels of insulin in our model were also associated with an elevated HOMA index 
(table 4. 2; fig.4.10) which suggests a reduction in insulin sensitivity in rats fed a diet inducing 
obesity.  Insulin has its primary effects in the periphery where it regulates blood glucose and 
stimulates glucose uptake by most tissues. In our laboratory cardiomyocytes isolated from the 
diet induced obesity rats have shown to have a reduced glucose uptake (Huisamen, 
unpublished data). Analogous to leptin, however, deficits in insulin signalling (e.g., insulin 
resistance) are associated with hyperphagia in humans. Animals that lack normal insulin 
signalling in the brain are also obese. Thus, insulin and leptin resistant states reflect the 
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decrease (or lack) in insulin and leptin sensitivity which has effects similar to those seen with 
deficiencies of these peptides.  
 
5.3. IMPACT OF THE MELATONIN VEHICLE (0.05% ETHANOL) 
 
Melatonin was dissolved in a small amount of ethanol and added to the drinking water to yield 
a final concentration of 0.05% (v/v). While epidemiological studies are in agreement about the 
protective effect of chronic low to moderate alcohol intake, there are conflicting reports 
regarding the effects of chronic intake of low ethanol concentrations (Dow et al., 2001; Guiraud 
et al., 2004).  Therefore to test the possible long-term additional effects of the vehicle, ethanol 
(0.05%) was added to the drinking water and its effects documented.   
 
After 16 weeks of administration, ethanol at this dosage did not have any significant effects on 
body weight, blood glucose and triglycerides as well as HDL-C levels in control or high calorie 
diet fed rats (fig. 4.2 & 4.3).  For example, blood triglyceride levels were (in mmol/L) 0.87±0.08 
in controls receiving drinking water only (C), and 0.69±0.12 in controls receiving drinking water 
with ethanol (CE). In  high calorie diet fed rats, triglyceride levels were (in mmol/L) 1.44±0.09 in 
rats receiving drinking water only (D), 1±0.22 in rats receiving drinking water with ethanol (DE) 
(fig. 4.3B).  It is evident from the above that 0.05% ethanol did not influence our findings. This 
is in contrast to the findings of Rimm et al. (1999) who demonstrated that light to moderate 
consumption of ethanol improved lipid homeostasis with increases in HDL-C and reduced 
platelet aggregation. However, a study done by Dow et al. (2001) using a rat model, found that 
consuming 15% (v/v) ethanol for 16 weeks failed to protect the heart against ischaemia and 
reperfusion injury. In addition, it has been shown that 30% (v/v) or less ethanol does not 
influence diabetes (Vural et al., 2001), the heart, or ion homeostasis (Oz et al., 2006).  Guiraud 
et al. (2004) also reported that chronic intake of 9% ethanol for 7 weeks was the minimal dose 
to protect the heart without inducing metabolic abnormalities in rats. 
 
5.4. MELATONIN AND DIET-INDUCED SYSTEMIC ALTERATIONS 
 
Melatonin, the primary secretion of the pineal gland, is involved in wide range of physiological 
actions (for review Pandi-Perumal et al., 2006) and is known to play a role in energy 
expenditure and body mass regulation in mammals (Bartness et al., 2002). The present study 
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demonstrated that melatonin is involved in body weight regulation in overweight animals.  After 
16 weeks of feeding and treatment, rats receiving melatonin in their drinking water had a 
significantly lower body mass compared to the untreated rats in both control and diet fed rats 
(fig.4.1).  Consistent with our study, daily oral melatonin supplementation has been shown to 
reduce the body weight of middle-aged rats (Wolden-Hanson et al., 2000).  A reduction in body 
weight gain has also been reported when melatonin was administered intraperitoneally to 
obese animals (Hussein et al., 2007; Prunet-Marcassus et al., 2003; She et al., 2009).  
 
 Although obesity is not accompanied by significant modifications of melatonin secretion in 
human adults (Rojdmark et al., 1991), the amplitude of the nocturnal pineal melatonin peak 
decreased significantly in high-fat fed rats (Cono et al., 2008). The role of melatonin in body 
weight regulation was also evidenced by the observation that the reduction in circulating 
melatonin in pinealectomized rats was followed by an increase in body weight and 
administration of melatonin in these pinealectomized animals reduced the body weight gain 
(Prunet-Marcassus et al., 2003).  
 
The underlying mechanisms by which melatonin affects energy metabolism and prevents body 
weight gain are not clear. Since melatonin agonist treatment leads to the same effects as 
melatonin (She et al., 2009), it is suggested that melatonin confers these effects by receptor-
mediated pathways. Melatonin’s effects are partly mediated through MT2 receptors present in 
adipose tissue (Brydon et al., 2001) and Prunet-Marcacuss et al. (2003) have suggested that  
it could be  due to activation of the sympathetic nervous system and its subsequent effects on 
lipolysis and adipose tissue plasticity (Bartness et al., 2002; Penicaud et al., 2000).  When they 
found no permanent changes in food consumption, Bojkova et al. (2006) proposed that the 
body mass reduction could be related to improvements in the compromised insulin and leptin 
signalling associated with obesity. For example, melatonin, leptin and insulin have been found 
to activate the same intracellular signalling pathways (Carvalheira et al., 2001; Morton et al., 
2005; Anhê et al., 2004; Picinato et al., 2008). Thus, the interrelationships between melatonin, 
insulin, leptin and adipose tissue may play a crucial role in weight loss.   
 
In the present study, chronic melatonin treatment reverted insulin and leptin levels of the diet 
fed animals to control levels (Table 4. 2; fig.4. 9 & 4.11). Adipose tissue weight was also 
reduced but to a lesser extent than the reduction in insulin and leptin levels (tables 4. 1 & 2; 
fig.4. 5, 4.9 & 4.11).  These data suggest that the reduction in fat content was in part due to 
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changes in these hormones. Thus, it can be speculated that melatonin may act initially on 
hypothalamic leptin and insulin receptor sensitivity (as these hormones do under normal 
conditions) and may consequently relay information about peripheral fat stores to central 
effectors in the hypothalamus to modify food intake and energy expenditure. On the other 
hand, in vitro melatonin treatment has been shown to possibly inhibit the adipocyte 
differentiation and limits adipose tissue hypertrophy (Alonso-Vale et al., 2005) by inhibiting 
fatty acid-induced triglyceride accumulation in cells exposed to physiological levels of oleic 
acid (Sanchez-Hidalgo et al., 2009). This could explain how melatonin treatment prevented the 
increase in triglycerides (fig.4.13) and eventually body fat accumulation and body weight gain 
in the diet-induced obesity group.   However, in the control group, melatonin treatment did not 
affect the lipid profile, insulin and leptin levels (fig. 4.8- 4.13) though the visceral fat and body 
weight was affected.  In non obese rats, the body weight reduction could be linked to the anti-
ageing properties of melatonin maintaining the metabolic/physiological parameters at youthful 
levels (Rasmussen et al., 1999; Wolden-Hanson et al., 2000). 
 
Insulin sensitivity as expressed by the HOMA index was reduced in treated compared with 
untreated diet fed rats (fig.4.10). Importantly, there was no significant difference between the 
HOMA index of both control and diet treated rats.  Since insulin levels exhibit a nocturnal drop, 
insulin production has been suggested to be controlled, at least in part, by melatonin. Indeed, 
both melatonin receptors MT1 and MT2 are expressed in pancreatic islets. Melatonin inhibits 
insulin secretion in rat pancreatic islets (Picinato et al., 2002) and enhances insulin sensitivity 
(action) in the central nervous system (Anhê et al., 2004) and peripheral tissues (Sartori et al., 
2009).  These observations could supply an explanation for the finding that melatonin reduced 
the fasting insulin levels as well as the HOMA index in the present study and elsewhere (She 
et al., 2009; Hussein et al., 2007; Wolden-Hanson et al., 2000; Pulschalski et al., 2003).   
 
Our data show that melatonin did not affect blood glucose levels in either control or diet fed 
rats groups (fig. 4. 8). In this regard, it has to be borne in mind that our model was pre-diabetic 
exhibiting normoglycaemia. Our study is in agreement with previous studies (Prunet-
Marcassus et al., 2003; Wolden-Hanson et al., 2000 ) and, because there were no melatonin 
effects on glucose, lipid profile, leptin as well as insulin  levels and HOMA index  in  control rats 
group (table 4.2 ; fig.4.1- 4.13), melatonin appears to act only when there is a metabolic 
disturbance.  This can explain why, in contrast to the present study, other studies have 
demonstrated that melatonin improved glucose homeostasis in insulin resistant mice (Sartori et 
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al., 2009) and reduced circulating glucose levels in the rat (She et al., 2009) and rabbit 
(Hussein et al., 2007) models of diet-induced obesity. 
 
5.5. MELATONIN AND THE HEART 
 
5.5.1. Melatonin and cardiac remodelling  
 
Cardiac remodelling is strongly associated with obesity (Alpert, 2001; Abel et al., 2008; Chess 
& Stanley, 2008).  The hearts isolated from obese rats weighed more than their age-matched 
controls (fig.4. 6). However, there was no difference between the heart weight to body weight 
(HW/BW) ratios of untreated control and diet fed groups (fig.4.7).  This is consistent with a 
previous study (Du Toit et al., 2008) and is possibly due to the fact that the HW/BW ratio may 
not be an accurate measurement of heart hypertrophy as shown by other authors (Du Toit et 
al., 2008; Brede et al., 2003; Saupe et al., 2003).  In contrast, when the ventricular weight to 
tibia length (VW/TL) ratio was used as indicator, hearts from obese rats were shown to be 
hypertrophied (Du Toit et al., 2008).  The increased heart weight or cardiac hypertrophy may 
be the result of the impact of haemodynamic overload and/or increased oxidative stress on the 
heart in diet-induced obesity (Abel et al., 2008; Chess & Stanley, 2008).  Although blood 
pressure was not determined in the present study to establish a possible link between the 
blood pressure, body weight and heart hypertrophy, a recent study by Du Toit et al. (2008) 
reported that 16 weeks of diet-induced obesity was unable to increase the systolic blood 
pressure in rats. Thus, myocardial hypertrophy could also result from other mechanisms such 
as insulin resistance and leptin resistance (Rider et al., 2009b).  The increases in serum and 
basal myocardial angiotensin II (AT II) have also been shown to be associated with 
hypertrophy in diet-induced obesity (Du Toit et al., 2005). 
 
Chronic melatonin treatment reduced the HW (fig.4.6) and consequently the HW/BW ratio in all 
groups (fig.4.7).  The reduction in HW was associated with a reduction in body weight and fat 
mass and improvement in leptin and insulin sensitivity (reduction of HOMA index) in diet fed 
rats as discussed above. The mechanisms of HW reduction by melatonin are not clear. Beside 
the possible reduction in haemodynamic overload via the antihypertensive effects of melatonin 
(Paulis & Simko, 2007), the reduction in visceral fat may also be involved (Rider et al., 2009a).  
In our study, the reduction of HW (21% in control and 29.2% in diet) did not follow the same 
pattern as did BW reduction (10.7% in control and 8.1% in diet).  Therefore, in diet fed rats, the 
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reduction in HW/BW ratio could be due to other factors such as increased insulin or leptin 
sensitivity.  Rider et al. (2009a) have recently suggested that the cardiac hypertrophy 
regression, as consequence of weight loss in obesity, is the result of the increase in 
expression of leptin receptors in the myocardium. This could possibly explain how melatonin 
prevented the increase in cardiac hypertrophy in diet-induced obesity rats. However, in control 
rats, the mechanism remains unclear.   After 10 weeks of melatonin administration, Markova et 
al. (2003) have also reported a reduced heart weight in young male rats fed a normal rat chow.  
Melatonin was recently shown to have antifibrotic effects in hypertensive rats (Paulis et al., 
2009) as well as antihypertrophic effects in hyperthyroid rats (Ghosh et al., 2007). This may be 
due to the direct and indirect antioxidant properties of melatonin (Simko et al., 2009).   
Whether there is a direct effect of melatonin on the heart weight and how it is accomplished 
requires additional investigation.   
 
5.5.2. Melatonin and myocardial function 
 
This section focuses on the basal function of the heart during normoxic conditions, before 
induction of ischaemia (the effects on post-ischaemic function will be addressed in the next 
section). It is well established that obesity is associated with myocardial dysfunction (Poirier et 
al., 2006) and in the present study, isolated hearts from high calorie diet fed rats exhibited 
decreased basal myocardial function (aortic output and work total) as measured in vitro (table 
4. 3).  This is in agreement with previous in vitro studies (Akki & Seymour, 2009; Essop et al., 
2009; Du Toit et al., 2005; Du Toit et al., 2008). The poor myocardial function in obesity has 
been ascribed to metabolic abnormalities including dyslipidaemia, glucose intolerance, insulin 
and leptin resistance, associated with impaired myocardial Ca2+ handling (Banerjee & 
Peterson, 2007; Lopaschuk et al., 2007; Chess & Stanley, 2008).  Obesity induced by a high-
fat diet causes cardiac upregulation of Ca2+ transport-related genes in the sarcoplasmic 
reticulum (Lima-leoporldo et al., 2008). This is also associated by mitochondrial dysfunction 
characterized by inefficient nutrient oxidation causing low ADP/O ratios (Kim et al., 2008; 
Essop et al., 2009).  Mitochondrial dysfunction also leads to an increased production of 
reactive oxygen species subsequent to inflammation, which exacerbates the insulin resistant 
state and causes poor cardiac contractility (Kim et al., 2008; Bugger & Abel, 2008).   
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Chronic melatonin treatment had no significant effects on myocardial function in controls as 
measured in vitro (table 4. 3). This is consistent with previous studies where melatonin 
administration had no significant effect on hemodynamic parameters before ischaemia in vivo 
(Sahna et al., 2005; Lee et al., 2002) and in vitro (Szarszoi et al., 2001; Lochner et al., 2006). 
However, chronic melatonin treatment improved the basal myocardial function (aortic output 
and work total) of diet fed group (table 4.3).  This could be due to the prevention of age-
dependent cardiac mitochondrial dysfunction (Reiter et al., 2002; Rodriguez et al., 2007) and 
improvement of myocardial calcium homeostasis by melatonin (Salie et al., 2001; Yeung et al., 
2008).  
 
5.5.3. Melatonin and ischaemia reperfusion injury   
  
Ischaemia/reperfusion damage is characterized by myocardial dysfunction, arrhythmias and 
cell death or myocardial infarction (for review see Opie, 2004).  It is the consequence of 
metabolic alterations resulting from insufficient oxygen supply or the hypoxic state during 
sustained ischaemia. This is followed (at reperfusion) by excessive oxygen/nitrogen radical 
production and increased Ca2+ overload, associated with the altered myocardial metabolism. In 
addition reperfusion is associated with restoration of physiological pH, inflammation and the 
opening of the mitochondrial permeability transition pore (MPTP) (non selective pore) (for 
review see Buja et al., 2005; Yellow & Hausenloy, 2007). 
  
5.5.3.1. Diet-induced obesity and ischaemia/reperfusion injury  
 
Epidemiological and animal studies have demonstrated that obesity and its related metabolic 
abnormalities including insulin resistance and dyslipidaemia have been associated with 
increased incidence of myocardial infarction (Fedorowski et al., 2009; Prasad et al., 2009; 
Ranjith et al., 2007; Porier et al., 2006). In the present study, after coronary artery occlusion 
and 30 minutes of reperfusion, isolated hearts from high calorie fed rats had a decline in post-
ischaemic myocardial function (aortic output and work total) compared to control rats (table 4.3 
& 4.4).   In addition, the hearts from the diet fed group had an increased infarct size (by 26 %) 
compared to their age matched controls (fig.4.18). This indicates an increased susceptibility to 
ischaemia/reperfusion damage for the diet-induced obesity rat hearts, consistent with several 
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previous studies (Akki & Seymour, 2009; Essop et al., 2009; Du Toit et al., 2005; Du Toit et al., 
2008; Morel et al., 2003).   
 
The mechanism linking obesity and myocardial I/R injury are poorly understood. Metabolic 
alterations associated with increased cytosolic Ca2+ accumulation, increased reactive oxygen 
species and mitochondrial dysfunction may play an important role (Kim et al., 2008). Thus, the 
exacerbation of post-ischaemic function recovery in obese animal could be attributed to a 
number of mechanisms, including increased ceramide production, lipoapoptosis, oxidative and 
nitrosative stress, inefficient energy metabolism, and alterations in cardiomyocyte Ca2+ 
regulation (Banerjee & Peterson, 2007; Chess & Stanley, 2008). The I/R injury in diet-induced 
obesity has been associated with increased cardiac inflammatory markers including 
chemokines and cytokines (Thakker et al., 2006), elevated serum TNF-α (Du Toit et al., 2005) 
and high circulating free fatty acids (Thakker et al., 2008).   It could also be the consequence 
of cascades of maladaptative metabolic changes of in vivo FFA metabolism (Morel et al., 2003; 
Lopaschuk et al., 2007).   
 
However, reports on ischaemia/reperfusion injury in animal models of obesity have been 
controversial: some investigators have found increased myocardial susceptibility to ischaemia 
and reperfusion injury consistent with our findings (as stated above), while other could not find 
any difference (Thim et al., 2006). Surprisingly, others have found a resistance to ischaemia 
and reperfusion injury with obesity (Bouhidel et al., 2008; Kristiansen et al., 2004).  These 
inconsistencies have been attributed to differences in body weight gain, type and age of animal 
model (Wang et al., 2004; Mozaffari et al., 2008).   It has been noted that mild diabetes 
generally renders the heart resistant to ischaemic injury since glucose treatment protected 
cardiomyocytes with diabetic phenotype against necrosis (Mozaffari et al., 2008).  
 
5.5.3.2. Effect of melatonin on functional recovery and infarct size  
 
In the present study, chronic melatonin did not affect the post-ischaemic myocardial function in 
control rats (tables 4.3 & 4.4; fig.4.14-17). However, infarct size was reduced by 58.1% 
(fig.4.18). This is consistent with previous studies on acute administration of melatonin before  
coronary artery ligation in vivo (Sahna et al., 2005; Lee et al., 2002) or in vitro (Lochner et al., 
2006) showing a reduction in infarct size with no significant effect on hemodynamic parameters 
during ischaemia and during reperfusion. The mechanism by which chronic melatonin 
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treatment improves ischaemia and reperfusion injury remains under investigation. Interestingly, 
in the isolated hearts from non obese rats, the cardioprotective effects of oral melatonin 
treatment persist for almost 4 days after melatonin withdrawal (Lochner al., 2006). Therefore, 
the observed cardioprotection could result from long term effects of melatonin via stimulation of 
antioxidant enzymes (Rodriguez et al., 2004).  In this regard, it can be speculated that chronic 
melatonin increased the antioxidant capacity of the heart by upregulation of antioxidant 
enzymes, changes in receptor populations, and their signalling (Lochner & Genade, 
Unpublished observations) which protect against the increase in intracellular calcium overload 
and free radical generation, the principal features of I/R injury (Yellon & Hausenloy, 2007).  
Melatonin has been shown to reduce infarct size by increasing the antioxidant glutathione 
(GSH) in vivo (Sahna et al., 2005) and reducing ROS generation and lipid peroxide 
concentration in vitro (Kaneko et al., 2000) in the heart.   
 
Beside the long term melatonin administration, using acute melatonin treatment, previous 
convincing in vitro and in vivo studies have demonstrated the protective effects of melatonin 
against I/R injury (Reiter & Tan 2003; Paulis & Simiko, 2007; Tengattini et al., 2008; 
Kucukakim et al., 2009).  In addition to the heart, melatonin also reduced the molecular and 
cellular damage resulting from I/R in other organs (Reiter et al., 2005; Gurlek et al., 2006; Siu 
et al., 2006).  This protection was attributed to its free radical scavenging and broad-spectrum 
antioxidant properties. On the other hand, acute melatonin administration was recently shown 
to protect the isolated heart via its anti-adrenergic actions (Genade et al., 2008). The anti-
adrenergic effects of melatonin have also been demonstrated in rat (Abete et al., 1997) and 
guinea pig (Arvola et al., 2006) heart papillary muscle. 
 
The reduction of infarct size was not accompanied by an improvement of myocardial function 
in control rats (CM) (in contrast to diet fed rats) (tables 4. 3 & 4; fig.4.14-17). This has been 
also reported by previous studies on acute melatonin effects in vivo (Lee et al., 2002 and 
Sahna et al., 2005) and in vitro (Lochner et al., 2006 and Genade et al., 2008).  A previous 
study done by Lochner et al., (2003) has demonstrated that a reduction in infarct size is not 
always accompanied by an improvement in functional recovery during reperfusion, due to 
concomitant stunning. In contrast, the oral melatonin pre-treatment (40 μl/mL) for 7 days 
followed by 24 hours of withdrawal, reduced infarct size and improved post-ischaemic function 
of the hearts subjected to 35 minutes coronary artery occlusion in vitro (Lochner et al., 2006).  
In our study, although melatonin was also dissolved in ethanol and added to the drinking water 
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at the same amount, it was orally  administered for 16 weeks instead of 7 days (Lochner et al., 
2006), without any withdrawal of melatonin before the heart perfusion.  Moreover, in the same 
study by Lochner et al. (2006), the short-term oral melatonin at the dose of 20μl/ml failed to 
protect the heart. It is therefore evident that the effects of melatonin depend on the dose 
administered, the time and the way of administration as well as the protocol followed as it was 
also noted  by other authors (Szarszoi et al., 2001; Chen et al., 2003; Arvola et al.,2006). The 
isolated hearts from diet fed rats treated with melatonin had improved post-ischaemic 
myocardial function (aortic output and work total) (table 4.4). This may suggest that the 
beneficial effects of melatonin in DIO override the effect of stunning during reperfusion.  
 
This is the first study investigating the effects of melatonin on the heart in obesity. Several 
factors eliciting protection should be considered: this could be related to the prevention of 
insulin and leptin resistance seen in diet fed rats and the associated metabolic alterations. This 
prevention is possibly associated with a decrease in reactive oxygen species generation and 
intracellular Ca2+ accumulation (see myocardial function). Interestingly, in diet fed rats, 
melatonin reduced systemic lipid peroxidation which could also play a role in the observed 
cardioprotection (Bertuglia & Reiter (2007). The other features of cardioprotection are 
discussed in the following section. 
5.5.4. Melatonin and cardiac intracellular signalling  
 
5.5.4.1. Reperfusion injury salvage kinases pathway 
 
To determine the effects of chronic melatonin administration on intracellular signalling in the 
normoxic heart under baseline conditions, hearts were freeze-clamped immediately after 
removal from the body and stored in liquid nitrogen until assayed for kinases of the RISK 
pathway (PKB/Akt, ERK42 and 44) and the pro-apoptotic kinase p38 MAPK. To evaluate the 
post-ischaemic protein changes, a model of global ischaemia was used to obtain a more 
homogeneous sample. 
 
Under baseline conditions, isolated hearts from rats fed a high calorie diet did not show any 
differences in the activation of PKB/Akt (fig.4.19), ERK42 (fig.4.20 A), and p38 MAPK (fig.4.23) 
compared to their age-matched controls.  ERK 44 activation was reduced in diet fed rats 
(fig.4.20B). In contrast, Li et al. (2005) have reported a significant increase in p38 MAPK 
activation in the hearts from obese diabetic rats.  This discrepancy is probably due to the fact 
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that we employed a pre-diabetic model. However, chronic melatonin treatment increased the 
activation of PKB/Akt and ERK 44 in control rats (fig.4.19 & 4.20) associated with a 
concomitant reduction in activation of p38 MAPK (fig.4. 23). Interestingly melatonin treatment 
had no effect on the basal activation patterns of these kinases in hearts from diet fed animals, 
which may be due to harmful effects of obesity. However, the reasons for these observations 
should be further investigated.  
 
To evaluate the long term effects of melatonin treatment on post-ischaemic protein changes, 
hearts were freeze-clamped after 10 minutes reperfusion following 20 minutes global 
ischaemia.  The high calorie diet did not affect the post ischaemic activation of PKB/Akt, 
(fig.4.21), ERK 42 and 44 (fig.4.22) and p38 MAPK (fig.4.23) compared to the control groups.  
In the control rats, melatonin increased post-ischaemic PKB/Akt but not ERK 42/44 and 
reduced p38 MAPK activation during reperfusion. In the diet fed rats, melatonin increased 
post-ischaemic PKB/Akt and ERK 42/44 and reduced p38 MAPK activation (fig.4.21, 4.22 &4. 
24).  These findings are consistent with previous studies where it has been shown that acute 
melatonin treatment of isolated rat hearts during reperfusion activated the RISK pathway and 
reduced p38 MAPK (Genade et al., 2008).   In addition, after administration of melatonin in 
rats, Anhê et al. (2004) also reported in vivo activation of PKB/Akt and ERK42 and 44 in the 
hypothalamus.  It is well-established that activation of the reperfusion injury salvage kinase 
pathway (RISK) is associated with cardioprotection (Hausenloy and Yellon 2007). Our results 
suggest that melatonin also induces cardioprotection via these kinases.   A link has been 
proposed between the RISK pathway and the mitochondrial permeability transition pore and 
recently, convincing evidence has been presented that the cardioprotective effects of 
melatonin are due to inhibition of the mitochondrial permeability transition pore (MPTP) 
opening (Petrosillo et al., 2009). In addition to activation of the RISK pathway, it has recently 
been shown that acute administration of melatonin to the isolated rat heart caused activation of 
STAT-3 (Lecour S, Unpublished observations), which could also act on the mitochondrial 
membrane permeability transition pore. 
 
Finally, the exact mechanism whereby melatonin increased activation of PKB/Akt and 
ERK42/44 and reduced p38 MAPK activation in diet fed rats remains unknown.  This could 
merely be a reflection of protection caused by the other effects of melatonin or due to effects of 
melatonin on the activity of phosphatases. The latter possibility has not yet been examined.  
As discussed above, high calorie diet induced-obesity is associated with systemic metabolic 
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alterations (increased circulating insulin and leptin) compared to the control rats.  It has been 
shown that crosstalk occurs between insulin and leptin signalling, both activating the insulin 
receptor substrate (IRS)-phosphatidylinositol-3-OH kinase (PI3K) pathway (Morton et al., 
2005) and the STAT-3 pathway (Carvalheira et al., 2001).  It can therefore be speculated that 
melatonin reverses the insulin resistance by mimicking the actions of insulin and leptin 
signalling via cross-talk between these signalling pathways, all leading to PKB/Akt and STAT-3 
activation. However, this possibility needs further investigation.  
5.5.4.2. AMPK and GLUT- 4 
 
Since we found that melatonin is implicated in body weight regulation, which is one of the 
features of metabolism abnormalities, we decided to examine the effects of melatonin on the 
activity of proteins involved in cardiac metabolism. In this regard we examined the effect of 
melatonin on post-ischaemic AMPK activation.  AMPK is considered a cellular energy 
metabolism sensor (for review see Hardie, 2004; Young et al., 2005).  However, chronic 
melatonin administration did not affect AMPK activity (fig.4.25), a finding consistent with 
previous studies. The administration of melatonin to C2C12 murine skeletal muscle (Hâ et al., 
2006) and hepatic (Shieh et al., 2009) cells did not affect the activity of AMPK-mediated 
pathway.   
 
In addition, we investigated the expression of the glucose transporter (GLUT-4), to determine 
whether melatonin possibly influenced carbohydrate metabolism in the heart.  However, 
chronic melatonin had no significant effect on total GLUT-4 expression (fig.4.25).  Sartori et al. 
(2009) did not find an effect of melatonin administration (i.p.) on in vivo skeletal muscle 
glucose uptake of obese mice.  In contrast, previous studies using hepatic (Shieh et al., 2009) 
and skeletal muscle (Hâ et al., 2006) cells have demonstrated that melatonin treatment did 
increase glucose uptake. This possibly occurs by activation of PKC-ζ and not AMPK-mediated 
pathways (Hâ et al., 2006). This possibility should be further evaluated in our model. 
 
5.6. MELATONIN AND OXIDATIVE STRESS 
 
Oxidative stress has been implicated in the aetiology and exacerbation of cardiovascular 
disease (Dhalla et al., 2000b). To investigate the myocardial antioxidant status in our model 
and the effects of melatonin, the myocardial (unperfused hearts) and serum glutathione levels 
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were determined in control and diet fed rats. Overnight fasted animals were used for these 
experiments.  In addition, serums from non fasted animals were essayed to quantify lipid 
peroxidation, a feature of oxidative damage. 
5.6.1. Melatonin and glutathione (GSH)  
 
Glutathione or L-γ-glutamyl-L-cysteinyl-glycine, or GSH, is the major low-molecular-mass thiol 
compound in plants and animals which lacks the toxicity associated with cysteine.  
It is therefore considered as a cellular thiol “redox buffer” to maintain a given thiol/disulfide 
redox potential and is regarded as the key antioxidant in animal tissue (Akerboom & Sies, 
1981).   
 
In the present study, melatonin treatment had no effect on myocardial or serum glutathione in 
both control and diet fed rats (table 4.5; fig.4. 27 & 4. 28).  In addition, serum and myocardial 
glutathione levels of the high calorie diet group were similar to those of control group.  
Consistent with our study, Essop et al. (2009) have also found no difference in the degree of 
oxidative stress-induced damage between rats fed a high calorie diet (for 16 weeks) and their 
age-matched controls. In the study done by Vincent et al. (1999) diet-induced obesity 
predisposed the myocardium to oxidative stress (lipid peroxidation) but the antioxidant 
glutathione levels were not different between obese and lean rats.  
 
Our data suggest that the pre-diabetic state does not affect cardiac glutathione content, 
consistent with the previous study by Vincent et al. (1999). In addition, melatonin treatment 
was without effect on this parameter. These findings are surprising since melatonin can 
activate glutathione reductase (GRd), glutathione peroxidase (GPx) and glucose-6 phosphate 
dehydrogenase (Reiter & Tan, 2003; Tengattini et al., 2008) and elevated levels of glutathione 
have been associated with the cardioprotective effects of melatonin treatment in vivo (Sahna et 
al., 2005).  
5.6.2. Melatonin and lipid peroxidation 
 
Accumulation of excessive FFA as triglyceride droplets in muscle and other non adipose 
tissues can induce excessive reactive oxygen species production and increase the level of 
oxidative stress which is implicated in pathogenesis of insulin resistance (Grattagliano et al., 
2008) and obesity (Vincent et al., 2007). The high calorie diet did not affect the serum lipid 
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peroxidation compared to control (table 4. 6). There were no differences between absolute 
concentrations of conjugate diene (CD) and thiobarbituric acid reactive substances (TBARS) 
though there were increases in triglyceride (TRIG) and phopholipid (PL) concentrations. This 
was associated with an increase in body weight gain, confirming the results found on fasting 
blood lipid profile (table 4. 2).  It increased TRIG and PL, presumably through increased VLDL 
containing fatty acids from condensed milk (saturated fatty acids) and/or endogenous 
synthesis (of saturated or monounsaturated fatty acids) (She et al., 2009).  
 
In the control rats, melatonin treatment had no discernible effect on TRIG, TC or PL (table 4. 
6).  Although the absolute concentration of CD tended to be less with melatonin, the other two 
peroxidation products (LOOH and TBARS) were not significantly different. When the lipid 
peroxidation products were normalised, the difference in CD became significant (see fig 4.29) 
but still no effect was seen on lipid hydroperoxide (LOOH) and TBARS. This may be indicative 
of the antioxidant activity of melatonin, or due to an effect of melatonin on unsaturated fatty 
acid metabolism (Nishida et al., 2002).  
 
TBARS assay reflects the overall oxidative stress (Anurag & Anuradha, 2002). In diet fed rats, 
melatonin treatment did not affect LOOH and CD levels (fig. 4. 29 &31) while the absolute and 
normalized TBARS levels were reduced (table 4.6; fig.4. 30). Since this does not appear to be 
the case in the control rats, it may be related to an effect of high calorie diet, where lipid 
peroxidation could be enhanced by the weight gain itself (decreased by melatonin) or the lipid 
metabolism relating to the liver and/or adipose tissue (Bonet et al., 2007). Although we did not 
measure lipid peroxidation in fasted serum to make a correlation, insulin levels and HOMA 
index have been identified as strong determinants of TBARS levels, suggesting a role for 
insulin resistance in increased lipid peroxidation or oxidative stress (Anurag & Anuradha, 
2002).   
 
Consistent with our findings melatonin was shown to reduce plasma lipid peroxidation (TBARS 
levels) in cardiomyopathic hamsters (Bertuglia & Reiter, 2007). In addition, melatonin reduced 
lipid peroxidation in post-ischaemic myocardial tissue and protected against apoptosis (Dobsak 
et al., 2003). These antioxidant properties of melatonin have been repeatedly demonstrated by 
several workers (Reiter & Tan, 2003, Tengattini et al., 2008) and are achieved via its direct 
free radical scavenging and antioxidant enzyme stimulatory activities. 
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CHAPTER SIX 
6. CONCLUSIONS AND FUTURE PERSPECTIVES 
6.1. CONCLUSIONS 
 
The strong association between obesity and cardiovascular disease has prompted several 
researchers to investigate their complex interrelationships. To our knowledge, this is the first study 
to investigate the effects of melatonin on the heart in obesity and insulin resistance.  Consistent 
with previous studies, the present study demonstrated successfully how diet-induced obesity 
increases myocardial susceptibility to ischaemia and reperfusion injury. The present study also 
demonstrated clearly the beneficial role of chronic melatonin consumption on myocardial function 
and ischaemia/reperfusion injury in a rat model of diet-induced obesity.  
 
Chronic oral melatonin treatment reversed the metabolic profile characteristic of dyslipidaemia, 
insulin resistance, and leptin resistance associated with increased body weight.  It maintained 
glucose concentration at control levels and protected the heart against ischaemia/reperfusion 
induced damage. Chronic melatonin treatment activated the reperfusion injury salvage kinase 
(RISK) pathway and reduced the pro-apoptotic kinase p38MAPK activation during reperfusion. 
Myocardial AMPK activation and GLUT-4 expression were however not affected by the treatment. 
In addition to its signalling effects, melatonin treatment reduced the lipid peroxidation (TBARS 
levels) in diet fed rats while having no effect on lipid peroxidation in control rats.  Myocardial and 
serum glutathione were also not affected by diet or/and melatonin treatment.  
 
Our original hypothesis was that melatonin, in view of its anti-oxidant and free radical scavenging 
properties could abrogate the harmful effects of obesity. In view of the development of a pre-
diabetic state only, it is possible that free radicals did not play such an important role in this model 
of diet-induced obesity.  However melatonin pretreatment did reduce lipid peroxidation in the obese 
animals, suggesting some role for its anti-oxidant and free radical scavenging properties in this 
scenario. In view of previous results from our laboratory (Lochner et al., Unpublished data) which 
showed that melatonin receptor antagonism abolished its long-term beneficial actions, as well as 
the findings of the present study, we would like to suggest that melatonin’s beneficial actions are 
very definitely receptor-mediated to a large extent. 
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Figure 6- 1 Hypothetical representation of the effects of melatonin on the heart in diet-induced 
obesity.  
 
Chronic melatonin consumption prevented the metabolic alterations associated with increased fat 
accumulation, insulin resistance and leptin resistance. It improved baseline and post ischaemic 
myocardial function and protected the heart against ischaemia and reperfusion injury. This was 
associated with an increased activation of PKB/Akt-ERK42/44 and a decreased activation of the 
pro-apoptotic kinase p38 MAPK during reperfusion.  HW: heart weight; BW: body weight; Visc fat: 
visceral fat; I/R: ischaemia and reperfusion injury; AO: aortic output, CF: coronary flow; CO: cardiac 
output; IFS: infarct size; Wtot: work total; TG: triglycerides; HDL-c: high density lipoprotein-
cholesterol. TBARS: thiobarbituric acid reactive substances. 
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6.2. FUTURE PERSPECTIVES 
                                                                                                                                                     
The present study demonstrated the beneficial effects of chronic melatonin treatment on the heart 
in obesity using the isolated heart, an ex vivo technique, without other physiological interference 
from other organs or functions. Thus, it is of paramount importance to test the present findings in 
an in vivo model. In addition, because of the time constraints we did not determine myocardial lipid 
peroxidation levels and apoptosis as well as functional recovery (following global ischaemia).  The 
interactions between melatonin, leptin and insulin in obesity should receive further attention with 
particular attention to the signalling pathways involved.  It is evident that the effects of melatonin 
should be evaluated in comprehensive clinical trials. The results obtained in this study suggest that 
melatonin should not only be taken prophylactically, but also by patients with ischaemic heart 
disease and in obesity. Melatonin is a cheap drug and can be purchased without prescription in 
South Africa. It therefore has enormous therapeutic potential in our society with its high prevalence 
of obesity and cardiovascular disease.  
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